<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004172" GROUP_ID="INJ" ID="577001081609315096" MERGED_FROM="" MODIFIED="2011-02-16 18:31:16 +0100" MODIFIED_BY="Emma Sydenham" REVIEW_NO="1" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2011-02-16 16:00:53 +0000" MODIFIED_BY="Emma M Sydenham">
<TITLE>Platelet-rich-plasmapheresis for minimising peri-operative allogeneic blood transfusion</TITLE>
<CONTACT>
<PERSON ID="14388" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Paul</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Carless</LAST_NAME>
<SUFFIX>BHSc, MMedSc (ClinEpid)</SUFFIX>
<POSITION>Research Academic</POSITION>
<EMAIL_1>Paul.Carless@newcastle.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Discipline of Clinical Pharmacology</DEPARTMENT>
<ORGANISATION>Faculty of Health, University of Newcastle</ORGANISATION>
<ADDRESS_1>Level 5, Clinical Sciences Building, Newcastle Mater Hospital</ADDRESS_1>
<ADDRESS_2>Edith Street, Waratah</ADDRESS_2>
<CITY>Newcastle</CITY>
<ZIP>2298</ZIP>
<REGION>New South Wales</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>61-2-49-211726</PHONE_1>
<PHONE_2>61-2-49-211856</PHONE_2>
<FAX_1>61-2-49-602088</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2011-02-16 15:59:59 +0000" MODIFIED_BY="Emma Sydenham">
<PERSON ID="14388" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Paul</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Carless</LAST_NAME>
<SUFFIX>BHSc, MMedSc (ClinEpid)</SUFFIX>
<POSITION>Research Academic</POSITION>
<EMAIL_1>Paul.Carless@newcastle.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Discipline of Clinical Pharmacology</DEPARTMENT>
<ORGANISATION>Faculty of Health, University of Newcastle</ORGANISATION>
<ADDRESS_1>Level 5, Clinical Sciences Building, Newcastle Mater Hospital</ADDRESS_1>
<ADDRESS_2>Edith Street, Waratah</ADDRESS_2>
<CITY>Newcastle</CITY>
<ZIP>2298</ZIP>
<REGION>New South Wales</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>61-2-49-211726</PHONE_1>
<PHONE_2>61-2-49-211856</PHONE_2>
<FAX_1>61-2-49-602088</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14462" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Fraser</FIRST_NAME>
<MIDDLE_INITIALS>D</MIDDLE_INITIALS>
<LAST_NAME>Rubens</LAST_NAME>
<SUFFIX>MD, MSc, FRCSC</SUFFIX>
<POSITION/>
<EMAIL_1>frubens@ottawaheart.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Surgery</DEPARTMENT>
<ORGANISATION>University of Ottawa Heart Institute</ORGANISATION>
<ADDRESS_1>Room H211</ADDRESS_1>
<ADDRESS_2>40 Ruskin Street</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4W7</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14378" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Danielle</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Anthony</LAST_NAME>
<SUFFIX>BA (Hons), BSSc</SUFFIX>
<POSITION>Research Interviewer</POSITION>
<EMAIL_1>danielle.anthony@newcastle.edu.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Discipline of Clinical Pharmacology</DEPARTMENT>
<ORGANISATION>Faculty of Health, University of Newcastle</ORGANISATION>
<ADDRESS_1>Level 5, Clinical Sciences Building, Newcastle Mater Hospital</ADDRESS_1>
<ADDRESS_2>Edith Street, Waratah</ADDRESS_2>
<CITY>Newcastle</CITY>
<ZIP>2298</ZIP>
<REGION>New South Wales</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>61-2-49-211856</PHONE_1>
<PHONE_2/>
<FAX_1>61-2-49-602088</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="4881" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Dianne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>O'Connell</LAST_NAME>
<SUFFIX>PhD</SUFFIX>
<POSITION>Senior Epidemiologist</POSITION>
<EMAIL_1>dianneo@nswcc.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cancer Epidemiology Research Unit</DEPARTMENT>
<ORGANISATION>Cancer Council</ORGANISATION>
<ADDRESS_1>PO Box 572</ADDRESS_1>
<ADDRESS_2>Kings Cross</ADDRESS_2>
<CITY>Sydney</CITY>
<ZIP>1340</ZIP>
<REGION>NSW</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>61-2-93341768</PHONE_1>
<PHONE_2/>
<FAX_1>61-2-93341778</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19692" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Henry</LAST_NAME>
<SUFFIX/>
<POSITION>CEO</POSITION>
<EMAIL_1>david.henry@ices.on.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Institute of Clinical Evaluative Sciences</ORGANISATION>
<ADDRESS_1>2075 Bayview Avenue</ADDRESS_1>
<ADDRESS_2>G1 06</ADDRESS_2>
<CITY>Toronto</CITY>
<ZIP>M4N 3M5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 416 480 4297</PHONE_1>
<PHONE_2/>
<FAX_1>+1 (416) 480-6048</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2009-05-13 13:14:33 +0100" MODIFIED_BY="Emma M Sydenham">
<UP_TO_DATE>
<DATE DAY="25" MONTH="3" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="25" MONTH="3" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="13" MONTH="7" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2011-02-16 16:00:53 +0000" MODIFIED_BY="Emma M Sydenham">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2011-02-16 16:00:53 +0000" MODIFIED_BY="Emma M Sydenham">
<DATE DAY="11" MONTH="2" YEAR="2011"/>
<DESCRIPTION>
<P>The editorial group is aware that a clinical trial by Prof. Joachim Boldt has been found to have been fabricated (<A HREF="http://archie.cochrane.org/sections/documents/view?document=540099072011521412&amp;format=REVMAN#REF-Boldt-2009">Boldt 2009</A>). As the editors who revealed this fabrication point out (<A HREF="http://archie.cochrane.org/sections/documents/view?document=540099072011521412&amp;format=REVMAN#REF-Reinhart-2011">Reinhart 2011</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?document=540099072011521412&amp;format=REVMAN#REF-Shafer-2011">Shafer 2011</A>), this casts some doubt on the veracity of other studies by the same author. All Cochrane Injuries Group reviews which include studies by this author have therefore been edited to show the results with this author's trials included and excluded. Readers can now judge the potential impact of trials by this author (
<LINK REF="STD-Boldt-1990" TYPE="STUDY">Boldt 1990</LINK>, <LINK REF="STD-Boldt-1993" TYPE="STUDY">Boldt 1993</LINK>, <LINK REF="STD-Menges-1996" TYPE="STUDY">Menges 1996</LINK>, <LINK REF="STD-Menges-1997" TYPE="STUDY">Menges 1997</LINK>) on the conclusions of the review.
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-02-11 10:52:04 +0000" MODIFIED_BY="Emma M Sydenham">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-02-11 10:52:04 +0000" MODIFIED_BY="Emma M Sydenham">
<DATE DAY="12" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>The search has been updated. Four new trials are included in the review. The Results and Conclusions sections have been amended.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-13 13:12:49 +0100" MODIFIED_BY="Emma M Sydenham">
<DATE DAY="27" MONTH="3" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>National Health and Medical Research Council of Australia</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-02-16 16:01:08 +0000" MODIFIED_BY="Emma M Sydenham">
<SUMMARY MODIFIED="2011-02-11 13:35:26 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-02-11 13:35:26 +0000" MODIFIED_BY="[Empty name]">Does platelet-rich plasmapheresis (PRP) reduce the need for donor blood</TITLE>
<SUMMARY_BODY MODIFIED="2009-05-14 13:42:16 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Platelet-rich plasmapheresis is a technique that involves a patient&#8217;s own blood (autologous whole blood) being withdrawn via an intravenous catheter into a device that separates the blood by centrifugation into red blood cells (RBC), plasma, and a highly concentrated platelet solution. This concentrated autologous platelet solution is returned to the patient at the end of the operation to optimise blood clotting and minimise bleeding. The review of trials found that while PRP can reduce post-operative blood loss and the need for blood transfusion, other techniques may be more effective.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-02-16 15:22:16 +0000" MODIFIED_BY="Emma M Sydenham">
<ABS_BACKGROUND>
<P>Concerns regarding the safety of transfused blood have generated considerable enthusiasm for the use of technologies intended to reduce the use of allogeneic blood (blood from an unrelated donor). Platelet-rich plasmapheresis (PRP) offers an alternative approach to blood conservation.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To examine the evidence for the efficacy of PRP in reducing peri-operative allogeneic red blood cell (RBC) transfusion, and the evidence for any effect on clinical outcomes such as mortality and re-operation rates.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-05-14 00:13:35 +0100" MODIFIED_BY="[Empty name]">
<P>We identified studies by searching MEDLINE (1950 to 2009), EMBASE (1980 to 2009), <I>The Cochrane Library </I>(Issue 1, 2009), the Internet (to March 2009) and the reference lists of published articles, reports, and reviews.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-05-14 13:42:06 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Controlled parallel group trials in which adult patients, scheduled for non-urgent surgery, were randomised to PRP, or to a control group which did not receive the intervention.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-05-14 14:07:03 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Primary outcomes measured were: the number of patients exposed to allogeneic RBC transfusion, and the amount of RBC transfused. Other outcomes measured were: the number of patients exposed to allogeneic platelet transfusions, fresh frozen plasma, and cryoprecipitate, blood loss, re-operation for bleeding, post-operative complications (thrombosis), mortality, and length of hospital stay. Treatment effects were pooled using a random-effects model. Trial quality was assessed using criteria proposed by Schulz <I>et al</I> (Schulz 1995).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-02-16 15:22:16 +0000" MODIFIED_BY="Emma M Sydenham">
<P>Twenty-two trials of PRP were identified that reported data for the number of patients exposed to allogeneic RBC transfusion. These trials evaluated a total of 1589 patients. The relative risk (RR) of exposure to allogeneic blood transfusion in those patients randomised to PRP was 0.73 (95%CI 0.59 to 0.90), equating to a relative risk reduction (RRR) of 27% and a risk difference (RD) of 19% (95%CI 10% to 29%). However, significant heterogeneity of treatment effect was observed (p &lt; 0.00001; I² = 79%). When the four trials by Boldt are excluded, the RR is 0.76 (95% CI 0.62 to 0.93). On average, PRP did not significantly reduce the total volume of RBC transfused (weighted mean difference [WMD] -0.69, 95%CI -1.93 to 0.56 units). Trials provided inadequate data regarding the impact of PRP on morbidity, mortality, and hospital length of stay. Trials were generally small and of poor methodological quality.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-05-01 03:44:50 +0100" MODIFIED_BY="[Empty name]">
<P>Although the results suggest that PRP is effective in reducing allogeneic RBC transfusion in adult patients undergoing elective surgery, there was considerable heterogeneity of treatment effects and the trials were of poor methodological quality. The available studies provided inadequate data for firm conclusions to be drawn regarding the impact of PRP on clinically important endpoints.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-02-16 15:22:45 +0000" MODIFIED_BY="Emma M Sydenham">
<BACKGROUND MODIFIED="2011-02-11 13:26:23 +0000" MODIFIED_BY="[Empty name]">
<P>Concerns regarding the safety of transfused blood have prompted a reconsideration of the role of allogeneic blood transfusion (whole blood or packed red cells from an unrelated donor). The risks associated with receiving transfusion of allogeneic blood that has been screened by a competent blood transfusion programme are considered minimal, with very low risks of transmission of HIV and hepatitis C (<LINK REF="REF-Whyte-1997" TYPE="REFERENCE">Whyte 1997</LINK>). However, this only applies where there is a safe, well-regulated supply. The majority of the world's population does not have access to such a system, and the risks of transfusion in developing countries may be much higher (<LINK REF="REF-McFarland-1997" TYPE="REFERENCE">McFarland 1997</LINK>). Considerable enthusiasm has been generated for the use of technologies intended to reduce the use of allogeneic blood (<LINK REF="REF-Bryson-1998" TYPE="REFERENCE">Bryson 1998</LINK>, <LINK REF="REF-Forgie-1998" TYPE="REFERENCE">Forgie 1998</LINK>, <LINK REF="REF-Huet-1999" TYPE="REFERENCE">Huet 1999</LINK>, <LINK REF="REF-Laupacis-1997" TYPE="REFERENCE">Laupacis 1997</LINK>). However, some of the alternatives to allogeneic blood have their own risks, and are expensive (<LINK REF="REF-Coyle-1999" TYPE="REFERENCE">Coyle 1999</LINK>, <LINK REF="REF-Fergusson-1999_x002f_a" TYPE="REFERENCE">Fergusson 1999/a</LINK>).</P>
<P>The International Study of Peri-Operative Transfusion (ISPOT- a ten-country study of evidence, attitudes and practices relating to the use of alternatives to peri-operative allogeneic blood transfusion) generated a number of systematic reviews (<LINK REF="REF-Bryson-1998" TYPE="REFERENCE">Bryson 1998</LINK>, <LINK REF="REF-Forgie-1998" TYPE="REFERENCE">Forgie 1998</LINK>, <LINK REF="REF-Huet-1999" TYPE="REFERENCE">Huet 1999</LINK>, <LINK REF="REF-Laupacis-1997" TYPE="REFERENCE">Laupacis 1997</LINK>) that examined the efficacy and safety of various technologies employed to minimise the need for peri-operative allogeneic blood transfusion. Amongst the technologies studied were: the anti-fibrinolytic drugs (aprotinin, tranexamic acid, and epsilon aminocaproic acid); desmopressin (deamino-8-D-arginine vasopressin - DDAVP); autologous blood donation by pre-operative deposit (PAD); acute normovolaemic haemodilution (ANH); and cell salvage (CS)/autotransfusion. Findings from these studies indicate that the use of PAD and ANH (techniques for re-infusing a patient's own blood), were associated with uncertain benefits. However, the use of technologies intended to reduce surgical blood loss, such as aprotinin and tranexamic acid, appear to lead to significant clinical benefits in terms of reducing the need for re-operation due to further bleeding. However, the safety of aprotinin in cardiac surgery was called into question in 2006 and 2007, when the results of a cohort study conducted by Mangano <I>et al</I> (<LINK REF="REF-Mangano-2006" TYPE="REFERENCE">Mangano 2006</LINK>, <LINK REF="REF-Mangano-2007" TYPE="REFERENCE">Mangano 2007</LINK>) showed that aprotinin increased the risk of renal failure, myocardial infarction, stroke and 5-year mortality (<LINK REF="REF-Ray-2008" TYPE="REFERENCE">Ray 2008</LINK>). In November 2007, based on the preliminary results of the BART study (<LINK REF="REF-Fergusson-2008" TYPE="REFERENCE">Fergusson 2008</LINK>), Bayer Pharmaceuticals suspended the worldwide marketing of aprotinin (Trasylol®). The final results of the BART study (a large randomised comparative trial of aprotinin, tranexamic acid and epsilon aminocaproic acid) published in the New England Journal of Medicine, May 29, 2008 (<LINK REF="REF-Fergusson-2008" TYPE="REFERENCE">Fergusson 2008</LINK>) showed that patients treated with aprotinin had a higher rate of death compared to those patients treated with either tranexamic acid (TXA) or epsilon aminocaproic acid (EACA). These results were confirmed by the updated meta-analysis by Henry <I>et al</I> (<LINK REF="REF-Henry-2009" TYPE="REFERENCE">Henry 2009</LINK>) which showed that the risk of death was consistently higher with the use of aprotinin compared to the lysine analogues, TXA and EACA. The search for a safe, cost-effective blood-conserving strategy continues.</P>
<P>As platelet-rich plasmapheresis (PRP) produces a highly concentrated, autologous platelet product, interest has grown for PRP as an alternative approach to blood conservation in the surgical setting (<LINK REF="REF-Triulzi-1995" TYPE="REFERENCE">Triulzi 1995</LINK>). The use of autologous platelets avoids the potential hazards associated with the use of random donor platelets, such as HLA alloimmunisation, platelet refractoriness and febrile non-haemolytic transfusion reactions. In the case of cardiac surgery, platelet dysfunction secondary to cardiopulmonary bypass (CPB) is one of the most significant factors leading to bleeding diathesis during the post-operative period (<LINK REF="REF-Boldt-1995" TYPE="REFERENCE">Boldt 1995</LINK>, <LINK REF="REF-Safwat-1998" TYPE="REFERENCE">Safwat 1998</LINK>). Theoretically, platelet-rich plasmapheresis preserves platelets, which optimises haemostasis and thereby reduces the potential for allogeneic blood transfusion.</P>
<P>Platelet-rich plasmapheresis is either performed pre-operatively (within 24 hours of surgery) or intra-operatively (after the induction of anaesthesia). It involves a patient's own blood (autologous whole blood) being withdrawn via a large bore intravenous catheter into a plasmapheresis or platelet sequestration device, which separates the blood by centrifugation into a platelet solution, plasma, and red blood cells (RBC) (<LINK REF="REF-Ruel-2001" TYPE="REFERENCE">Ruel 2001</LINK>). The plasma and red cell component is usually re-administered to the patient immediately, whereas the platelet component is collected, temporarily stored, and then returned to the patient at the end of the surgery (<LINK REF="REF-Ruel-2001" TYPE="REFERENCE">Ruel 2001</LINK>, <LINK REF="REF-Triulzi-1995" TYPE="REFERENCE">Triulzi 1995</LINK>). In the case of surgery involving CPB, PRP reinfusion usually occurs after the neutralisation of heparin (<LINK REF="REF-Gravlee-1994" TYPE="REFERENCE">Gravlee 1994</LINK>). Haemodynamic stability is maintained during the blood withdrawal phase of the PRP procedure by volume replacement therapy with crystalloid and/or colloid fluids, the reinfusion of withdrawn RBC, and the occasional use of vasopressor agents (<LINK REF="REF-Safwat-1998" TYPE="REFERENCE">Safwat 1998</LINK>). A number of cycles, taking 10-15 minutes for each cycle, may be required to achieve a PRP target volume of 10-20ml/kg, or approximately 20% of the patient's plasma volume (<LINK REF="REF-Gilcher-1989" TYPE="REFERENCE">Gilcher 1989</LINK>). It has been recommended that the target platelet yield should be at least 20% of the circulating platelet mass or 2.6 x 10¹¹ platelets (in the case of a 70kg male with a platelet count of 250,000u/L) (<LINK REF="REF-Gilcher-1989" TYPE="REFERENCE">Gilcher 1989</LINK>). Such a platelet yield is equivalent to approximately five units of random donor platelets.</P>
<P>This review builds on a systematic review conducted by Rubens <I>et al.</I> (<LINK REF="REF-Rubens-1998" TYPE="REFERENCE">Rubens 1998</LINK>). It examines the evidence of the efficacy of PRP in reducing the need for allogeneic red blood cell transfusion in elective adult surgery, and whether there is a greater reduction in allogeneic transfusion demonstrated in identifiable patient sub-groups.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To examine the effects of platelet-rich plasmapheresis (PRP) in minimising peri-operative allogeneic blood transfusion, and on other clinical outcomes.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-02-16 15:09:29 +0000" MODIFIED_BY="Emma M Sydenham">
<SELECTION_CRITERIA MODIFIED="2009-05-06 04:16:55 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Randomised controlled trials with a concurrent control group.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>The study participants were adults (over 18 years). The surgery being conducted was elective or non-urgent.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>The intervention considered was platelet-rich plasmapheresis, performed during the pre-operative or intra-operative period. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-05-06 04:16:55 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-03-03 02:47:52 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Number of patients in the intervention and control groups who were transfused with allogeneic and/or autologous blood</LI>
<LI>Volume of allogeneic and/or autologous blood transfused (expressed as units of blood)</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-05-06 04:16:55 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Number of patients exposed to allogeneic platelet transfusion, fresh frozen plasma (FFP), and cryoprecipitate</LI>
<LI>Volume of allogeneic platelets, FFP, and cryoprecipitate transfused</LI>
<LI>Blood loss</LI>
<LI>Re-operation for bleeding</LI>
<LI>Adverse events (e.g. hypotension)</LI>
<LI>Mortality</LI>
<LI>Thrombosis</LI>
<LI>Length of hospital stay</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-05-13 13:38:05 +0100" MODIFIED_BY="Emma M Sydenham">
<ELECTRONIC_SEARCHES MODIFIED="2009-05-13 13:38:05 +0100" MODIFIED_BY="Emma M Sydenham">
<P>The literature search was conducted using the following electronic databases:</P>
<UL>
<LI>MEDLINE (1966-March 2009)</LI>
<LI>EMBASE (1980-March 2009)</LI>
<LI>Cochrane Library (Issue 1, 2009)</LI>
</UL>
<P>The search strategy can be found in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>We searched the bibliographies of eligible trials, review articles, and reports for any potentially relevant studies. In addition to the computer database searches, we searched Google Scholar&#8482; and searched manufacturer web sites to identify any reports or projects relevant to the review.</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-02-16 15:09:29 +0000" MODIFIED_BY="Emma M Sydenham">
<STUDY_SELECTION MODIFIED="2009-05-13 13:20:43 +0100" MODIFIED_BY="Emma M Sydenham">
<P>The titles and abstracts identified in the searches were screened for relevance and selected for inclusion if they fulfilled the eligibility criteria. To be eligible for inclusion, studies had to include adult patients, scheduled for elective or non-urgent surgery, who were randomised to platelet-rich plasmapheresis or to a control group that did not receive PRP treatment. We used an article extraction form to extract information regarding study methodology, length of follow-up, outcomes investigated, the presence or absence of a transfusion protocol, the type of surgery, and treatment outcomes. Two of the authors (PAC, DMA) examined articles for inclusion/exclusion criteria with disagreements resolved by consensus.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-03-03 22:37:53 +0000" MODIFIED_BY="[Empty name]">
<P>We extracted data from studies using a data extraction form and then entered data into Review Manager (RevMan). Data on the following outcomes were recorded: the number of patients exposed to allogeneic and/or autologous blood, the amount of blood transfused, the number of patients experiencing post-operative complications (re-operation for bleeding, thrombosis), blood loss, mortality and hospital length of stay. Information on patient demographics (age and sex) and the presence or absence of a transfusion protocol were also recorded. The number of patients who were enrolled, randomised and completed the study was also documented.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-05-14 13:45:22 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Studies were assessed for methodological quality by two raters using the criteria proposed by Schulz <I>et al</I> (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). This criteria contains four items of assessment: double-blinding, allocation concealment, participant exclusion (withdrawal post randomisation), and methods used to achieve randomisation. In the case of double-blinding, allocation concealment, and participant exclusion, three numeric values (i.e. 0, 1, 2) were allocated to each of the three scales within each of these items. For example, trials judged to have adequately concealed treatment allocation scored 2, whereas trials judged not to have concealed treatment allocation scored 0. In the case of the method used to achieve randomisation, two numeric values (i.e. 0, 1) were allocated to each of the two scales within this item of assessment. Therefore, trials scored 1 if the method used to generate allocation sequences was judged to have been adequate (e.g. random number table, computer random number generator), whereas inadequate or unreported methods scored 0.</P>
<P>Inter-rater agreement for each item of methodological quality assessment was assessed by comparing the observed or achieved agreement (the proportion of studies for which the two raters assigned the same score) with that expected by chance (the agreement that would be achieved if the raters assigned scores at random). STATA® statistical software was used to calculate agreement and kappa statistics (&#954;). Disagreements were resolved by consensus.</P>
<P>The methodological quality of included trials was also assessed with particular emphasis on allocation concealment, which was ranked as follows:</P>
<UL>
<LI>Grade A - Adequate concealment</LI>
<LI>Grade B - Uncertain</LI>
<LI>Grade C - Inadequate allocation concealment</LI>
</UL>
</QUALITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2009-05-14 13:45:32 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Funnel plots were inspected for evidence of publication bias.</P>
<P>Authors were contacted where possible to obtain missing data and/or clarify issues pertaining to study methodology.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-05-13 13:23:20 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Dichotomous data (e.g. number of patients transfused, patients requiring re-operation for bleeding) and continuous data (e.g. units of blood transfused and blood loss) were analysed using <LINK REF="REF-Review-Manager" TYPE="REFERENCE">Review Manager</LINK> (RevMan). If standard deviations (SD) or standard error of means (SEM) were not reported for continuous data (or were unable to be calculated from the reported data) the study was not included in the meta-analysis. Outcomes were expressed as pooled relative risks (RR), risk differences (RD), or weighted mean differences (WMD) using a random effects model. The presence of heterogeneity of treatment effect was assessed using the Q statistic, which has an approximate chi-square distribution with degrees of freedom equal to the number of studies minus one (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>). A p-value less than or equal to 0.10 was used to define statistically significant heterogeneity. The I² statistic was used to quantify inconsistency across trials. The I² statistic describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>; <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
<P>Blood transfusion data reported as millilitres (mls) transfused were converted to units by dividing by 300.</P>
<P>
<U>Mathematical notation</U>
<BR/>Values expressed in scientific notation are interpreted as follows:<BR/>Mean platelet yields: n x 10¹¹/L = n x 10 to the 11th power per litre<BR/>Mean platelet counts: n x 10³/µL = n x 10 to the 3rd power per micro litre</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-02-11 20:10:01 +0000" MODIFIED_BY="[Empty name]">
<P>We performed analysis of <I>a-priori </I>subgroups to determine whether effect sizes varied according to factors such as; the type of surgery, the use of transfusion protocols, the haemoglobin transfusion trigger level, the use of cell salvage, the mean platelet count of PRP, the mean platelet yield, the mean PRP volume collected, and study methodological quality. Funnel plots were inspected for evidence of publication bias.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-02-16 15:09:29 +0000" MODIFIED_BY="Emma M Sydenham">
<P>The editorial group is aware that a clinical trial by Prof. Joachim Boldt has been found to have been fabricated (<A HREF="http://archie.cochrane.org/sections/documents/view?document=540099072011521412&amp;format=REVMAN#REF-Boldt-2009">Boldt 2009</A>). As the editors who revealed this fabrication point out (<A HREF="http://archie.cochrane.org/sections/documents/view?document=540099072011521412&amp;format=REVMAN#REF-Reinhart-2011">Reinhart 2011</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?document=540099072011521412&amp;format=REVMAN#REF-Shafer-2011">Shafer 2011</A>), this casts some doubt on the veracity of other studies by the same author. All Cochrane Injuries Group reviews which include studies by this author have therefore been edited to show the results with this author's trials included and excluded. Readers can now judge the potential impact of trials by this author on the conclusions of the review.
</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-02-16 15:22:45 +0000" MODIFIED_BY="Emma M Sydenham">
<STUDY_DESCRIPTION MODIFIED="2009-05-14 14:08:18 +0100" MODIFIED_BY="Emma M Sydenham">
<SEARCH_RESULTS MODIFIED="2009-05-14 14:07:42 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Of the 34 randomised controlled trials of platelet-rich plasmapheresis identified, 26 fulfilled the inclusion criteria. These 26 trials were conducted in the following countries: United States (n = 11), Germany (n = 5), Italy (n = 2), Switzerland (n = 2), Australia (n = 1), Egypt (n = 1), Taiwan (n = 1), France (n = 1), Singapore (n = 1) and United Kingdom (n = 1). Twenty-four trials were conducted in the setting of cardiac surgery and two were conducted in vascular surgery (<LINK REF="STD-Godet-1995" TYPE="STUDY">Godet 1995</LINK>, <LINK REF="STD-Safwat-2002" TYPE="STUDY">Safwat 2002</LINK>). Trials were published between 1990 and 2003. There were two non-English studies; one was published in German (<LINK REF="STD-Klein-2001" TYPE="STUDY">Klein 2001</LINK>) and one in French (<LINK REF="STD-Godet-1995" TYPE="STUDY">Godet 1995</LINK>). These trials were translated before being included in the analysis. Of the 26 included trials, only two (<LINK REF="STD-Armellin-1995" TYPE="STUDY">Armellin 1995</LINK>, <LINK REF="STD-Armellin-1997" TYPE="STUDY">Armellin 1997</LINK>) had more than 100 patients in each trial arm. The remaining 24 trials were generally small. Overall, the mean number of patients in each trial arm was 33 (range: 9-138).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-05-14 14:08:18 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Of the 26 included trials, eight were conducted by four similar research groups (two by each group). These trials are as follows: (1) Armellin 1995 (<LINK REF="STD-Armellin-1995" TYPE="STUDY">Armellin 1995</LINK>), Armellin 1997(<LINK REF="STD-Armellin-1997" TYPE="STUDY">Armellin 1997</LINK>), (2) Boldt 1990 (<LINK REF="STD-Boldt-1990" TYPE="STUDY">Boldt 1990</LINK>), Boldt 1993 (<LINK REF="STD-Boldt-1993" TYPE="STUDY">Boldt 1993</LINK>), (4) Christenson 1996/a (<LINK REF="STD-Christenson-1996_x002f_a" TYPE="STUDY">Christenson 1996/a</LINK>), Christenson 1996/b (<LINK REF="STD-Christenson-1996_x002f_b" TYPE="STUDY">Christenson 1996/b</LINK>), and (4) Menges 1996 (<LINK REF="STD-Menges-1996" TYPE="STUDY">Menges 1996</LINK>), Menges 1997 (<LINK REF="STD-Menges-1997" TYPE="STUDY">Menges 1997</LINK>). After a thorough comparative assessment of these trials none were deemed by the authors to be duplicate publications.</P>
<P>Of the 21 trials that provided demographic data, the average age of the study participants ranged from 37.2 to 68 years for those randomised to an intervention group, and 37.6 to 79.7 years for those randomised to a control group. Overall, the ratio of males to females in the PRP group was 3.5:1 compared to 3.2:1 for the controls. These data suggest that patients in the control arms of the included trials were slightly older than those in the intervention arms and that there were slightly more males randomised to the intervention arms than the control arms.</P>
<SUBSECTION>
<HEADING LEVEL="4">Description of Intervention</HEADING>
<P>Of the 26 included trials, 11 reported the volume of platelet-rich plasma (PRP) harvested per patient (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). Nine trials reported harvesting 10ml/kg of PRP, one reported the harvesting of 8-10ml/kg, and one reported the harvesting of 15 ml/kg of PRP per patient. Fifteen trials reported the actual volumes (mean+/-sd) of PRP collected, and these ranged from 220 ml to 892 ml per patient (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). Fourteen trials reported the mean platelet counts of the harvested PRP product, which ranged from 150 x 10³/uL to 864 x 10³/uL (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). The platelet yields also varied considerably, with nine trials reporting mean platelet yields of between 1.2 x 10¹¹/L and 3.4 x 10¹¹/L (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>).</P>
<P>The majority of devices used to produce the platelet-rich plasma were manufactured by Haemonetics (n = 20). A summary of the types (models) of devices used is provided below.</P>
<P>Summary of PRP devices used:</P>
<OL>
<LI>Haemonetics Ultralite Plasma Collecting System (PCS) (n = 3)</LI>
<LI>Haemonetics Plasma Saver (n = 10)</LI>
<LI>Haemonetics MCS3p (n = 1)</LI>
<LI>Haemonetics PCS V50 (n = 2)</LI>
<LI>Haemonetics 5000 (n = 1)</LI>
<LI>Haemonetics 7000 (n = 1)</LI>
<LI>Haemonetics Cell Saver IV (n = 1)</LI>
<LI>Medtronic Elmd-500 (n = 2)</LI>
<LI>Medtronic Electromedics AT 1000 (n = 3)</LI>
<LI>Haemonetics or Electromedics (n = 1)</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Co-interventions</HEADING>
<P>The majority of trials (77%) reported the use of co-interventions (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>). In the current series of trials co-interventions were those treatments designed to either minimise blood loss (e.g. anti-fibrinolytic drugs), or minimise the need for allogeneic blood (ANH, PAD, CS).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cell salvage (CS)</HEADING>
<P>Cell salvage was the most frequently used co-intervention, with 16 trials reporting its use in both trial arms (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Cell salvage involves the reinfusion of blood collected from the operative field, either directly with filtration only or after centrifugation and washing. It is performed during the intra- and/or postoperative periods. Three trials (<LINK REF="STD-Jones-1990" TYPE="STUDY">Jones 1990</LINK>, <LINK REF="STD-Shore_x002d_Lesserson-1995" TYPE="STUDY">Shore-Lesserson 1995</LINK>, <LINK REF="STD-Triulzi-1995" TYPE="STUDY">Triulzi 1995</LINK>) reported re-transfusing shed mediastinal blood to patients during the post-operative period. Six trials (<LINK REF="STD-Armellin-1995" TYPE="STUDY">Armellin 1995</LINK>, <LINK REF="STD-Armellin-1997" TYPE="STUDY">Armellin 1997</LINK>, <LINK REF="STD-Boldt-1990" TYPE="STUDY">Boldt 1990</LINK>, <LINK REF="STD-Boldt-1993" TYPE="STUDY">Boldt 1993</LINK>, <LINK REF="STD-Menges-1996" TYPE="STUDY">Menges 1996</LINK>, <LINK REF="STD-Menges-1997" TYPE="STUDY">Menges 1997</LINK>) reported they specifically did not use autotransfused blood from the mediastinal drainage systems during the post-operative period. Trials that exclusively used cell salvage devices to haemo-concentrate the contents of cardiopulmonary bypass circuits were not included in the cell salvage stratum for a-priori subgroup analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Anti-fibrinolytic therapy</HEADING>
<P>Three trials (<LINK REF="STD-Liu-1998" TYPE="STUDY">Liu 1998</LINK>, <LINK REF="STD-Stover-2000" TYPE="STUDY">Stover 2000</LINK>, <LINK REF="STD-Wajon-2001" TYPE="STUDY">Wajon 2001</LINK>) reported the use of the anti-fibrinolytic agent, epsilon aminocaproic acid (EACA). Liu <I>et al</I> (<LINK REF="STD-Liu-1998" TYPE="STUDY">Liu 1998</LINK>) administered EACA as a bolus dose of 150mg/kg prior to CPB. Stover <I>et al</I> (<LINK REF="STD-Stover-2000" TYPE="STUDY">Stover 2000</LINK>) administered 150mg/kg of EACA as a loading dose over 30 minutes, added 75mg/kg to the CPB circuit priming volume, and maintained a 20mg/kg/hr infusion of EACA throughout the operation. Wajon <I>et al</I> (<LINK REF="STD-Wajon-2001" TYPE="STUDY">Wajon 2001</LINK>) administered 10g of EACA as a bolus dose prior to the commencement of CPB. The use of aprotinin was reported by one trial (<LINK REF="STD-Armellin-1995" TYPE="STUDY">Armellin 1995</LINK>). The administration of this agent was not equally distributed between the intervention and control groups, with slightly more patients in the PRP group (29%) than in the control group (25%) receiving aprotinin treatment. The use of post-operative tranexamic acid (TXA) was reported by one trial (<LINK REF="STD-Ford-2002" TYPE="STUDY">Ford 2002</LINK>). For this trial two patients randomised to PRP received post-operative TXA whereas no patient randomised to control was treated with TXA at any stage.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Multiple co-interventions</HEADING>
<P>One trial (<LINK REF="STD-Godet-1995" TYPE="STUDY">Godet 1995</LINK>) reported the use of CS, PAD and ANH. The trial conducted by Jones <I>et al</I> (<LINK REF="STD-Jones-1990" TYPE="STUDY">Jones 1990</LINK>) reported the use of both CS and ANH. Exposure to these co-interventions within trials appeared to be equally distributed across groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Transfusion protocols</HEADING>
<P>The number of trials reporting the use of transfusion protocols varied according to the type of blood product (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Twenty-four trials (92%) reported the use of transfusion protocols for RBCs, 18 trials (69%) reported the use of protocols for platelet transfusion, 18 trials (69%) reported the use of protocols to guide the transfusion of fresh frozen plasma (FFP), and four trials (15%) reported the use of protocols to guide the transfusion of cryoprecipitate.</P>
<SUBSECTION>
<HEADING LEVEL="5">Red blood cells (RBC)</HEADING>
<P>Of the 24 trials that reported the use of transfusion protocols to guide red cell transfusion practice (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>), 24 reported the use of a transfusion threshold or "trigger", that being the haemoglobin (Hb) or haematocrit (Hct) value, at which point a transfusion of allogeneic and/or autologous blood was considered necessary. There was significant variation between trials in the transfusion threshold used. In general, the Hb transfusion thresholds ranged from 6.0 to 8.0 g/dL for the intra-operative period, and ranged from 6.6 to 10.0 g/dL (Hct 20-30%) for the post-operative period.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Platelets (PLT)</HEADING>
<P>Eighteen trials reported the use of transfusion protocols to guide platelet transfusion (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Eleven trials reported platelet transfusion thresholds of 100 x 10<SUP>9</SUP>/L, three trials transfused platelets when the platelet count fell below 50 x 10<SUP>9</SUP>/L, and two trials transfused platelets when the platelet count fell below 75 x 10<SUP>9</SUP>/L and 80 x 10<SUP>9</SUP>/L, respectively. Platelet transfusion thresholds were either used in isolation or used in combination with other transfusion criteria including, evidence of active or diffuse bleeding post bypass (in the case of trials involving cardiac surgery). Of those 18 trials that reported the use of protocols for platelet transfusion, only one transfused platelets solely on the basis of excessive mediastinal chest tube drainage (&gt;200ml/hr for two consecutive hours).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Fresh frozen plasma (FFP)</HEADING>
<P>Nineteen trials reported the use of transfusion protocols to guide the transfusion of FFP (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). However, there was considerable variation in the transfusion strategies used. Five trials transfused FFP when the prothrombin time (PT) was greater than 150% of control values, whereas one trial transfused FFP when the PT was greater than 120% of control values. Two trials transfused FFP on the basis of diffuse uncontrollable bleeding and laboratory evidence of coagulopathy. Both of these trials failed to describe a specific threshold for FFP transfusion. Fourteen trials transfused FFP on the basis of either prothrombin times (PT), partial thromboplastin times (PTT), or activated partial thromboplastin times (APTT). Prothrombin times ranged from 15-16 seconds and PTT ranged from 20-35 seconds (or a PTT ratio of 1:3). An APTT&gt;45 seconds was used by two trials as an indicator for FFP transfusion. One trial transfused FFP when the INR was &gt;1.4 whereas another trial transfused FFP when the INR was &gt;1.5 and the APTT was &gt;45 seconds. Although one trial (<LINK REF="STD-DelRossi-1990" TYPE="STUDY">DelRossi 1990</LINK>) reported FFP transfusion on the basis of an elevated APTT, no specific threshold was described.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cryoprecipitate</HEADING>
<P>Four trials reported the use of protocols to guide the transfusion of cryoprecipitate (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Three trials transfused cryoprecipitate for a fibrinogen count &lt;100mg/dL and one trial transfused cryoprecipitate for a fibrinogen count &lt;150mg/dL. One trial (<LINK REF="STD-Triulzi-1995" TYPE="STUDY">Triulzi 1995</LINK>) reported the application of topical cryoprecipitate during surgery for small vessel bleeding not adequately controlled by surgical haemostasis.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration of cardiopulmonary bypass (CPB)</HEADING>
<P>Twenty-two of the 24 cardiac trials included in this review reported the duration of cardiopulmonary bypass. The duration of CPB varied considerably between trials ranging from around 73 minutes to 143 minutes (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). Given the varying degree of surgical complexity across these trials this is not an unexpected finding.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-04-30 00:48:44 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-four of the 26 included trials were assessed for methodological quality by two raters. Quality assessment of the two trials requiring translation (<LINK REF="STD-Godet-1995" TYPE="STUDY">Godet 1995</LINK>, <LINK REF="STD-Klein-2001" TYPE="STUDY">Klein 2001</LINK>) was performed by one rater. These trials were therefore excluded from the analysis of the reliability of the quality assessment procedure.</P>
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<P>Using the quality assessment instrument based on the Schulz criteria (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>), for the item assessing allocation concealment, all 24 trials scored 0 (out of maximum score of 2). There was 100% agreement between the two raters. As the method used to conceal treatment allocation was not clearly described in any trial, all 24 trials were classified as Grade B using the Cochrane criterion to grade allocation concealment (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>Using the Schulz criteria (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>), one trial (4.2%) was assessed to be double-blind, seven trials (29.2%) the method of blinding was unclear, and for 16 trials (66.7%) outcomes assessment was judged not to be performed in a blinded fashion (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). There was 83% agreement (&#1082; = 0.60) between the two raters.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Generation of allocation sequences</HEADING>
<P>For 19 trials, the method used to generate allocation sequences (randomisation) was either inadequate or not reported. Only five trials described methods for generating allocation sequences judged to be adequate. These five trials used either a computer random number generator or a random number table to generate allocation sequences. Using the Schulz criteria (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>), for the item assessing the method used to generate allocation sequences, five trials scored 1, and 19 scored 0 (out of a maximum score of 1)(<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). There was 95.8% (&#1082; = 0.88) agreement between the raters.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Inclusion of all randomised participants</HEADING>
<P>Of the 24 trials assessed for methodological quality, 14 used intention-to-treat analysis or reported no exclusions, and six reported exclusions that were judged unlikely to cause bias. For four trials, exclusions were either not described, or the exclusions created differential loss in the comparison groups. Using the Schulz criteria (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>), consensus scores were: 2 for 14 trials, 1 for 6 trials, and 0 for 4 trials (out of a maximum score of 2). There was 83.3% agreement (&#1082; = 0.70) between the two raters for this item. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Aggregate scores</HEADING>
<P>Based on the Schulz criteria (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>) no trial scored more than 4 out of a possible score of 7. Aggregated quality scores were (out of a possible score of 7): 4 for 2 trials, 3 for 4 trials, 2 for 13 trials, 1 for 2 trials, and 0 for 3 trials. </P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-02-16 15:22:45 +0000" MODIFIED_BY="Emma M Sydenham">
<P>Twenty-two trials of PRP reported data on the number of patients receiving an allogeneic RBC transfusion. These trials included a total of 1589 patients, of whom 801 were randomised to PRP. The relative risk (RR) of receiving an allogeneic blood transfusion in patients randomised to PRP was 0.73 (95%CI 0.59 to 0.90), representing a statistically significant relative risk reduction (RRR) of 27%. Heterogeneity of treatment effect was statistically significant (p&lt;0.00001; I² = 79%). The absolute risk reduction (ARR) was 19% (RD -0.19, 95%CI -0.29 to -0.10). This equates to a number needing to be treated (NNT) of 5.3 (95%CI 3.5 to 10.0) to avoid a single patient having an allogeneic blood transfusion. (When the 
<LINK REF="STD-Boldt-1990" TYPE="STUDY">Boldt 1990</LINK>, <LINK REF="STD-Boldt-1993" TYPE="STUDY">Boldt 1993</LINK>, <LINK REF="STD-Menges-1996" TYPE="STUDY">Menges 1996</LINK> and <LINK REF="STD-Menges-1997" TYPE="STUDY">Menges 1997</LINK> trials were excluded from the analysis, the RR was 0.76 (95% CI 0.62 to 0.93).)
</P>
<SUBSECTION>
<HEADING LEVEL="3">Type of surgery</HEADING>
<P>All but two of the included trials (<LINK REF="STD-Godet-1995" TYPE="STUDY">Godet 1995</LINK>, <LINK REF="STD-Safwat-2002" TYPE="STUDY">Safwat 2002</LINK>) were conducted in the context of cardiac surgery, so stratification of the data by the type of surgery (subgroup analysis) proved uninformative.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Effect of transfusion protocols</HEADING>
<P>As there were only two trials (<LINK REF="STD-Ereth-1993" TYPE="STUDY">Ereth 1993</LINK>, <LINK REF="STD-Farouk-2003" TYPE="STUDY">Farouk 2003</LINK>) that did not report the use of a transfusion protocol to guide RBC transfusion, subgroup analysis was uninformative.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Transfusion threshold ("trigger") levels</HEADING>
<P>For the four trials that used Hb transfusion thresholds of 6.6-7.0g/dL the relative risk of receiving an allogeneic RBC transfusion was 0.33 (95%CI 0.18 to 0.62). Heterogeneity of treatment effect was statistically significant (p = 0.01; I² = 72%). For the seven trials that reported using Hb transfusion thresholds of 8.0-8.5g/dL the relative risk of receiving an allogeneic RBC transfusion was 0.89 (95%CI 0.64 to 1.25). Heterogeneity of treatment effect was statistically significant (p = 0.07; I² = 48%). (When <LINK REF="STD-Menges-1996" TYPE="STUDY">Menges 1996</LINK> and <LINK REF="STD-Menges-1997" TYPE="STUDY">Menges 1997</LINK> were excluded, RR was 1.00 (95% CI 0.86 to 1.16).) For the four trials that reported using Hb transfusion thresholds of 9.0g/dL, the relative risk of receiving an allogeneic RBC transfusion was 0.78 (95%CI 0.63 to 0.97; I² = 49%). (With 
<LINK REF="STD-Boldt-1990" TYPE="STUDY">Boldt 1990</LINK> excluded, RR was 0.79 (95% CI 0.64 to 0.98).) For the three trials that used Hb transfusion thresholds of 10.0g/dL the relative risk of receiving an allogeneic RBC transfusion was 1.10 (95%CI 0.59 to 2.07; I² = 18%). (With 
<LINK REF="STD-Boldt-1993" TYPE="STUDY">Boldt 1993</LINK> excluded, RR 1.25 (0.85 to 1.85).)
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Effect of cell salvage</HEADING>
<P>
<B>Intra-operative cell salvage</B>
</P>
<P>In 16 trials patients in both the PRP and control groups were exposed to intra-operative cell salvage. For those trials that reported the use of intra-operative cell salvage, the risk of exposure to allogeneic RBC transfusion was reduced by a relative 29% in those patients randomised to PRP (RR 0.71, 95%CI 0.54 to 0.93). Heterogeneity of treatment effect was statistically significant (p &lt; 0.00001; I² = 83%). (With 
<LINK REF="STD-Boldt-1990" TYPE="STUDY">Boldt 1990</LINK>, <LINK REF="STD-Boldt-1993" TYPE="STUDY">Boldt 1993</LINK> and <LINK REF="STD-Menges-1997" TYPE="STUDY">Menges 1997</LINK> excluded, the RR was 0.75 (95% CI 0.58 to 0.97).) For the six trials that did not report the use of intra-operative cell salvage the relative risk of receiving an allogeneic RBC transfusion was 0.71 (95%CI 0.45 to 1.11). Heterogeneity of treatment effect was statistically significant (p = 0.0001; I² = 79%).</P>
<P>
<B>Post-operative cell salvage</B>
</P>
<P>Only three trials reported the use of post-operative cell salvage. For these trials the relative risk of exposure to allogeneic RBC transfusion was 0.84 (95%CI 0.42 to 1.70). Heterogeneity of treatment effect was statistically significant (p &lt; 0.002; I² = 85%). For the 19 trials that did not report the use of post-operative cell salvage the relative risk of receiving an allogeneic RBC transfusion was 0.70 (95%CI 0.55 to 0.89). Heterogeneity of treatment effect was statistically significant (p = 0.0001; I² = 79%). (With 
<LINK REF="STD-Boldt-1990" TYPE="STUDY">Boldt 1990</LINK>, <LINK REF="STD-Boldt-1993" TYPE="STUDY">Boldt 1993</LINK>, <LINK REF="STD-Menges-1996" TYPE="STUDY">Menges 1996</LINK> and <LINK REF="STD-Menges-1997" TYPE="STUDY">Menges 1997</LINK> excluded, the RR was 0.74 (95% CI 0.59 to 0.93).)
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Effect of PRP volume</HEADING>
<P>Three small trials reported average PRP collection volumes of 701ml or more per patient. These trials included a total of 82 patients, of whom 41 were randomised to PRP. For these trials the relative risk of receiving an allogeneic blood transfusion was 0.96 (95%CI 0.44 to 2.12; I² = 3%). (When the 
<LINK REF="STD-Boldt-1993" TYPE="STUDY">Boldt 1993</LINK> trial was excluded from the analysis, the RR was 1.12 (95% CI 0.50 to 2.51).) Five trials reported average PRP collection volumes of between 501-700ml. These trials included a total of 362 patients of whom 181 were randomised to PRP. For these trials the relative risk of receiving an allogeneic blood transfusion was 0.77 (95%CI 0.43 to 1.10). Heterogeneity of treatment effect was statistically significant (p = 0.002; I² = 77%). Four trials reported average PRP collection volumes of between 301-500ml per patient. These trials included a total of 184 patients of whom 90 were randomised to PRP. The relative risk of receiving an allogeneic blood transfusion was 0.42 (95%CI 0.15 to 1.20). Heterogeneity of treatment effect was statistically significant (p &lt; 0.00001; I² = 96%). One trial reported an average PRP volume of 233ml per patient. For this trial the relative risk of receiving an allogeneic red cell transfusion was 0.20 (95%CI 0.03 to 1.56).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Effect of platelet yield</HEADING>
<P>Four trials reported mean platelet yields of between 3.0-3.5 x 10¹¹/L. These trials included a total of 209 subjects, of whom 101 were randomised to PRP. The relative risk of receiving an allogeneic blood transfusion was 0.31 (95%CI 0.05 to 2.02). Heterogeneity between these trials was statistically significant (p &lt; 0.00001; I² = 96%). Two trials reported mean platelet yields of between 2.5-2.9 x 10¹¹/L. For these trials the relative risk of receiving an allogeneic blood transfusion was 0.48 (95%CI 0.32 to 0.73; I² = 0%). Four trials reported mean platelet yields of less than 1.8 x 10¹¹/L. These trials included a total of 409 patients of whom 205 were randomised to PRP. The relative risk of receiving an allogeneic blood transfusion was 0.98 (95%CI 0.68 to 1.40). Heterogeneity between these trials was statistically significant (p = 0.05; I² = 61%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Effect of mean platelet count of PRP</HEADING>
<P>Two trials, conducted by the same group (<LINK REF="STD-Christenson-1996_x002f_a" TYPE="STUDY">Christenson 1996/a</LINK>, <LINK REF="STD-Christenson-1996_x002f_b" TYPE="STUDY">Christenson 1996/b</LINK>), reported mean platelet counts of the PRP of between 700-870 x 10³/uL. For these trials the relative risk of receiving an allogeneic blood transfusion was 0.11 (95%CI 0.04 to 0.29).</P>
<P>Two trials (<LINK REF="STD-Stover-2000" TYPE="STUDY">Stover 2000</LINK>, <LINK REF="STD-Wajon-2001" TYPE="STUDY">Wajon 2001</LINK>) reported a mean platelet count of the PRP between 550-600 x 10³/uL. These trials included a total of 139 patients of whom 66 were randomised to PRP. For these trials the relative risk of receiving an allogeneic blood transfusion was 0.89 (95%CI 0.63 to 1.25; I² = 0%).</P>
<P>
One analysis consists of two trials conducted by Prof. Boldt (<LINK REF="STD-Boldt-1990" TYPE="STUDY">Boldt 1990</LINK>, <LINK REF="STD-Boldt-1993" TYPE="STUDY">Boldt 1993</LINK>), and reported mean platelet counts of the PRP of between 250-350 x 10³/uL. These trials included a total of 54 patients of whom 27 were randomised to PRP. For these two small trials the relative risk of receiving an allogeneic blood transfusion was 0.17 (95%CI 0.02 to 1.31; I² = 0%).</P>
<P>Two trials, conducted by the same group with Prof. Boldt (<LINK REF="STD-Menges-1996" TYPE="STUDY">Menges 1996</LINK>, <LINK REF="STD-Menges-1997" TYPE="STUDY">Menges 1997</LINK>), reported mean platelet counts of the PRP of less than 250 x 10³/uL. These trials included a total of 80 patients of whom 40 were randomised to PRP. For these two small trials the relative risk of receiving an allogeneic blood transfusion was 0.09 (95%CI 0.01 to 0.67; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Volume of RBCs transfused</HEADING>
<P>Eight trials reported data for the total volume of allogeneic RBC transfused during the intra-operative and post-operative periods. Overall there was no evidence of a significant reduction in the total volume of red blood cells transfused. The reduced volume with PRP was minimal and not statistically significant (WMD -0.69 units, 95%CI -1.93 to 0.56 units). Heterogeneity between these trials was statistically significant (p &lt; 0.00001; I² = 90%). Although the use of PRP appeared to reduce the amount of RBC transfused during the intra-operative and post-operative periods, the observed reductions were small and not clinically significant (WMD -0.15 units, 95%CI -0.30 to -0.01 units; WMD -0.44 units, 95%CI -0.65 to -0.22 units; respectively).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Platelet transfusion</HEADING>
<P>Ten trials reported data for the number of patients receiving allogeneic platelet transfusions. These trials included a total of 516 patients of whom 253 were randomised to PRP. The use of PRP reduced the rate of allogeneic platelet transfusion by a relative 51% (RR 0.49, 95%CI 0.28 to 0.85; I² = 7%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Volume of platelet transfusion</HEADING>
<P>Five trials reported data for the volume of allogeneic platelets transfused. These trials included a total of 321 patients of whom 162 were randomised to PRP. On average, the use of PRP reduced the volume of allogeneic platelet transfusions by around one unit per patient (WMD -0.96 units, 95%CI -0.96 to -0.37 units; I² = 45%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Fresh frozen plasma (FFP) transfusion</HEADING>
<P>Nine trials reported data for the number of patients receiving fresh frozen plasma (FFP) transfusions. These trials included a total of 484 patients of whom 248 were randomised to PRP. Although there appeared to be a trend toward a reduction in the number of patients receiving FFP transfusions in the PRP group, the result did not reach statistical significance (RR 0.44, 95%CI 0.17 to 1.12). Heterogeneity of treatment effect was statistically significant (p = 0.003; I² = 67%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Volume of FFP transfused</HEADING>
<P>Eleven trials reported data for the volume of FFP transfused (units). These trials included a total of 1027 patients of whom 513 were randomised to PRP. On average, the use of PRP resulted in a saving of around 0.5 units of FFP per patient (WMD -0.49 units, 95%CI -0.79 to -0.20 units). Heterogeneity between these trials was statistically significant (p = 0.09; I² = 46%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cryoprecipitate transfusion</HEADING>
<P>Three trials reported data for the number of patients receiving cryoprecipitate transfusions. These trials included a total of 152 patients of whom 77 were randomised to PRP. The relative risk of receiving a cryoprecipitate transfusion for those treated with PRP compared to control was 0.73 (95%CI 0.20 to 2.61; I² = 33%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Volume of cryoprecipitate transfused</HEADING>
<P>Three trials reported data for the volume of cryoprecipitate transfused (units). These trials included a total of 223 patients of whom 115 were randomised to PRP. On average there appeared to be a trend toward a decrease in the volume of cryoprecipitate transfused in PRP treated patients compared to control, however the result failed to reach statistical significance (WMD -0.76 units, 95%CI -2.18 to 0.66 units; I² = 51%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blood loss</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Intra-operative blood loss</HEADING>
<P>Five trials reported data for intra-operative blood loss. These trials included a total of 210 patients of whom 105 were randomised to PRP. The use of PRP did not appear to impact on intra-operative blood loss (WMD -127.54 mls, 95%CI -402.05 to 146.98 mls). Heterogeneity of treatment effect was statistically significant (p &lt; 0.00001; I² = 90%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Post-operative blood loss (0-12 hours)</HEADING>
<P>Four trials reported data for blood loss assessed during the first 12 hours of the post-operative period. These trials included a total of 654 patients of whom 324 were randomised to PRP. The use of PRP did not appear to reduce blood loss during this period of assessment (WMD -43.70 mls, 95%CI -89.76 to 2.37 mls; I² = 33%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Post-operative blood loss (0-24 hours)</HEADING>
<P>Nine trials reported data for blood loss assessed during the first 24 hours of the post-operative period. These trials included a total of 371 patients of whom 194 were randomised to PRP. PRP reduced blood loss on average by 247 mls per patient (WMD -247.17 mls, 95%CI -396.45 to -97.90 mls). Heterogeneity of treatment effect was statistically significant (p &lt; 0.00001; I² = 92%). (When the 
<LINK REF="STD-Boldt-1990" TYPE="STUDY">Boldt 1990</LINK>, <LINK REF="STD-Boldt-1993" TYPE="STUDY">Boldt 1993</LINK>, <LINK REF="STD-Menges-1996" TYPE="STUDY">Menges 1996</LINK> and <LINK REF="STD-Menges-1997" TYPE="STUDY">Menges 1997</LINK> trial data were excluded, the WMD was -161.05 mls (95% CI -367.59 to -45.49 mls).)
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Post-operative blood loss (0-48 hours)</HEADING>
<P>Two trials reported data for blood loss assessed during the first 48 hours of the post-operative period. These trials included a total of 58 patients of whom 29 were randomised to PRP. PRP reduced blood loss on average by 284 mls per patient (WMD -284.49 mls, 95%CI -348.75 to -220.24 mls; I² = 39%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Total post-operative blood loss</HEADING>
<P>Seven trials reported data for the total volume of blood lost during the post-operative period. These trials included a total of 787 patients of whom 389 were randomised to PRP. PRP reduced blood loss on average by 230 mls per patient (WMD -230.10 mls, 95%CI -374.42 to -85.79 mls). Heterogeneity of treatment effect was statistically significant (p &lt; 0.00001; I² = 82%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<P>Five trials of PRP reported mortality data. These trials included a total of 488 patients, of whom 246 were randomised to PRP. There were only two reported deaths, one occurred in the control group of the trial conducted by Christenson <I>et al</I> (<LINK REF="STD-Christenson-1996_x002f_a" TYPE="STUDY">Christenson 1996/a</LINK>) and the other occurred in the PRP group of the trial conducted by Wajon <I>et al</I> (<LINK REF="STD-Wajon-2001" TYPE="STUDY">Wajon 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Re-operation for bleeding</HEADING>
<P>Five trials of PRP reported data for re-operation for bleeding. These trials included a total of 529 patients of whom 265 were randomised to PRP. Ten patients in total, three in the PRP group and seven in the control group, required re-operation for bleeding. The relative risk for re-operation for bleeding in patients randomised to PRP compared to control was 0.56 (95%CI 0.15 to 2.13; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Stroke</HEADING>
<P>Only one trial reported data for stroke (<LINK REF="STD-Ford-2002" TYPE="STUDY">Ford 2002</LINK>). This single trial reported two events of stroke both occurring in patients randomised to PRP treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Length of hospital stay</HEADING>
<P>Five trials reported data for hospital length of stay. These trials included a total of 351 patients of whom 177 were randomised to PRP. On average the length of hospital stay was reduced by 1.04 days in those randomised to PRP compared to control. However, this result did not reach statistical significance (WMD -1.04 days, 95%CI -2.25 to 0.18 days; I² = 42%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Hypotension</HEADING>
<P>One trial provided data for hypotension (<LINK REF="STD-Shore_x002d_Lesserson-1995" TYPE="STUDY">Shore-Lesserson 1995</LINK>). This trial included a total of 44 patients of whom 25 were randomised to PRP. During the infusion of PRP, 15 of the 25 PRP patients (60%) and three of the 19 control patients (16%) experienced hypotension (mean arterial pressure &lt; 60mmHg) necessitating clinical intervention with intravenous calcium chloride (10-15 mg/kg) and/or epinephrine boluses. The relative risk of developing hypotension (MAP &lt; 60mmHg) during the same time period for PRP treated patients compared to control was 3.8 (95%CI 1.28 to 11.26).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-05-14 14:10:04 +0100" MODIFIED_BY="Emma M Sydenham">
<P>We identified 26 randomised trials of PRP carried out in 10 countries over a 13-year time period. These trials evaluated 1712 patients from similar patient populations. The results of the meta-analysis indicated that the use of PRP, in adult patients undergoing elective surgery, reduced the number of patients receiving a peri-operative allogeneic RBC transfusion by a relative 27% (RR 0.73, 95%CI 0.59 to 0.90), and provided an approximate 19% reduction in the average absolute risk (ARR) of receiving an allogeneic blood transfusion (RD -0.19, 95%C I -0.29 to -0.10), equating to a number needing to be treated (NNT) of 5.3. The results also showed that PRP reduced the rate of allogeneic platelet transfusion by a relative 51% (RR 0.49, 95%CI 0.28 to 0.85), reduced the volume of allogeneic platelets transfused (WMD -0.96 units, 95%CI -1.56 to -0.37 units), reduced the volume of FFP transfused (WMD -0.49 units, 95%CI -0.79 to -0.20 units), and reduced post-operative blood loss (0-24 hours) on average by 247 mls per patient (95%CI 97.90 to 396.45 mls). However, for the main outcomes studied, substantial heterogeneity in treatment effect was observed.</P>
<SUBSECTION>
<HEADING LEVEL="2">Sources of heterogeneity</HEADING>
<P>For the main outcomes of this review (number of patients receiving an allogeneic red cell transfusion and volume of blood transfused) significant heterogeneity was observed (p &lt; 0.00001; I² = 79%). The observed variation in treatment effects was in terms of both the size and the direction of effect with relative risk estimates for red cell transfusion exposure ranging from 0.07 to 1.29. Of the 22 trials that provided data for the proportion of patients exposed to allogeneic red cell transfusion, over half (68%) found that PRP did not statistically significantly reduce the probability of receiving a red cell transfusion. In an attempt to explain this marked heterogeneity for this outcome a number of subgroup analyses were performed. Trials were stratified by the type of operation, the use of a transfusion protocol, the use of cell salvage (a co-intervention), the mean platelet count of PRP, the mean platelet yield, the mean PRP volume collected, and trial methodological quality.</P>
<P>As 91% of the trials were conducted in the setting of cardiac surgery, and 18 of 22 trials reported the use of transfusion protocols, stratification of the data by these subgroups failed to explain the observed variability in treatment effects.</P>
<P>Subgroup analysis of trials that reported the use of cell salvage also failed to adequately explain the marked heterogeneity. For the 16 trials that reported the use of intra-operative cell salvage and provided data for the proportion of patients exposed to allogeneic blood transfusion, heterogeneity was statistically significant (p &lt; 0.00001; I² = 83%) with the relative risks (for receiving a red cell transfusion) ranging from 0.07 to 1.29. For the six trials that did not report the use of intra-operative cell salvage and provided data for the proportion of patients exposed to allogeneic blood transfusion, heterogeneity was statistically significant (p &lt; 0.005; I² = 70%) with the relative risks (for receiving a red cell transfusion) ranging from 0.09 to 1.28. Only three trials reported the use of post-operative cell salvage.</P>
<P>Mean platelet yield appeared to explain some of the variability in treatment effects. For the four trials that reported mean platelet yields of less than 1.8 x 10¹¹/L the relative risk (for exposure to red cell transfusion) was 0.98, compared to 0.48 for the two trials that reported mean platelet yields of between 2.5-2.9 x 10¹¹/L, and 0.31 for four trials that reported mean platelet yields of between 3.0-3.5 x 10¹¹/L. These results suggest that a higher mean platelet yield may be associated with a decrease in exposure to red cell transfusion. However, with such a small number of trials in each strata, these apparent associations may well be due to the play of chance.</P>
<P>Further subgroup analysis by the mean platelet count of PRP did not convincingly establish the reason for the heterogeneity in treatment effect for red cell transfusion. However, this subgroup analysis was hampered by the small number of trials in each of the four strata analysed. It should be noted that three of these four strata were dominated by trials conducted by the same research groups.</P>
<P>In exploring the potential sources of heterogeneity in treatment effect, it was important to determine whether there were differences (imbalance) between the intervention and control groups (within trials) in the proportion of patients exposed to those blood products that augment coagulation in the presence of microvascular bleeding (i.e. platelets, fresh frozen plasma (FFP), cryoprecipitate), potentially minimising exposure to allogeneic red cell transfusion. The concern therefore was confounding introduced by the use of co-interventions.</P>
<P>When the data for platelet, FFP, and cryoprecipitate transfusion were aggregated separately, differential transfusion of these blood products was quite apparent. The pooled relative risks showed PRP treatment was associated with statistically significant reductions in both exposure to platelets (RR 0.49, 95%CI 0.28 to 0.85), the volume of platelets transfused (WMD -0.96 units, 95%CI -1.56 to -0.37 units) and the volume of FFP transfused (WMD -0.49 units, 95%CI -0.79 to -0.20 units). Although there was a trend toward reduced exposure to both FFP and cryoprecipitate transfusion in those patients randomised to PRP, these results did not reach statistical significance (RR 0.44, 95%CI 0.17 to 1.12) and (RR 0.73, 95%CI 0.20 to 2.61), respectively. Overall these results indicate that PRP patients were not exposed any more frequently to these blood components (co-interventions) than the controls. Had PRP patients been transfused more frequently than the controls, confounding introduced by the use of these co-interventions may have biased the results in favour of PRP treatment.</P>
<P>As the majority of trials reported the use of protocols to guide the transfusion of platelets and FFP (82% of trials for platelets and 86% of trials for FFP), it is assumed that the decision to transfuse patients was based on well-defined haematological indicators rather than clinician subjectivity. Far fewer trials reported the use of protocols to guide the transfusion of cryoprecipitate (18%). However, there were insufficient numbers of studies to look separately at the effects of these transfusion protocols. Moreover, overall compliance with such transfusion protocols was not discussed by any of the trials reviewed. This is a particularly salient issue for randomised controlled trials where the main study outcome is a practice variable, that is, the decision to transfuse a patient with allogeneic red cells, rather than a clinical variable. Due to the degree of subjectivity involved in the decision to transfuse, it is conceivable that the main study outcome in these trials, allogeneic red cell transfusion, may have contributed to the observed heterogeneity.</P>
<P>The impact of trial methodological quality on treatment effect was difficult to determine, as all trials were of poor quality. No trial was judged as having adequate allocation concealment and only one trial were judged to be double-blind.</P>
<P>Trial size is another issue that requires further discussion. Of the 22 trials that provided data for the number of patients receiving an allogeneic red cell transfusion, only two trials had greater than 100 patients in each trial arm. The remaining 20 trials randomised between 10 and 65 patients to each trial arm. It is important to consider whether or not the results of these two larger trials have impacted on the overall results of the meta-analysis. Although the two largest trials (<LINK REF="STD-Armellin-1995" TYPE="STUDY">Armellin 1995</LINK>, <LINK REF="STD-Armellin-1997" TYPE="STUDY">Armellin 1997</LINK>) showed statistically significant reductions in exposure to allogeneic red cell transfusion with relative risk reductions of 31% (RR 0.69, 95%CI 0.55 to 0.86) and 25% (RR 0.75, 95%CI 0.61 to 0.93) respectively, in aggregate they provided 16.5% of the information (weight) in the analysis. Further, by removing the data for these two trials from the analysis, the results remained virtually unchanged, with the relative risk of exposure to allogeneic red cell transfusion changing from 0.73 (95%CI 0.59 to 0.90) to 0.69 (95%CI 0.53 to 0.91).</P>
<P>It is also difficult to say, with any great certainty, whether the results of the two larger trials (<LINK REF="STD-Armellin-1995" TYPE="STUDY">Armellin 1995</LINK>, <LINK REF="STD-Armellin-1997" TYPE="STUDY">Armellin 1997</LINK>) represent the true treatment effect of PRP, as both trials were conducted by the same research team and as such may not be generalisable to different populations in different geographical locations. Whether or not trial size had any impact on treatment effect (size and/or direction of effect) is difficult to quantify and answer conclusively. The most salient point of this discussion is that, the majority of trials were particularly small and in most instances, inadequately powered to detect the observed differences in transfusion exposure rates.</P>
<P>When trials were stratified by the transfusion trigger level, the results were inconsistent across subgroups. For the four trials that reported Hb trigger levels of 6.6-7.0g/dL, the risk of receiving an allogeneic RBC transfusion in those patients randomised to PRP was statistically significantly reduced on average by a relative 67% (RR 0.33, 95%CI 0.18 to 0.62). A statistically significant reduction was also observed for the four trials that reported higher Hb transfusion trigger levels of 9.0g/dL (RR 0.78, 95%CI 0.63 to 0.97). However, for the seven trials that reported using Hb transfusion trigger levels of 8.0-8.5g/dL the relative risk of receiving an allogeneic RBC transfusion in those patients randomised to PRP was not statistically significant (RR 0.89, 95%CI 0.0.64 to 1.25). For the three trials that reported using a Hb transfusion trigger of 10.0g/dL, a statistically non-significant increase in risk was observed (RR 1.10, 95%CI 0.59 to 2.07). As three of the four subgroups involved six trials performed by the same investigators (<LINK REF="STD-Armellin-1995" TYPE="STUDY">Armellin 1995</LINK>, <LINK REF="STD-Armellin-1997" TYPE="STUDY">Armellin 1997</LINK>, <LINK REF="STD-Christenson-1996_x002f_a" TYPE="STUDY">Christenson 1996/a</LINK>, <LINK REF="STD-Christenson-1996_x002f_b" TYPE="STUDY">Christenson 1996/b</LINK>, <LINK REF="STD-Menges-1996" TYPE="STUDY">Menges 1996</LINK>, <LINK REF="STD-Menges-1997" TYPE="STUDY">Menges 1997</LINK>), it is difficult to draw any firm conclusions from such analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Sources of bias</HEADING>
<P>The majority of trials (85%) were small, with less than 50 participants in each arm. Reliance on small trials raises concerns about the effects of publication bias. Funnel plot assessment revealed some evidence of publication bias in the form of a 'missing' population of small negative trials (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). As the presence of publication bias may lead to an over-estimation of benefit of treatment effect the results may need to be viewed with some degree of caution.</P>
<P>The main study outcome used in these trials was a practice variable - the decision to transfuse a patient with allogeneic red cells. This requires a degree of subjectivity on the part of clinicians, and as the majority of trials were unblinded, this is a source of bias which may have potentially influenced the results in favour of PRP.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Methodological quality of studies</HEADING>
<P>The overall methodological quality of the trials was poor (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). Of the 24 trials assessed for methodological quality, only one was judged to be double-blind, the method used to conceal the treatment allocation schedule was not described in any trial, and 79% of the trials failed to describe the method used to generate the allocation sequences (randomisation process). In light of the poor methodological quality of the trials reviewed, substantial biases (e.g. selection bias, performance bias), may have been introduced, exaggerating the true magnitude of beneficial effect of PRP.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Other clinical outcomes</HEADING>
<P>Mortality, re-operation for bleeding, and hospital length of stay did not appear to be influenced by the use of PRP. However, in individual trials the numbers of events were small, therefore it is difficult to draw any firm conclusions regarding the impact of PRP on important clinical outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Adverse effects of the PRP procedure</HEADING>
<P>As with any medical procedure, plateletpheresis is not without certain risks, the most common of which is hypotension. Of the 26 trials of platelet-rich plasmapheresis reviewed here, only one (<LINK REF="STD-Shore_x002d_Lesserson-1995" TYPE="STUDY">Shore-Lesserson 1995</LINK>) reported complications related to the procedure. This trial reported five episodes (20% of PRP patients) of moderate hypotension (mean arterial blood pressures (MAP) less than 60mmHg) during the collection phase of PRP. Three of these five patients were successfully treated with volume expansion and boluses of IV phenylephrine. Haemodynamic instability such as this may well be the result of inadequate fluid replacement during the withdrawal of blood into the plasmapheresis circuit leading to hypovolemia. A further 15 patients required treatment for hypotension during the infusion of PRP and were treated with epinephrine infusions and calcium chloride boluses (10-15mg/kg). As postulated by the authors, hypotension such as that experienced in this trial may have been attributable to hypocalcaemia caused by the infusion of large quantities of citrate (preservative agent used in the storage of PRP) during the rapid infusion of PRP. However, the PRP product, as reported by the authors, was administered slowly in patients with normal hepatic function. Such unexplained hypotension in patients with a history of cardiovascular disease undergoing CABG surgery is of concern. As this trial was the only one of 26 trials to report such significant hypotension in PRP treated patients, it may well be that certain aspects of the techniques employed differed to those of the other trials and therefore it is difficult to generalise these results. Although hypotension appears to be a relatively rare event in the use of PRP, the reviewers caution readers to the potential risk.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Clinical significance of results</HEADING>
<P>The true value of avoiding allogeneic blood transfusion remains debatable. Conceivably, those concerned with the risks of transfusion-transmitted disease will be more interested in avoiding transfusion completely, rather than reducing the volume of blood transfused (<LINK REF="REF-Henry-2007" TYPE="REFERENCE">Henry 2007</LINK>). However, the importance of avoiding transfusion depends on the probability of avoiding disease transmission, or other adverse effects that have been attributed to blood transfusion such as alloimmunisation, febrile non-haemolytic transfusion reaction, or immunosuppression (<LINK REF="REF-Blumberg-1997" TYPE="REFERENCE">Blumberg 1997</LINK>). The rate of transmission of HIV or viral hepatitis is very low in most developed countries, because of the quality of donor blood screening (<LINK REF="REF-Coyle-1999" TYPE="REFERENCE">Coyle 1999</LINK>, <LINK REF="REF-Whyte-1997" TYPE="REFERENCE">Whyte 1997</LINK>). However, this is not the case in developing countries where donor blood is inadequately screened, and the prevalence of viral pathogens amongst donors is high (<LINK REF="REF-Kimball-1995" TYPE="REFERENCE">Kimball 1995</LINK>, <LINK REF="REF-McFarland-1997" TYPE="REFERENCE">McFarland 1997</LINK>). In settings such as these there may be greater clinical value in a range of interventions that diminish or negate the need for allogeneic blood. However, the costs of such interventions may be prohibitive in developing countries.</P>
<P>The best evidence reviewed here applies to the use of platelet-rich plasmapheresis in elective adult surgery. The vast majority of the data have been collected in the context of cardiac surgery, where blood loss is often substantial. This review identified only one randomised trial of platelet-rich plasmapheresis in a setting other than cardiac surgery. Consequently, the applicability of the results to clinical settings where blood loss is minor are questionable. Although there are a number of interventions used in cardiac surgery to reduce perioperative allogeneic red cell transfusion, some are particularly expensive and do not represent cost-effective alternatives (<LINK REF="REF-Fergusson-1999_x002f_a" TYPE="REFERENCE">Fergusson 1999/a</LINK>). In the field of cardiac surgery, there is growing evidence that the use of anti-fibrinolytic drugs (aprotinin, tranexamic acid, epsilon aminocaproic acid), and the acceptance of lower transfusion thresholds, may offer the most effective approaches for managing the transfusion requirements of patients in this high-risk setting (<LINK REF="REF-Henry-2007" TYPE="REFERENCE">Henry 2007</LINK>, <LINK REF="REF-Hill-2001" TYPE="REFERENCE">Hill 2001</LINK>). However, the use of aprotinin in cardiac surgery has been questioned, with the results of the large randomised comparative trial conducted by Fergusson <I>et al </I>(<LINK REF="REF-Fergusson-2008" TYPE="REFERENCE">Fergusson 2008</LINK>) showing a higher rate of death in those patients randomised to aprotinin compared to those patients treated with either tranexamic acid (TXA) or epsilon aminocaproic acid (EACA). Although this trial (BART study) showed a modest reduction in the risk of massive bleeding in those patients treated with aprotinin (RR 0.79, 95%CI 0.59 to 1.05) the relative risk of death in the aprotinin group, as compared with that in both groups receiving lysine analogues (TXA and EACA), was 1.53 (95% CI 1.06 to 2.22). An updated meta-analysis conducted by Henry <I>et al</I> (<LINK REF="REF-Henry-2009" TYPE="REFERENCE">Henry 2009</LINK>), including the data from the BART study (<LINK REF="REF-Fergusson-2008" TYPE="REFERENCE">Fergusson 2008</LINK>), showed that the risk of death was consistently higher with the use of aprotinin compared to the lysine analogues. Based on their findings, Henry <I>et al</I> (<LINK REF="REF-Henry-2009" TYPE="REFERENCE">Henry 2009</LINK>) recommended that either TXA or EACA should be used to prevent bleeding after cardiac surgery rather than aprotinin.</P>
<P>As a relatively new technology the true efficacy of platelet-rich plasmapheresis is yet to be definitively ascertained. It is a procedure not without certain risks to patient health. This and other reviews (<LINK REF="REF-Hardy-1996" TYPE="REFERENCE">Hardy 1996</LINK>, <LINK REF="REF-Rubens-1998" TYPE="REFERENCE">Rubens 1998</LINK>, <LINK REF="REF-Ruel-2001" TYPE="REFERENCE">Ruel 2001</LINK>) have highlighted the potential for hypovolaemia, hypothermia (during the sequestration procedure), and citrate-induced hypocalcaemia (during the transfusion of the harvested platelets). Questions have also been raised about the quality of platelets harvested. Centrifugation during plateletpheresis has been shown to significantly impair platelet function to an extent that the platelets remain refractory to stimulation for a four to six-hour period (<LINK REF="REF-Gutensohn-1997" TYPE="REFERENCE">Gutensohn 1997</LINK>). Although platelet-rich plasmapheresis has been shown to reduce post-operative blood loss, it cannot limit intra-operative blood loss which can be significant in re-operative cardiac patients due to vascular adhesions (<LINK REF="REF-Rubens-1998" TYPE="REFERENCE">Rubens 1998</LINK>). Therefore, the use of PRP in this sub-group of patients appears not to be warranted. Another important issue is time. The trials reviewed here described sequestration times of 20-92 minutes. Whether plateletpheresis extends operative times is difficult to determine from the current literature as the studies generally reported 'surgery times' which do not necessarily include the time taken to insert lines, or prepare and operate equipment specific to PRP. Where platelet-rich plasmapheresis fits within the spectrum of potential alternatives to allogeneic red cell transfusion is currently unclear, as studies that examine its cost-effectiveness are yet to be identified.</P>
<P>On the basis of the current available evidence it is difficult to recommend the use of PRP for the purpose of minimising perioperative allogeneic blood transfusion in elective adult surgery. Further large, methodologically rigorous, randomised controlled trials of PRP are needed.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-05-11 05:22:16 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-05-11 05:22:16 +0100" MODIFIED_BY="[Empty name]">
<P>The use of platelet-rich plasmapheresis in adult elective surgery cannot be justified on the basis of the evidence reviewed, as better proven technologies are currently available.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Further large, methodologically rigorous, randomised controlled trials of PRP, using clinical outcomes, in different surgical procedures need to be conducted to clarify the efficacy of this technique.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS/>
<CONFLICT_OF_INTEREST MODIFIED="2008-09-17 18:20:46 +0100" MODIFIED_BY="Emma M Sydenham">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-05-14 13:48:01 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Danielle Anthony (University of Newcastle) conducted the original literature searches, obtained relevant papers, applied inclusion/exclusion criteria to retrieved papers and quality assessed trials; Paul Carless (University of Newcastle) updated literature searches, extracted study data, quality assessed trials, co-ordinated the project and co-wrote review; David Henry (University of Newcastle) provided methodological expertise and co-wrote review; Dianne O'Connell (University of Newcastle) provided statistical consultancy for the review; Fraser Rubens (Ottawa Heart Institute) provided expert opinion.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2011-02-16 16:01:08 +0000" MODIFIED_BY="Emma M Sydenham">
<P>The editorial group is aware that a clinical trial by Prof. Joachim Boldt has been found to have been fabricated (<A HREF="http://archie.cochrane.org/sections/documents/view?document=540099072011521412&amp;format=REVMAN#REF-Boldt-2009">Boldt 2009</A>). As the editors who revealed this fabrication point out (<A HREF="http://archie.cochrane.org/sections/documents/view?document=540099072011521412&amp;format=REVMAN#REF-Reinhart-2011">Reinhart 2011</A>; <A HREF="http://archie.cochrane.org/sections/documents/view?document=540099072011521412&amp;format=REVMAN#REF-Shafer-2011">Shafer 2011</A>), this casts some doubt on the veracity of other studies by the same author. All Cochrane Injuries Group reviews which include studies by this author have therefore been edited to show the results with this author's trials included and excluded. Readers can now judge the potential impact of trials by this author (
<LINK REF="STD-Boldt-1990" TYPE="STUDY">Boldt 1990</LINK>, <LINK REF="STD-Boldt-1993" TYPE="STUDY">Boldt 1993</LINK>, <LINK REF="STD-Menges-1996" TYPE="STUDY">Menges 1996</LINK>, <LINK REF="STD-Menges-1997" TYPE="STUDY">Menges 1997</LINK>) on the conclusions of the review.
</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-02-16 15:08:40 +0000" MODIFIED_BY="Emma M Sydenham">
<STUDIES MODIFIED="2009-05-14 14:16:18 +0100" MODIFIED_BY="Emma M Sydenham">
<INCLUDED_STUDIES MODIFIED="2009-03-11 03:18:16 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Armellin-1995" NAME="Armellin 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;1. Armellin G, Sorbara C, Bonato R, Pittarello D, Toniolo E, Giron GP. Effects of intraoperative plasmapheresis in cardiac surgery.  Acta Anesthesia Italica  1995;46(Suppl. 1):17-22.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Armellin G, Sorbara C, Bonato R, Pittarello D, Toniolo E, Giron GP</AU>
<TI>Effects of intraoperative plasmapheresis in cardiac surgery</TI>
<SO>Acta Anesthesia Italica</SO>
<YR>1995</YR>
<VL>46</VL>
<NO>Suppl. 1</NO>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Armellin-1997" NAME="Armellin 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;2. Armellin G, Sorbara C, Bonato R, Pittarello D, Dal Cero P, Giron G. Intraoperative plasmapheresis in cardiac surgery.  Journal of Cardiothoracic &amp;amp; Vascular Anesthesia  1997;11(1):13-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Armellin G, Sorbara C, Bonato R, Pittarello D, Dal Cero P, Giron G</AU>
<TI>Intraoperative plasmapheresis in cardiac surgery</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>1</NO>
<PG>13-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boey-1993" NAME="Boey 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;3. Boey SK, Ong BC, Dhara SS. Preoperative plateletpheresis does not reduce blood loss during cardiac surgery.  Canadian Journal of Anaesthesia  1993;40(9):844-50.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boey SK, Ong BC, Dhara SS</AU>
<TI>Preoperative plateletpheresis does not reduce blood loss during cardiac surgery</TI>
<SO>Canadian Journal of Anaesthesia</SO>
<YR>1993</YR>
<VL>40</VL>
<NO>9</NO>
<PG>844-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boldt-1990" NAME="Boldt 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;4. Boldt J, von Bormann B, Kling D, Jacobi M, Moosdorf R, Hempelmann G. Preoperative plasmapheresis in patients undergoing cardiac surgery procedures.  Anesthesiology  1990;72(2):282-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, von Bormann B, Kling D, Jacobi M, Moosdorf R, Hempelmann G</AU>
<TI>Preoperative plasmapheresis in patients undergoing cardiac surgery procedures</TI>
<SO>Anesthesiology</SO>
<YR>1990</YR>
<VL>72</VL>
<NO>2</NO>
<PG>282-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boldt-1993" NAME="Boldt 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;6. Boldt J, Zickmann B, Ballesteros M, Oehmke S, Stertmann F, Hempelmann G. Influence of acute preoperative plasmapheresis on platelet function in cardiac surgery. [see comments].  Journal of Cardiothoracic &amp;amp; Vascular Anesthesia  1993;7(1):4-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Zickmann B, Ballesteros M, Oehmke S, Stertmann F, Hempelmann G</AU>
<TI>Influence of acute preoperative plasmapheresis on platelet function in cardiac surgery</TI>
<SO>Journal of Cardiothoracic &amp; Vascular Anesthesia</SO>
<YR>1993</YR>
<VL>7</VL>
<NO>1</NO>
<PG>4-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christenson-1996_x002f_a" NAME="Christenson 1996/a" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;7. Christenson JT, Reuse J, Badel P, Simonet F, Schmuziger M. Plateletpheresis before redo CABG diminishes excessive blood transfusion. [see comments].  Annals of Thoracic Surgery  1996;62(5):1373-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christenson JT, Reuse J, Badel P, Simonet F, Schmuziger M</AU>
<TI>Plateletpheresis before redo CABG diminishes excessive blood transfusion</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1996</YR>
<VL>62</VL>
<NO>5</NO>
<PG>1373-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christenson-1996_x002f_b" MODIFIED="2008-09-17 18:24:17 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Christenson 1996/b" YEAR="1996">
<REFERENCE MODIFIED="2008-09-17 18:24:17 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christenson JT, Reuse J, Badel P, Nowicki B, Simonet F, Schmuziger M</AU>
<TI>Autologous platelet sequestration in patients undergoing coronary artery bypass grafting</TI>
<SO>European Journal of Cardio-Thoracic Surgery</SO>
<YR>1996</YR>
<VL>10</VL>
<PG>1083-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DelRossi-1990" NAME="DelRossi 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;DelRossi AJ, Cernaianu AC, Vertrees RA, Wacker CJ, Fuller SJ, Cilley JHJ, Baldino WA. Platelet-rich plasma reduces postoperative blood loss after cardiopulmonary bypass. Journal of Thoracic &amp;amp; Cardiovascular Surgery .1990;100(2):281-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DelRossi AJ, Cernaianu AC, Vertrees RA, Wacker CJ, Fuller SJ, Cilley JHJ, Baldino WA</AU>
<TI>Platelet-rich plasma reduces postoperative blood loss after cardiopulmonary bypass</TI>
<SO>Journal of Thoracic &amp; Cardiovascular Surgery</SO>
<YR>1990</YR>
<VL>100</VL>
<NO>2</NO>
<PG>281-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ereth-1993" NAME="Ereth 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;10. Ereth MH, Oliver WCJ, Beynen FM, Mullany CJ, Orszulak TA, Santrach PJ, Ilstrup DM, Weaver AL, Williamson KR. Autologous platelet-rich plasma does not reduce transfusion of homologous blood products in patients undergoing repeat valvular surgery. [see comments].  Anesthesiology  1993;79(3):540-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ereth MH, Oliver WCJ, Beynen FM, Mullany CJ, Orszulak TA, Santrach PJ, Ilstrup DM, Weaver AL, Williamson KR</AU>
<TI>Autologous platelet-rich plasma does not reduce transfusion of homologous blood products in patients undergoing repeat valvular surgery</TI>
<SO>Anesthesiology</SO>
<YR>1993</YR>
<VL>79</VL>
<NO>3</NO>
<PG>540-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farouk-2003" MODIFIED="2009-03-11 03:18:16 +0000" MODIFIED_BY="[Empty name]" NAME="Farouk 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-03-11 03:18:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farouk M, El-Halafawy Y, Hememy W, Khedr H, Sadek H</AU>
<TI>Effect of autologous platelet-rich plasma on blood loss and haemostatic functions in patients undergoing open-heart surgery</TI>
<SO>Egyptian Journal of Anaesthesia</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>3</NO>
<PG>225-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferraris-1993" NAME="Ferraris 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;11. Ferraris VA, Berry WR, Klingman RR. Comparison of blood reinfusion techniques used during coronary artery bypass grafting.  Annals of Thoracic Surgery  1993;56(3):433-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferraris VA, Berry WR, Klingman RR</AU>
<TI>Comparison of blood reinfusion techniques used during coronary artery bypass grafting</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1993</YR>
<VL>56</VL>
<NO>3</NO>
<PG>433-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ford-2002" MODIFIED="2009-03-04 01:57:02 +0000" MODIFIED_BY="[Empty name]" NAME="Ford 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-03-04 01:57:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ford SM, Unsworth-White MJ, Aziz T, Tooze JA, van Besouw JP, Bevan DH, Treasure T</AU>
<TI>Platelet pheresis is not a useful adjunct to blood-sparing strategies in cardiac surgery</TI>
<SO>Journal of Cardiothoracic &amp; Vascular Anesthesia</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>3</NO>
<PG>321-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Godet-1995" NAME="Godet 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;12. Godet G, Canessa R, Arock M, Baron JF, Kieffer E, Viars P. [Effects of platelet-rich plasma on hemostasis and transfusion requirement in vascular surgery]. [see comments]. [French].  Annales Francaises d Anesthesie et de Reanimation  1995;14(3):265-70.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Godet G, Canessa R, Arock M, Baron JF, Kieffer E, Viars P</AU>
<TI>Effects of platelet-rich plasma on hemostasis and transfusion requirement in vascular surgery</TI>
<SO>Annales Francaises d Anesthesie et de Reanimation</SO>
<YR>1995</YR>
<VL>14</VL>
<NO>3</NO>
<PG>265-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1990" NAME="Jones 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;13. Jones JW, McCoy TA, Rawitscher RE, Lindsley DA. Effects of intraoperative plasmapheresis on blood loss in cardiac surgery.  Annals of Thoracic Surgery  1990;49(4):585-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones JW, McCoy TA, Rawitscher RE, Lindsley DA</AU>
<TI>Effects of intraoperative plasmapheresis on blood loss in cardiac surgery</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1990</YR>
<VL>49</VL>
<NO>4</NO>
<PG>585-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klein-2001" NAME="Klein 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;14. Klein M, Probst C, Richter N-O, Zotz R, Schulte HD, Gams E. The preoperative harvesting of autologous platelets in order to reduce homologous blood transfusions in cardiac surgery.  Zeitschrift fur Herz-, Thorax- und Gefasschirurgie  2001;15(2):43-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klein M, Probst C, Richter N-O, Zotz R, Schulte HD, Gams E</AU>
<TI>The preoperative harvesting of autologous platelets in order to reduce homologous blood transfusions in cardiac surgery</TI>
<SO>Zeitschrift fur Herz-, Thorax- und Gefasschirurgie</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>2</NO>
<PG>43-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-1998" MODIFIED="2008-09-17 18:24:31 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Liu 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-09-17 18:24:31 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu YC, Tsai TP</AU>
<TI>The effect of coagulation protection with combination of epsilon aminocaproic acid and plasma saver in open-heart surgery</TI>
<SO>Acta Anaesthesiology Singapore</SO>
<YR>1998</YR>
<VL>36</VL>
<PG>149-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menges-1996" NAME="Menges 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;15. Menges T, Wagner RM, Welters I, Ruwoldt R, Boldt J, Hempelmann G. The role of the protein C-thrombomodulin system and fibrinolysis during cardiovascular surgery: influence of acute preoperative plasmapheresis.  Journal of Cardiothoracic &amp;amp; Vascular Anesthesia  1996;10(4):482-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Menges T, Wagner RM, Welters I, Ruwoldt R, Boldt J, Hempelmann G</AU>
<TI>The role of the protein C-thrombomodulin system and fibrinolysis during cardiovascular surgery: influence of acute preoperative plasmapheresis</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>4</NO>
<PG>482-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menges-1997" NAME="Menges 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;16. Menges T, Welters I, Wagner RM, Boldt J, Dapper F, Hempelmann G. The influence of acute preoperative plasmapheresis on coagulation tests, fibrinolysis, blood loss and transfusion requirements in cardiac surgery.  European Journal of Cardio-Thoracic Surgery  1997;11(3):557-63.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Menges T, Welters I, Wagner RM, Boldt J, Dapper F, Hempelmann G</AU>
<TI>The influence of acute preoperative plasmapheresis on coagulation tests, fibrinolysis, blood loss and transfusion requirements in cardiac surgery</TI>
<SO>European Journal of Cardio-Thoracic Surgery</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>3</NO>
<PG>557-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quigley-1995" NAME="Quigley 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;17. Quigley RL, Perkins JA, Caprini JA, Haney E, Switzer SS, Wallock ME, Hoff WJ, Kuehn BE, Arentzen CE, Alexander JC. The haemostatic effectiveness of autologous platelet rich plasma sequestered after heparin administration and institution of cardiopulmonary bypass.  Perfusion  1995;10(2):101-10.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quigley RL, Perkins JA, Caprini JA, Haney E, Switzer SS, Wallock ME, Hoff WJ, Kuehn BE, Arentzen CE, Alexander JC</AU>
<TI>The haemostatic effectiveness of autologous platelet rich plasma sequestered after heparin administration and institution of cardiopulmonary bypass</TI>
<SO>Perfusion</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>2</NO>
<PG>101-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Safwat-2002" MODIFIED="2009-03-04 01:54:54 +0000" MODIFIED_BY="[Empty name]" NAME="Safwat 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-03-04 01:53:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Safwat AM, Bush R, Prevec W, Reitan JA</AU>
<TI>Intraoperative use of platelet-plasmapheresis in vascular surgery</TI>
<SO>Journal of Clinical Anesthesia</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>1</NO>
<PG>10-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shore_x002d_Lesserson-1995" NAME="Shore-Lesserson 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;19. Shore-Lesserson L, Reich DL, DePerio M, Silvay G. Autologous platelet-rich plasmapheresis: risk versus benefit in repeat cardiac operations. [see comments].  Anesthesia &amp;amp; Analgesia  1995;81(2):229-35.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shore-Lesserson L, Reich DL, DePerio M, Silvay G</AU>
<TI>Autologous platelet-rich plasmapheresis: risk versus benefit in repeat cardiac operations</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1995</YR>
<VL>81</VL>
<NO>2</NO>
<PG>229-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stammers-1993" NAME="Stammers 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;20. Stammers AH, Kratz J, Johnson T, Crumbley J, Merrill J. Hematological assessment of patients undergoing plasmapheresis during cardiac surgery.  Journal of Extra-Corporeal Technology  1993;25(1):6-14.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stammers AH, Kratz J, Johnson T, Crumbley J, Merrill J</AU>
<TI>Hematological assessment of patients undergoing plasmapheresis during cardiac surgery</TI>
<SO>Journal of Extra-Corporeal Technology</SO>
<YR>1993</YR>
<VL>25</VL>
<NO>1</NO>
<PG>6-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stover-2000" NAME="Stover 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;22. Stover EP, Siegel LC, Hood PA, O'Riordan GE, McKenna TR. Platelet-rich plasma sequestration, with therapeutic platelet yields, reduces allogeneic transfusion in complex cardiac surgery.  Anesthesia &amp;amp; Analgesia  2000;90(3):509-16.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stover EP, Siegel LC, Hood PA, O'Riordan GE, McKenna TR</AU>
<TI>Platelet-rich plasma sequestration, with therapeutic platelet yields, reduces allogeneic transfusion in complex cardiac surgery</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2000</YR>
<VL>90</VL>
<NO>3</NO>
<PG>509-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Triulzi-1995" NAME="Triulzi 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Triulzi DJ, Gilmor GD, Ness PM, Baumgartner WA, Schultheis LW</AU>
<TI>Efficacy of autologous fresh whole blood or platelet-rich plasma in adult cardiac surgery</TI>
<SO>Transfusion</SO>
<YR>1995</YR>
<VL>35</VL>
<NO>8</NO>
<PG>627-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wajon-2001" MODIFIED="2009-03-04 01:54:29 +0000" MODIFIED_BY="[Empty name]" NAME="Wajon 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-03-04 01:54:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wajon P, Gibson J, Calcroft R, Hughes C, Thrift B</AU>
<TI>Intraoperative plateletpheresis and autologous platelet gel do not reduce chest tube drainage or allogeneic blood transfusion after reoperative coronary artery bypass graft</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>2001</YR>
<VL>93</VL>
<NO>3</NO>
<PG>536-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wong-1994" NAME="Wong 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;25. Wong CA, Franklin ML, Wade LD. Coagulation tests, blood loss, and transfusion requirements in platelet-rich plasmapheresed versus nonpheresed cardiac surgery patients.  Anesthesia &amp;amp; Analgesia  1994;78(1):29-36.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wong CA, Franklin ML, Wade LD</AU>
<TI>Coagulation tests, blood loss, and transfusion requirements in platelet-rich plasmapheresed versus nonpheresed cardiac surgery patients</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1994</YR>
<VL>78</VL>
<NO>1</NO>
<PG>29-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-05-14 14:16:18 +0100" MODIFIED_BY="Emma M Sydenham">
<STUDY DATA_SOURCE="PUB" ID="STD-Reich-1991" NAME="Reich 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;18. Reich DL, Koorn R, Vitale S, DePerio M, Silvay G. Platelet-rich plasmapheresis during cardiac reoperations.  Anesthesiology  1991;75(3A):A987&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reich DL, Koorn R, Vitale S, DePerio M, Silvay G</AU>
<TI>Platelet-rich plasmapheresis during cardiac reoperations</TI>
<SO>Anesthesiology</SO>
<YR>1991</YR>
<VL>75</VL>
<NO>3A</NO>
<PG>A987</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stover-1996" MODIFIED="2009-05-14 14:16:18 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Stover 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-05-14 14:16:18 +0100" MODIFIED_BY="Emma M Sydenham" NOTES="&lt;p&gt;21. Stover EP, Siegel LC, Hood PA, O'Riordan GE. Platelet-rich plasmapheresis with therapeutc platelet yield reduces allogemic red blood cell and platelet transfusions in high-risk cardiac surgery.  Anesthesiology  1996;85(3A):A68&lt;/p&gt;" NOTES_MODIFIED="2009-05-14 14:16:18 +0100" NOTES_MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stover EP, Siegel LC, Hood PA, O'Riordan GE</AU>
<TI>Platelet-rich plasmapheresis with therapeutic platelet yield reduces allogeneic red blood cell and platelet transfusions in high-risk cardiac surgery</TI>
<SO>Anesthesiology</SO>
<YR>1996</YR>
<VL>85</VL>
<NO>3A</NO>
<PG>A68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stover-1997" NAME="Stover 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stover EP, Siegel LC, Hood PA</AU>
<TI>Platelet-rich plasmapheresis reduces allogeneic platelet transfusions and cost in cardiac surgery</TI>
<SO>British Journal of Anaesthesiology</SO>
<YR>1997</YR>
<VL>78</VL>
<NO>Suppl. 2</NO>
<PG>35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tobe-1993" MODIFIED="2009-03-06 01:35:09 +0000" MODIFIED_BY="[Empty name]" NAME="Tobe 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-03-06 01:35:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tobe CE, Vocelka C, Sepulvada R, Gillis B, Nessly M, Verrier ED, Hofer BO</AU>
<TI>Infusion of autologous platelet rich plasma does not reduce blood loss and product use after coronary artery bypass. A prospective, randomized, blinded study</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1993</YR>
<VL>105</VL>
<NO>6</NO>
<PG>1007-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Triulzi-1992" NAME="Triulzi 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Triulzi DJ, Gilmore GD, Ness PM, Schultheis L, Baumgartner WA</AU>
<TI>A prospective randomised trial of fresh autologous blood products in adult cardiac surgery</TI>
<SO>Blood</SO>
<YR>1992</YR>
<VL>80</VL>
<NO>10, Suppl. 1</NO>
<PG>363a</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-03-04 01:54:01 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-02-16 15:08:40 +0000" MODIFIED_BY="Emma M Sydenham">
<ADDITIONAL_REFERENCES MODIFIED="2011-02-16 15:08:40 +0000" MODIFIED_BY="Emma M Sydenham">
<REFERENCE ID="REF-Blumberg-1997" MODIFIED="2008-09-17 18:25:11 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Blumberg 1997" TYPE="JOURNAL_ARTICLE">
<AU>Blumberg N</AU>
<TI>Allogeneic transfusion and infection: economic and clinical implications</TI>
<SO>Seminars in Hematolology.</SO>
<YR>1997</YR>
<VL>34</VL>
<NO>3 Suppl 2</NO>
<PG>34-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boldt-1995" MODIFIED="2008-09-17 18:25:41 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Boldt 1995" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J</AU>
<TI>Acute platelet-rich plasmapheresis for cardiac surgery</TI>
<SO>Journal of Cardiothoracic &amp; Vascular Anesthesia</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>1</NO>
<PG>79-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boldt-2009" MODIFIED="2011-02-16 15:08:40 +0000" MODIFIED_BY="Emma M Sydenham" NAME="Boldt 2009" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Suttner S, Brosch C, Lehmann A, Roehm K, Mengitsu A</AU>
<TI>Cardiopulminary bypass priming using a high dose of a balanced hydroxyethyl starch versus an albumin-based priming strategy</TI>
<SO>Anesthesia &amp; Analgesia</SO>
<YR>2009</YR>
<VL>109</VL>
<PG>1752-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bryson-1998" NAME="Bryson 1998" TYPE="JOURNAL_ARTICLE">
<AU>Bryson GL, Laupacis A, Wells GA</AU>
<TI>Does acute normovolemic hemodilution reduce perioperative allogeneic transfusion? A meta-analysis. The International Study of Perioperative Transfusion</TI>
<SO>Anesthesia &amp; Analgesia.</SO>
<YR>1998</YR>
<VL>86</VL>
<NO>1</NO>
<PG>9-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coyle-1999" NAME="Coyle 1999" TYPE="JOURNAL_ARTICLE">
<AU>Coyle D, Lee KM, Fergusson DA, Laupacis A</AU>
<TI>Economic analysis of erythropoietin use in orthopaedic surgery</TI>
<SO>Transfusion Medicine.</SO>
<YR>1999</YR>
<VL>9</VL>
<NO>1</NO>
<PG>21-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2009-05-14 14:03:13 +0100" MODIFIED_BY="Emma M Sydenham" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials.</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1996" MODIFIED="2008-08-20 12:31:38 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Dickersin 1996" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Larson K</AU>
<TI>Establishing and maintaining an international register of RCTs (Computer Program)</TI>
<SO>Oxford. United Kingdom: Cochrane Collaboration.</SO>
<YR>1996</YR>
<PB>Cochrane Collaboration</PB>
<CY>Oxford.United Kingdom.(UK)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fergusson-1999_x002f_a" MODIFIED="2009-05-14 14:03:22 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Fergusson 1999/a" TYPE="JOURNAL_ARTICLE">
<AU>Fergusson D, van Walraven C, Coyle D, Laupacis A</AU>
<TI>Economic evaluations of technologies to minimize perioperative transfusion: a systematic review of published studies. International Study of Peri-operative Transfusion (ISPOT) investigators</TI>
<SO>Transfusion Medicine Reviews.</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>2</NO>
<PG>106-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fergusson-2008" MODIFIED="2009-05-14 14:03:58 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Fergusson 2008" TYPE="JOURNAL_ARTICLE">
<AU>Fergusson DA, Hebert PC, Mazer D, Fremes S, MacAdams C, Murkin JM, Teoh K, et al</AU>
<TI>A comparison of aprotinin and lysine analogues in high-risk cardiac surgery</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>358</VL>
<NO>22</NO>
<PG>2319-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Forgie-1998" MODIFIED="2009-05-14 14:04:13 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Forgie 1998" TYPE="JOURNAL_ARTICLE">
<AU>Forgie MA, Wells PS, Laupacis A, Fergusson D</AU>
<TI>Preoperative autologous donation decreases allogeneic transfusion but increases exposure to all red blood cell transfusion: results of a meta-analysis. International Study of Perioperative Transfusion (ISPOT) Investigators</TI>
<SO>Archives of Internal Medicine.</SO>
<YR>1998</YR>
<VL>158</VL>
<NO>6</NO>
<PG>610-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilcher-1989" MODIFIED="2009-05-14 14:04:24 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Gilcher 1989" TYPE="JOURNAL_ARTICLE">
<AU>Gilcher RO</AU>
<TI>Product quality and storage. Experience on over 600 cases</TI>
<SO>Proceeding Autologous Platelet-Rich Plasma Symposium. Baltimore, Haemonetics Corporation</SO>
<YR>1989</YR>
<VL>September 10</VL>
<PG>18-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gravlee-1994" MODIFIED="2008-09-17 18:26:16 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Gravlee 1994" TYPE="JOURNAL_ARTICLE">
<AU>Gravlee GP</AU>
<TI>Effectiveness of intraoperative autologous whole blood and platelet-rich plasma in cardiac surgery</TI>
<SO>Annals of the Academy of Medicine, Singapore.</SO>
<YR>1994</YR>
<VL>23</VL>
<NO>6 Suppl</NO>
<PG>65-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gutensohn-1997" MODIFIED="2008-09-17 18:26:03 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Gutensohn 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gutensohn K, Maerz M, Kuehnl P</AU>
<TI>Alteration of platelet-associated membrane glycoproteins during extracorporeal apheresis of peripheral blood progenitor cells</TI>
<SO>Journal of Hematotherapy</SO>
<YR>1997</YR>
<VL>6</VL>
<NO>4</NO>
<PG>315-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hardy-1996" MODIFIED="2008-09-17 18:26:22 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Hardy 1996" TYPE="JOURNAL_ARTICLE">
<AU>Hardy JF, Belisle S, Janvier G, Samama M</AU>
<TI>Reduction in requirements for allogeneic blood products: nonpharmacologic methods</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1996</YR>
<VL>62</VL>
<NO>6</NO>
<PG>1935-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henry-2007" MODIFIED="2009-05-11 05:59:13 +0100" MODIFIED_BY="[Empty name]" NAME="Henry 2007" TYPE="COCHRANE_REVIEW">
<AU>Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, McClelland B, Laupacis A, Fergusson D</AU>
<TI>Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<PB>John Wiley &amp; Sons, Ltd.</PB>
<IDENTIFIERS MODIFIED="2009-05-11 05:59:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-05-11 05:59:13 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001886.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Henry-2009" MODIFIED="2009-05-11 07:14:30 +0100" MODIFIED_BY="[Empty name]" NAME="Henry 2009" TYPE="JOURNAL_ARTICLE">
<AU>Henry DA, Carless P, Fergusson D, Laupacis A</AU>
<TI>The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis</TI>
<SO>CMAJ</SO>
<YR>2009</YR>
<VL>180</VL>
<NO>2</NO>
<PG>183-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2009-03-04 01:18:48 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2009-05-14 14:04:38 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hill-2001" MODIFIED="2009-05-14 14:16:54 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Hill 2001" TYPE="COCHRANE_REVIEW">
<AU>Hill SR, Carless PA, McClelland B, Henry DA, Henderson KM, Carson J, Hebert PC</AU>
<TI>Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-08-20 12:35:30 +0100" MODIFIED_BY="Emma M Sydenham">
<IDENTIFIER MODIFIED="2008-08-20 12:35:30 +0100" MODIFIED_BY="Emma M Sydenham" TYPE="DOI" VALUE=" 10.1002/14651858.CD002042"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Huet-1999" MODIFIED="2008-09-17 18:26:41 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Huet 1999" TYPE="JOURNAL_ARTICLE">
<AU>Huet C, Salmi LR, Fergusson D, Koopman-van Gemert AW, Rubens F, Laupacis</AU>
<TI>A meta-analysis of the effectiveness of cell salvage to minimize perioperative allogeneic blood transfusion in cardiac and orthopedic surgery. International Study of Perioperative Transfusion (ISPOT) Investigators</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1999</YR>
<VL>89</VL>
<NO>4</NO>
<PG>861-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kimball-1995" MODIFIED="2008-09-17 18:26:58 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Kimball 1995" TYPE="JOURNAL_ARTICLE">
<AU>Kimball AM, Berkley S, Ngugi E, Gayle H</AU>
<TI>International aspects of the AIDS/HIV epidemic</TI>
<SO>Annual Review of Public Health</SO>
<YR>1995</YR>
<VL>16</VL>
<PG>253-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Laupacis-1997" MODIFIED="2008-09-17 18:27:03 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Laupacis 1997" TYPE="JOURNAL_ARTICLE">
<AU>Laupacis A, Fergusson D</AU>
<TI>Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1997</YR>
<VL>85</VL>
<NO>6</NO>
<PG>1258-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mangano-2006" MODIFIED="2009-05-13 13:32:23 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Mangano 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mangano DT, Tudor IC, Dietzel C, Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation</AU>
<TI>The risk associated with aprotinin in cardiac surgery</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<NO>4</NO>
<PG>353-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mangano-2007" MODIFIED="2009-05-12 01:35:22 +0100" MODIFIED_BY="[Empty name]" NAME="Mangano 2007" TYPE="JOURNAL_ARTICLE">
<AU>Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, et al</AU>
<TI>Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery</TI>
<SO>JAMA</SO>
<YR>2007</YR>
<VL>297</VL>
<NO>5</NO>
<PG>471-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McFarland-1997" MODIFIED="2008-09-22 16:29:31 +0100" MODIFIED_BY="Emma M Sydenham" NAME="McFarland 1997" TYPE="JOURNAL_ARTICLE">
<AU>McFarland W, Mvere D, Shandera W, Reingold A</AU>
<TI>Epidemiology and prevention of transfusion-associated human immunodeficiency virus transmission in sub-Saharan Africa</TI>
<SO>Vox Sanguinis</SO>
<YR>1997</YR>
<VL>72</VL>
<NO>2</NO>
<PG>85-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ray-2008" MODIFIED="2009-05-12 01:38:42 +0100" MODIFIED_BY="[Empty name]" NAME="Ray 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ray WA</AU>
<TI>Learning from aprotinin--mandatory trials of comparative efficacy and safety needed</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>358</VL>
<NO>8</NO>
<PG>840-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reinhart-2011" MODIFIED="2011-02-11 13:21:06 +0000" MODIFIED_BY="[Empty name]" NAME="Reinhart 2011" TYPE="JOURNAL_ARTICLE">
<AU>Reinhart K, Takala J</AU>
<TI>Hydroxyethyl Starches: What Do We Still Know?</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2011</YR>
<VL>112</VL>
<NO>3</NO>
<PG>507-511</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager" MODIFIED="2009-05-13 13:22:55 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Review Manager" TYPE="COMPUTER_PROGRAM">
<AU>The Nordic Cochrane Centre</AU>
<TI>Review Manager</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robinson-2002" MODIFIED="2009-05-11 06:07:35 +0100" MODIFIED_BY="[Empty name]" NAME="Robinson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Robinson KA, Dickersin K</AU>
<TI>Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>150-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rubens-1998" MODIFIED="2008-09-17 18:27:20 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Rubens 1998" TYPE="JOURNAL_ARTICLE">
<AU>Rubens FD, Fergusson D, Wells PS, Huang M, McGowan JL, Laupacis A</AU>
<TI>Platelet-rich plasmapheresis in cardiac surgery: a meta-analysis of the effect on transfusion requirements</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1998</YR>
<VL>116</VL>
<NO>4</NO>
<PG>641-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ruel-2001" MODIFIED="2008-09-17 18:27:48 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Ruel 2001" TYPE="JOURNAL_ARTICLE">
<AU>Ruel MA, Rubens FD</AU>
<TI>Non-pharmacological strategies for blood conservation in cardiac surgery</TI>
<SO>Canadian Journal of Anaesthesia</SO>
<YR>2001</YR>
<VL>48</VL>
<NO>4(Suppl), April</NO>
<PG>S13-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Safwat-1998" MODIFIED="2008-09-17 18:27:56 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Safwat 1998" TYPE="JOURNAL_ARTICLE">
<AU>Safwat AM</AU>
<TI>The intraoperative use of plateletpheresis: A review</TI>
<SO>Seminars in Anesthesia</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>3</NO>
<PG>216-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2009-05-14 14:05:16 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, et al</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shafer-2011" MODIFIED="2011-02-11 13:10:46 +0000" MODIFIED_BY="[Empty name]" NAME="Shafer 2011" TYPE="JOURNAL_ARTICLE">
<AU>Shafer SL</AU>
<TI>Shadow of Doubt</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>March 2011</YR>
<VL>112</VL>
<NO>3</NO>
<PG>498-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Triulzi-1995" MODIFIED="2008-09-17 18:27:38 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Triulzi 1995" TYPE="JOURNAL_ARTICLE">
<AU>Triulzi DJ, Ness PM</AU>
<TI>Intraoperative hemodilution and autologous platelet rich plasma collection: two techniques for collecting fresh autologous blood</TI>
<SO>Transfusion Science</SO>
<YR>1995</YR>
<VL>16</VL>
<NO>1</NO>
<PG>33-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whyte-1997" MODIFIED="2008-09-17 18:28:09 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Whyte 1997" TYPE="JOURNAL_ARTICLE">
<AU>Whyte GS, Savoia HF</AU>
<TI>The risk of transmitting HCV, HBV or HIV by blood transfusion in Victoria</TI>
<SO>Medical Journal of Australia</SO>
<YR>1997</YR>
<VL>166</VL>
<NO>11</NO>
<PG>584-6</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2011-02-16 15:08:40 +0000" MODIFIED_BY="Emma M Sydenham"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-05-14 14:12:04 +0100" MODIFIED_BY="Emma M Sydenham">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-05-14 14:12:04 +0100" MODIFIED_BY="Emma M Sydenham" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-05-14 13:48:14 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Armellin-1995">
<CHAR_METHODS MODIFIED="2009-03-04 02:14:05 +0000" MODIFIED_BY="[Empty name]">
<P>Method of blinding, randomisation and allocation concealment was not described. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-04 02:41:20 +0000" MODIFIED_BY="[Empty name]">
<P>261 consecutive cardiac surgery patients were randomised to one of two groups:</P>
<P>(1) Intraoperative plasmapheresis group: n = 128; M/F = 111/17; mean (+/-SD) age = 58.4 (12.5) years.</P>
<P>(2) Control group: n = 128; M/F = 86/42; mean age (+/-SD) = 60.8 (11.3) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-04 02:27:48 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Intra-operative plasmapheresis was performed after the induction of anaesthesia harvesting 10 ml/kg autologous platelet-rich plasma (PRP) using the PCS Haemonetics Ultralite system.<BR/>(2) Control group were managed without PRP.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:48:14 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patients transfused allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>Coagulation levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-04 02:28:54 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 1/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:49:15 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Armellin-1997">
<CHAR_METHODS MODIFIED="2009-05-14 13:49:10 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Method of randomisation and allocation concealment was not described.<BR/>Only the anaesthesiologist and the perfusionist were aware of group allocations.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-04 02:41:54 +0000" MODIFIED_BY="[Empty name]">
<P>293 consecutive cardiac surgery patients were randomised to one of two groups:<BR/>(1) Intraoperative plasmapheresis group: n = 137; M/F = 92/50; mean (+/-SD) age = 59 (12.3) years.<BR/>(2) Control group: n = 138; M/F = 92/50; mean (+/-SD) age = 61.1 (12) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-14 13:49:15 +0100" MODIFIED_BY="Emma M Sydenham">
<P>(1) Intra-operative plasmapheresis (IP) was performed after the induction of anaesthesia harvesting 10 ml/kg autologous platelet-rich plasma (PRP) using the PCS Haemonetics Ultralite system.<BR/>(2) Control group were managed without PRP.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:48:23 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patients transfused allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>Coagulation levels.<BR/>Excessive bleeding (n).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-04 02:44:03 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:49:40 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Boey-1993">
<CHAR_METHODS MODIFIED="2009-03-04 02:47:30 +0000" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment was not described.<BR/>All patients were operated on by the same surgeon.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-04 02:48:58 +0000" MODIFIED_BY="[Empty name]">
<P>40 consecutive primary myocardial revascularisation patients were randomised to one of two groups:<BR/>(1) Plateletpheresis group: n = 19; M/F = 17/2; mean (+/-SD) age = 59.1 (9.1) years.<BR/>(2) Control group: n = 20; M/F = 14/6; mean (+/-SD) age = 63.4 (8.4) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-04 02:49:28 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Plateletpheresis was performed immediately before surgery harvesting 10 ml/kg autologous platelet-rich plasma (PRP) using the PCS Haemonetics Ultralite system.<BR/>(2) Control group were managed without PRP.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:49:40 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Units of allogeneic blood transfused.<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>Coagulation levels.<BR/>Mortality (n).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-04 02:49:56 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:49:55 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Boldt-1990">
<CHAR_METHODS MODIFIED="2009-03-04 02:52:49 +0000" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-04 02:54:48 +0000" MODIFIED_BY="[Empty name]">
<P>45 aortocoronary bypass surgery patients were randomised to one of three groups:<BR/>(1) APP-PPP group: n = 15; M/F = not specified; mean (+/-SD) age = 62.8 (5.1) years.<BR/>(2) APP-PRP group: n = 15; M/F = not specified; mean (+/-SD) age = 59.0 (3.3) years.<BR/>(3) Control group: n = 15; M/F = not specified; mean (+/-SD) age = 63.7 (4.4) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-14 13:49:51 +0100" MODIFIED_BY="Emma M Sydenham">
<P>(1) Acute pre-operative plasmapheresis (APP) was performed after the induction of anesthesia harvesting 10 ml/kg autologous platelet-poor plasma (PPP) using the PCS V50 Haemonetics system.<BR/>(2) Acute pre-operative plasmapheresis (APP) was performed after the induction of anesthesia harvesting 10 ml/kg autologous platelet-rich plasma (PRP) using the PCS V50 Haemonetics system.<BR/>(3) Control group were managed without PRP or PPP.</P>
<P>NB: All groups received intra-operative cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:49:55 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patients transfused allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>Coagulation levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-04 03:00:51 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 0/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:50:23 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Boldt-1993">
<CHAR_METHODS MODIFIED="2009-03-04 03:18:25 +0000" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment was not described.<BR/>The surgical team were blinded to patient grouping.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-04 03:20:25 +0000" MODIFIED_BY="[Empty name]">
<P>36 coronary artery bypass surgery (CABG) patients were randomised to one of three groups:<BR/>(1) PPP group: n = 12; M/F = 12/0; mean (+/-SD) age = 56.0 (8.8) years.<BR/>(2) PRP group n = 12; M/F =12/0; mean (+/-SD) age = 60.5 (9.2) years.<BR/>(3) Control group: n = 12; M/F = 12/0; mean (+/-SD) age = 58.9 (8.2) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-04 03:21:07 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Acute pre-operative plasmapheresis (APP) was performed before the onset of the operation harvesting 10 ml/kg of autologous platelet-poor plasma (PPP) using the Haemonetics PCS V50 system.<BR/>(2) Acute pre-operative plasmapheresis (APP) was performed before the onset of the operation harvesting 10 ml/kg of autologous platelet-rich plasma (PRP) using the Haemonetics PCS V50 system.<BR/>(3) Control group were managed without PRP or PPP.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:50:23 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patients transfused allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>Coagulation levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-04 03:22:07 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:51:06 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Christenson-1996_x002f_a">
<CHAR_METHODS MODIFIED="2009-03-04 03:23:38 +0000" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-04 03:35:48 +0000" MODIFIED_BY="[Empty name]">
<P>40 redo coronary artery bypass grafting (CABG) patients were randomised to one of two groups:<BR/>(1) Platelet-rich plasma group: n = 20<BR/>(2) Control group: n = 20<BR/>NB: M/F of both groups = 33/7; mean (range) age of both groups = 63.4 (42-80) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-14 13:50:57 +0100" MODIFIED_BY="Emma M Sydenham">
<P>(1) Platelet-rich plasmapheresis (PRP) was performed after the induction of anaesthesia harvesting 20-30% circulating platelets using the Elmd-500 autotransfusion/platelet sequestration device (Medtronic).<BR/>(2) Control group were managed without PRP.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:51:06 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patients transfused allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>Coagulation levels.<BR/>Hospital length of stay (days).<BR/>Mortality (n).<BR/>ICU length stay (hrs).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-04 03:38:15 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 14:10:40 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Christenson-1996_x002f_b">
<CHAR_METHODS MODIFIED="2009-03-04 03:40:31 +0000" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-04 03:41:16 +0000" MODIFIED_BY="[Empty name]">
<P>60 primary and redo coronary artery bypass grafting (CABG) patients were randomised to one of two groups:<BR/>(1) Platelet sequestration group: n = 30<BR/>(2) Control group n = 30<BR/>NB: M/F of both groups = 51/9; mean (range) age of both groups = 62 (38-82) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-14 13:51:11 +0100" MODIFIED_BY="Emma M Sydenham">
<P>(1) Platelet sequestration harvesting platelet-rich plasma (PRP) was performed after the induction of anaesthesia using the Elmd-500 system (Medtronic).<BR/>(2) Control group were managed without PRP.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 14:10:40 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patients transfused allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>Coagulation levels.<BR/>Hospital length of stay (days).<BR/>ICU length of stay (hrs).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-04 03:44:20 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:51:27 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-DelRossi-1990">
<CHAR_METHODS MODIFIED="2009-03-04 03:45:16 +0000" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-04 03:47:32 +0000" MODIFIED_BY="[Empty name]">
<P>18 heart operation patients were randomised to one of two groups:<BR/>(1) Platelet-rich plasmapheresis group: n = 9; M/F = not reported; mean (+/-SD) age = 59.0 (1.8) years.<BR/>(2) Control group: n = 9; M/F = not reported; mean (+/-SD) age = 58.2 (3.4) years.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-14 13:51:22 +0100" MODIFIED_BY="Emma M Sydenham">
<P>(1) Platelet-rich plasmapheresis (PRP) was performed after the induction of anaesthesia using the Haemonetics Plasma Saving system.<BR/>(2) Control group were managed without PRP.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:51:27 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Units of allogeneic blood transfused.<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>Coagulation levels.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-04 03:49:03 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:52:14 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Ereth-1993">
<CHAR_METHODS MODIFIED="2009-05-14 13:52:07 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Method of randomisation and allocation concealment was not described.<BR/>Once patients were positioned and the PRP device connected, the anaesthesia staff were replaced by new anaesthesia staff. One member of the new staff was an anaesthesiologist-investigator. To blind all other operating room staff, PRP equipment and autotransfusion staff were visually isolated by surgical drapes. Collection tubing in the Sham procedure group was clamped simulating PRP collection.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-04 04:12:29 +0000" MODIFIED_BY="[Empty name]">
<P>56 repeat valvular surgery patients were randomised to one of two groups:<BR/>(1) Platelet-rich plasmapheresis group: n = 28; M/F = 18/10; mean (+/-SD) age = 68.0 (11.1) years.<BR/>(2) Control group: n = 28; M/F = 18/10; mean (+/-SD) age = 66.0 (11.6) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-04 04:14:09 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Platelet-rich plasmapheresis (PRP) harvested 15-20% of plasma volume using the Haemonetics Plasma Saver system.<BR/>(2) Control group received a sham procedure involving the same preparation as for the experimental group. The patient's blood in this group was drawn only through the collection tubing. Both ends were clamped and the tube remained filled with blood, simulating ongoing PRP collection.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:52:14 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Units of allogeneic blood transfused.<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>Coagulation levels.<BR/>Deep venous thrombosis (n).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-04 04:16:31 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7</P>
<P>No transfusion protocol described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:52:36 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Farouk-2003">
<CHAR_METHODS MODIFIED="2009-04-27 05:03:18 +0100" MODIFIED_BY="[Empty name]">
<P>Methods of randomisation and allocation concealment were not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-27 05:01:49 +0100" MODIFIED_BY="[Empty name]">
<P>30 patients undergoing coronary artery bypass grafting (CABG) or valve replacement surgery were randomised to one of three groups:</P>
<P>(1) Platelet-rich plasmapheresis group: n = 10; M/F = 4/6; mean (+/-SD) age = 37.2 (13.3) years</P>
<P>(2) Acute normovolaemic haemodilution group: n = 10; M/F = 6/4; mean (+/-SD) age = 34.1 (12.1) years</P>
<P>(3) Control group: n = 10; M/F = 6/4; mean (+/-SD) age = 37.6 (12.1) years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-27 05:22:21 +0100" MODIFIED_BY="[Empty name]">
<P>(1) Platelet-rich plasmapheresis (PRP) group had 20-25% of plasma volume harvested. Plasma volume collected was replaced by Haes-Steril 6% solution. Blood collected was transferred to the blood bank where it was centrifuged by the JOUAN CR 412 centrifugation machine (at a speed of 2400 rpm, a temperature of 22°C and for a 10-minute interval) into platelet-rich plasma and packed red blood cells. Erythrocytes separated were returned to the patient immediately before initiation of CPB, while collected PRP remained undisturbed in an insulated bag until after protamine neutralisation of heparin, when it was given 10 minutes later.</P>
<P>(2) Acute normovolaemic haemodilution group had 20% of the blood volume withdrawn immediately after the induction of anaesthesia. The final haematocrit was not allowed to decrease below 30%. The same amount was replaced by Haes-Steril 6%. Blood was collected in a citrate-phosphate-dextrose-adenine blood donor bag, remained undisturbed until after protamine neutralisation of heparin, when it was given 10 minutes later.</P>
<P>(3) Control group received the same preparation and operative techniques as the PRP group. There was no collection of any autologous blood product and the patient was managed in a standard manner.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:52:36 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patients transfused allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Number of patients transfused fresh frozen plasma (n).<BR/>Volume of fresh frozen plasma transfused (mls).<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-27 05:25:57 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:53:28 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Ferraris-1993">
<CHAR_METHODS MODIFIED="2009-03-04 05:01:28 +0000" MODIFIED_BY="[Empty name]">
<P>Patients were divided into high and low risk categories initially. This categorisation was made according to a ratio of template bleeding time to packed red blood cell volume. Within these groups, patients were randomised according to a simple blocked randomisation scheme. The method used to conceal treatment allocation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-27 04:56:50 +0100" MODIFIED_BY="[Empty name]">
<P>100 patients undergoing coronary artery bypass grafting (CABG) were randomised to one of three groups:<BR/>(1) Platelet-rich plasmapheresis group: n = 35<BR/>(2) Whole blood group: n = 30<BR/>(3) Control group: n = 35<BR/>NB: Demographic data were not reported<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-04 05:05:42 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Platelet-rich plasmapheresis (PRP) group had 8-10 ml/kg of autologous PRP harvested immediately before the operation using the Haemonetics Plasma Saver system.<BR/>(2) Autologous whole blood was harvested after systemic heparinization and immediately before institution of CPB.<BR/>(3) Control group were managed without PRP.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:53:28 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Units of allogeneic blood transfused.<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>Coagulation levels.<BR/>Mortality (n).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-04 05:07:23 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 0/7</P>
<P>Transfusion protocol used.<BR/>Data used in the analysis came from the high risk groups only, due to a lack of data in other groups.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:53:47 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Ford-2002">
<CHAR_METHODS MODIFIED="2009-03-04 22:18:43 +0000" MODIFIED_BY="[Empty name]">
<P>Patients were randomly assigned to either pheresis or control group by a process of minimisation using computer software.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-04 22:23:30 +0000" MODIFIED_BY="[Empty name]">
<P>54 patients undergoing elective routine coronary artery bypass graft surgery and valve replacement were randomly allocated to one of two groups:</P>
<P>(1) Platelet-pheresis group: n = 25; M/F = 17/8; median (range) age = 65 (59-73) years</P>
<P>(2) Control group: n = 29; M/F = 22/7; median (range) age = 69 (62-73) years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-04 23:39:53 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Platelet-pheresis was performed in the anaesthetic room before the induction of anaesthesia using the Haemonetics MCS3p apheresis system. Approximately 6 cycles were required to achieve a standard donation in excess of 2.5 x 10¹¹ platelets in a plasma volume of 300 ml. The platelet harvest was retransfused over a 20-minute period.</P>
<P>(2) Control group were managed without PRP.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:53:47 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patients transfused allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>Stroke (n).<BR/>Re-exploration for bleeding (n).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-04 23:56:53 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:54:19 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Godet-1995">
<CHAR_METHODS MODIFIED="2009-03-05 00:02:18 +0000" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-05 00:03:35 +0000" MODIFIED_BY="[Empty name]">
<P>20 abdominal infra-renal aortic aneurysmectomy patients were randomly allocated to one of two groups:<BR/>(1) Platelet-rich plasmapheresis group: n = 10<BR/>(2) Control group: n = 10<BR/>NB: Demographic data not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-14 13:54:19 +0100" MODIFIED_BY="Emma M Sydenham">
<P>(1) Platelet-rich plasmapheresis (PRP) harvesting 10 ml/kg of platelet-rich plasma was performed over 40-50 minutes prior to the induction of anaesthesia using the PCS Haemonetics system. Each unit of PRP was transfused to the patient after aortic declamping.<BR/>(2) Control group were managed without PRP.</P>
<P>NB: Autologous transfusion techniques were available to all patients (i.e. predonation of autologous blood, pre-operative normovolaemic haemodilution, and intra-operative cell salvage)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:54:09 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patients transfused allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>Coagulation levels.<BR/>
<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-05 00:08:19 +0000" MODIFIED_BY="[Empty name]">
<P>French language publication.</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:55:15 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Jones-1990">
<CHAR_METHODS MODIFIED="2009-03-05 00:19:38 +0000" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-05 00:20:53 +0000" MODIFIED_BY="[Empty name]">
<P>100 consecutive coronary artery bypass patients were randomised to one of two groups:<BR/>(1) Platelet-rich plasmapheresis group: n = 50; M/F = 39/11; mean (+/-SD) age = 61.37 (9.2) years.<BR/>(2) Control group: n = 50; M/F = 37/13; mean (+/-SD) age = 61.27 (10.6) years.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-05-14 13:54:23 +0100" MODIFIED_BY="Emma M Sydenham">
<P>(1) Platelet-rich plasma (PRP) was harvested after the induction of anaesthesia using the Haemonetics 5000 system. PRP harvesting was terminated either at the accumulation of 1000 ml of PRP or at the administration of heparin sodium. The PRP was reinfused when the sternum was closed.<BR/>(2) Control group were managed without PRP.<BR/>NB: Patients in both groups received normovolaemic haemodilution and cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:55:15 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patients transfused allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>Mortality (n).<BR/>Re-operation for bleeding (n).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-05 00:27:27 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:55:28 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Klein-2001">
<CHAR_METHODS MODIFIED="2009-03-05 01:35:51 +0000" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-05 01:30:43 +0000" MODIFIED_BY="[Empty name]">
<P>40 low-risk coronary artery bypass grafting (CABG) patients were randomised to one of two groups:<BR/>(1) Plateletpheresis group: n = 20; M/F = 20/0; mean (+/-SD) age = 60.6 (6.7) years.<BR/>(2) Control group: n = 20; M/F= 20/0; mean (+/-SD) age = 60.0 (8.6) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-05 01:33:45 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Plateletpheresis harvesting of platelet-rich plasma (PRP) was performed 15-25 hours before cardiopulmonary bypass (CPB). The PRP contained yields of 2.93 x 10¹¹ platelets. Platelets were retransfused post-operatively after the administration of protamine.<BR/>(2) Control group were managed without PRP.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:55:28 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patients transfused allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>Coagulation levels.<BR/>Re-operation for bleeding (n).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-05 01:40:43 +0000" MODIFIED_BY="[Empty name]">
<P>German language publication.</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:55:33 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Liu-1998">
<CHAR_METHODS MODIFIED="2009-03-05 01:50:10 +0000" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-05 02:21:28 +0000" MODIFIED_BY="[Empty name]">
<P>60 open-heart surgery patients were randomised to one of three groups:<BR/>(1) Platelet-rich plasmapheresis + epsilon aminocaproic acid group: n = 20; M/F = not reported; mean (+/-SD) age = 67 (12) years.<BR/>(2) Epsilon aminocaproic acid group: n = 20; M/F = not reported; mean (+/-SD) age = 65 (9) years.<BR/>(3) Control group: n = 20; M/F = not reported; mean (+/-SD) age = 64 (11) years.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-05 02:33:53 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Platelet-rich plasmapheresis (PRP) was performed before CPB, harvesting 10 ml/kg using a Haemonetics plasma saver. PRP was reinfused at the end of CPB with heparin completely neutralised by protamine. Patients also received 150 mg/kg of intravenous epsilon aminocaproic acid (EACA) before CPB.<BR/>(2) EACA group received 150 mg/kg of intravenous EACA before CPB.<BR/>(3) Control group were managed without PRP or EACA.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:55:33 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Units of allogeneic blood transfused.<BR/>Blood loss (ml).<BR/>Haematological levels.<BR/>Coagulation levels.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-05 02:30:29 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:55:39 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Menges-1996">
<CHAR_METHODS MODIFIED="2009-03-05 02:37:17 +0000" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-05 02:38:49 +0000" MODIFIED_BY="[Empty name]">
<P>60 coronary artery bypass grafting (CABG) patients were randomised to one of three groups:<BR/>(1) Platelet-poor plasmapheresis group: n = 20; M/F = 20/0; mean (+/-SD) age = 55.3 (8.2) years.<BR/>(2) Platelet-rich plasmapheresis: n = 20; M/F = 20/0; mean (+/-sd) age = 60.5 (9.2) years.<BR/>(3) Control group: n = 20; M/F = 20/0; mean (+/-SD) age = 58.7 (8.1) years.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-05 02:44:35 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Platelet-poor plasmapheresis (PPP) harvesting 10 ml/kg was performed after the induction of anesthesia using a Haemonetics Plasma Collecting System (PCS - V250).<BR/>(2) Platelet-rich plasmapheresis (PRP) harvesting 10 ml/kg was performed after the induction of anesthesia using a Haemonetics Plasma Collecting System (PCS - V250).<BR/>(3) Control group were managed without PRP or PPP.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:55:39 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patients transfused allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>Coagulation levels.<BR/>Re-bleeding events (n).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-05 03:25:35 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:55:43 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Menges-1997">
<CHAR_METHODS MODIFIED="2009-03-05 03:27:12 +0000" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-05 03:28:11 +0000" MODIFIED_BY="[Empty name]">
<P>40 coronary artery bypass grafting (CABG) patients were randomised to one of two groups:<BR/>(1) Platelet-rich plasmapheresis group: n = 20; M/F = 11/9; mean (+/-SD) age = 61.1 (8.6) years.<BR/>(2) Control group: n = 20; M/F = 13/7; mean (+/-SD) age = 79.7 (7.3) years.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-05 03:32:36 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Platelet-rich plasmapheresis (PRP) harvesting 10 ml/kg over 25 minutes was performed before incision using a Haemonetics device (discontinuous flow centrifugation technique). PRP was returned to the patient at the end of surgery after heparin reversal with protamine.<BR/>(2) Control group were managed without PRP.</P>
<P>NB: All patients received intra-operative cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:55:43 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patients transfused allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Blood loss (ml).<BR/>Haematological levels.<BR/>Coagulation levels.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-05 03:33:33 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:55:48 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Quigley-1995">
<CHAR_METHODS MODIFIED="2009-03-05 03:46:07 +0000" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-05 03:47:17 +0000" MODIFIED_BY="[Empty name]">
<P>126 consecutive patients undergoing elective cardiopulmonary bypass were randomly allocated to one of two groups:<BR/>(1) Platelet-rich plasmapheresis group: n = 64; M/F = 51/13; mean (+/-SD) age = 64 (12) years<BR/>(2) Control group: n = 52; M/F = 39/13; mean (+/-SD) age = 66 (11) years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-05 03:47:34 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Platelet-rich plasmapheresis group: after heparinisation and institution of CPB, blood was diverted from the venous portion of the CPB circuit to the cell saver (Haemonetics Cell Saver IV) at 300 ml/min with a centrifuge speed of 4750 rpm. Blood elements were separated according to density into PRP and erythrocytes. PRP was diverted into a blood storage bag as the cell saver bowl filled. Upon completion of the PRP sequestration, the red blood cells were returned to the circuit. The PRP was stored at room temperature without agitation and had an expiry time of 4 hours.<BR/>(2) Control group: standard CPB circuit was used. No autologous blood components were sequestered.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:55:48 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patients transfused allogeneic blood (n).<BR/>Coagulation profiles.<BR/>Platelet activation analysis.<BR/>Blood loss (mls).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-05 03:51:30 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:56:03 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Safwat-2002">
<CHAR_METHODS MODIFIED="2009-03-05 04:02:35 +0000" MODIFIED_BY="[Empty name]">
<P>Patients were randomised to groups by drawing coded slips of paper from a bag. These slips of paper were placed in a bag in groups of 10 (5 APP and 5 control) to ensure equal patient numbers in the two groups. The patients were blinded from treatment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-05 04:09:54 +0000" MODIFIED_BY="[Empty name]">
<P>33 patients undergoing elective aortic reconstruction were randomly allocated to one of two groups:</P>
<P>(1) Platelet-rich plasmapheresis group: n = 15; M/F = 14/1; mean (+/-SD) age = 68 (6) years.</P>
<P>(2) Control group: n = 15; M/F = 14/1; mean (+/-SD) age = 65 (13) years.</P>
<P>NB: Two patients from the control group and one patient from the PRP group were excluded from the final analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-05 04:31:20 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Platelet-rich plasmapheresis group underwent plasmapheresis using the Electromedics AT1000 (Medtronic) autotransfusion unit. An average of 20 minutes was required to complete blood withdrawal and separation of the blood components. A volume of blood was withdrawn to obtain approximately 300 ml of PRP from each patient. After the reversal of heparin with protamine and all arterial clamps were released, the autologous PPP and PRP were re-infused.</P>
<P>(2) Control group were managed without PRP.</P>
<P>NB: An autotransfusion device (cell salvage) was used to collect and re-infuse autologous red blood cells during the course of the operation in both groups.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:56:03 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patients transfused allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>Coagulation levels.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-05 04:31:01 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 4/7</P>
<P>Transfusion protocol was used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:56:16 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Shore_x002d_Lesserson-1995">
<CHAR_METHODS MODIFIED="2009-03-05 04:33:07 +0000" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequences was made by a table of 52 random numbers with prospective assignment of patients. Concealment of treatment allocation was not described. Investigators recruiting patients were unaware of the treatment group to which patients would be assigned. Eight patients were withdrawn from the study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-05 04:34:26 +0000" MODIFIED_BY="[Empty name]">
<P>52 repeat open-heart surgery patients were randomised to one of two groups:<BR/>(1) Platelet-rich plasmapheresis: n = 25; M/F = not reported; mean (+/-SD) age = 64 (11) years.<BR/>(2) Control group: n = 19; M/F = not reported; mean (+/-SD) age = 77 (15) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-06 03:37:48 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Platelet-rich plasmapheresis (PRP) harvesting 15 ml/kg was performed after the establishment of appropriate invasive monitoring and intravascular access using Haemonetics Plasma Saver®.<BR/>(2) Control group were managed without PRP.<BR/>NB: Patients in both groups received intra- and post-operative cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:56:16 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patients transfused allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>Coagulation levels.<BR/>Hypotension during procedure (n).<BR/>Re-operation for bleeding (n).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-05 04:36:47 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:56:25 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Stammers-1993">
<CHAR_METHODS MODIFIED="2009-03-05 04:44:16 +0000" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment was not described. Study reports that post-operative management and care staff were blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-05 04:45:18 +0000" MODIFIED_BY="[Empty name]">
<P>115 cardiac surgery patients were randomised to one of two groups:<BR/>(1) Platelet-rich plasmapheresis group: n = 63; M/F = 54/9; mean (+/-SD) = 60.4 (10.0) years.<BR/>(2) Control group: n = 52; M/F = 45/7; mean (+/-SD) = 61.8 (10.8) years.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-05 04:51:03 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Platelet-rich plasmapheresis (PRP) harvesting 20% of circulating plasma volume was performed using the Haemonetics Plasma Saver®.<BR/>(2) Control group were managed without PRP.</P>
<P>NB: Autotransfusion with a cell washing system (Cell Saver 4, Haemonetics) was employed and ultrafiltration was included when deemed necessary by the perfusionist.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:56:25 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patiens transfused allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Blood loss (ml).<BR/>Haematological levels.<BR/>Coagulation levels.<BR/>Hospital length of stay (days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-05 04:52:35 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:56:33 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Stover-2000">
<CHAR_METHODS MODIFIED="2009-03-05 05:16:12 +0000" MODIFIED_BY="[Empty name]">
<P>Method of randomisation and allocation concealment was not described. Seven patients were withdrawn from the study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-05 05:21:16 +0000" MODIFIED_BY="[Empty name]">
<P>62 repeat coronary artery bypass grafting (CABG) or CABG/valve surgery patients were randomised to one of two groups:<BR/>(1) Platelet-rich plasmapheresis group: n = 26; M/F = 22/4; mean (+/-SD) age = 67 (11) years.<BR/>(2) Control group: n = 29; M/F = 21/8; mean (+/-SD) = 70 (8) years.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-06 03:13:09 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Platelet-rich plasmapheresis (PRP) was performed using an AT1000, Medtronic, Electromedics device. Blood was initially removed from the patient at a rate of 100 ml/min at a centrifuge speed of 5600 rpm. Once the centrifuge bowl was filled the centrifuge speed was reduced to 2400 rpm and the PRP was removed at a blood draw rate of 50 ml/min. The PRP removed consisted of the buffy coat and a 1-min elution of the red cell layer. A maximum of six passes was permitted. Platelet-poor plasma (PPP) and red cell components were returned to the patient.<BR/>(2) Control group were managed without PRP.<BR/>NB: Cell salvage (Electromedics AT1000, Medtronic) was used for both groups. All patients received 150 mg/kg of epsilon aminocaproic acid (EACA) over 30 minutes, followed by an infusion of 20 mg/kg/hr throughout the operation, in addition 75 mg/kg of EACA was added to the cardiopulmonary circuit priming volume.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:56:33 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patients transfused allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Haematological levels.<BR/>Coagulation levels.<BR/>Blood loss (mls).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-05 05:28:20 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 0/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:56:43 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Triulzi-1995">
<CHAR_METHODS MODIFIED="2009-03-06 02:05:26 +0000" MODIFIED_BY="[Empty name]">
<P>Patients were randomised to treatment or control by use of a random number table. Concealment of treatment allocation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-06 01:58:48 +0000" MODIFIED_BY="[Empty name]">
<P>70 primary or repeat cardiac surgery patients were randomised to one of three groups:<BR/>(1) Platelet-rich plasmapheresis: n = 24; M/F = 16/8; mean (+/-SD) age = 59 (13) years.<BR/>(2) Intraoperative hemodilution: n = 18; M/F = 15/3; mean (+/-SD) = 58 (11) years.<BR/>(3) Control group: n = 28; M/F = 23/5; mean (+/-SD) age = 62 (11) years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-06 02:04:05 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Platelet-rich plasmapheresis (PRP) harvesting 20% plasma volume was performed after the induction of anesthesia using the Haemonetics Plasma Saver®. The volume of PRP targeted for collection was 20% of the patients plasma volume.<BR/>(2) Intraoperative hemodilution (IH) was performed after the induction of anesthesia. The volume of whole blood targeted for removal was 17+/-2% of the circulating blood volume.<BR/>(3) Control group were managed without PRP or IH.</P>
<P>NB: All groups were exposed to intra- and post-operative cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:56:43 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patients transfused allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>Coagulation levels.<BR/>Length of stay in hospital (days).<BR/>Length of stay in ICU (days).<BR/>Hours on ventilator.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-06 02:06:03 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 3/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 13:56:52 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Wajon-2001">
<CHAR_METHODS MODIFIED="2009-03-06 02:17:49 +0000" MODIFIED_BY="[Empty name]">
<P>Patients were randomised to treatment or control by using a random number table. Method of concealing treatment allocation was not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-06 02:22:29 +0000" MODIFIED_BY="[Empty name]">
<P>90 patients undergoing repeat coronary artery bypass graft surgery were randomly assigned to one of two groups:</P>
<P>(1) Platelet-rich plasmapheresis group: n= 40; M/F = 36/4; mean (+/-SD) age = 66 (8) years.</P>
<P>(2) Control group: n = 44; M/F =37/7; mean (+/-SD) age = 65 (9) years.</P>
<P>NB: One patient from the control group and five patients from the PRP group were excluded from the fianl analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-06 02:35:03 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Platelet-rich plasmapheresis was commenced after the induction of anaesthesia by use of the Electromedics AT1000 cell saver. Blood was separated into three components by using the direct-draw modified buffy coat method of plateletpheresis. Blood was initially withdrawn from the patient at 100 ml/min into a 225-ml bowl at 5600 rpm and the platelet-poor plasma (PPP) separated. The centrifuge was then slowed to 2400 rpm and the draw rate reduced to 50 ml/min, allowing the PRP in the buffy coat and upper red cell layer to be collected. Between 2500-3000 ml of blood was processed in 3-6 passes, each taking approximately 10 minutes. The majority of the PPP and red cells were returned to the patient immediately. Approximately 50 ml of PRP was reserved to produce platelet gel. This was applied to suture lines, raw areas, and sternal edges.</P>
<P>(2) Control were managed without PRP or platelet gel.</P>
<P>NB: Before CPB all patients received IV EACA 10 g. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 13:56:52 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Number of patients transfused allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Blood loss (mls).<BR/>Haematological levels.<BR/>Coagulation levels.<BR/>Hospital length of stay (days).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-06 02:38:29 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 2/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-14 14:12:04 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Wong-1994">
<CHAR_METHODS MODIFIED="2009-05-14 14:12:04 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Method of randomisation and allocation concealment was not described. Two patients were withdrawn from the final analysis.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-03-06 02:42:46 +0000" MODIFIED_BY="[Empty name]">
<P>40 cardiac surgery patients were randomised to one of two groups:<BR/>(1) Platelet-rich plasmapheresis group: n = 20; M/F = 15/5; mean (+/-SD) age = 58 (16) years.<BR/>(2) Control group: n = 20; M/F = 12/8; mean (+/-SD) = 67 (8) years.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-03-06 02:52:19 +0000" MODIFIED_BY="[Empty name]">
<P>(1) Platelet-rich plasmapheresis (PRP) was performed immediately after the induction of anaesthesia using the Haemonetics Plasma Saving System. Approximately 30% of the estimated plasma volume to a maximum of 1 litre of PRP was harvested from each patient. Blood was withdrawn into a 225 ml bowl and centrifuged at 3500 rpm for 10-20 min. The PRP was collected along with the first 25 ml of red blood cells. The remaining red blood cells were returned to the patient immediately. The cycle was repeated until the calculated PRP volume had been harvested. Harvesting took approximately 30 minutes.<BR/>(2) Control group were managed without PRP.<BR/>NB: Patients in both groups received cell salvage.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-17 18:24:01 +0100" MODIFIED_BY="Emma M Sydenham">
<P>No. of patients exposed to allogeneic blood (n).<BR/>Units of allogeneic blood transfused.<BR/>Haematological levels.<BR/>Coagulation levels.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-03-06 02:53:09 +0000" MODIFIED_BY="[Empty name]">
<P>Quality assessment score (Schulz criteria): 1/7</P>
<P>Transfusion protocol used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-03-06 02:55:05 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-09-17 18:24:03 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Reich-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-17 18:24:03 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Insufficient data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-17 18:24:04 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Stover-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-17 18:24:04 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Duplicate article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-17 18:24:05 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Stover-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-17 18:24:05 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Duplicate article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-06 02:55:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tobe-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-06 02:55:05 +0000" MODIFIED_BY="[Empty name]">
<P>Both intervention and control groups received PRP. The control group received PRP before heparinisation and the intervention group received PRP after heparin reversal.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-17 18:24:06 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Triulzi-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-17 18:24:06 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Duplicate article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-03-04 01:54:01 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-05-11 07:38:33 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-05-11 07:35:21 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-04 02:33:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Armellin-1995">
<DESCRIPTION>
<P>Method of randomisation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-04 02:44:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Armellin-1997">
<DESCRIPTION>
<P>Method of randomisation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-04 02:50:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boey-1993">
<DESCRIPTION>
<P>Method of randomisation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-04 02:57:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boldt-1990">
<DESCRIPTION>
<P>Method of randomisation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-04 03:22:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Boldt-1993">
<DESCRIPTION>
<P>Method of randomisation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-04 03:39:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Christenson-1996_x002f_a">
<DESCRIPTION>
<P>Method of randomisation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-04 03:44:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Christenson-1996_x002f_b">
<DESCRIPTION>
<P>Method of randomisation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-04 03:48:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DelRossi-1990">
<DESCRIPTION>
<P>Method of randomisation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-04 04:15:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ereth-1993">
<DESCRIPTION>
<P>Method of randomisation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-27 05:26:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farouk-2003">
<DESCRIPTION>
<P>Method of randomisation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-04 05:07:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferraris-1993">
<DESCRIPTION>
<P>Method of randomisation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-04 23:57:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ford-2002">
<DESCRIPTION>
<P>Computer randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-11 07:35:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Godet-1995">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-05 00:28:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jones-1990">
<DESCRIPTION>
<P>Method of randomisation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-05 01:49:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klein-2001">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-05 02:32:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-1998">
<DESCRIPTION>
<P>Method of randomisation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-05 03:25:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Menges-1996">
<DESCRIPTION>
<P>Method of randomisation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-05 03:33:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Menges-1997">
<DESCRIPTION>
<P>Method of randomisation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-05 03:52:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quigley-1995">
<DESCRIPTION>
<P>Method of randomisation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-05 04:30:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Safwat-2002">
<DESCRIPTION>
<P>Coded slips of paper were drawn from a bag</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-05 04:37:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shore_x002d_Lesserson-1995">
<DESCRIPTION>
<P>Random number table was used to randomise patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-05 04:52:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stammers-1993">
<DESCRIPTION>
<P>Method of randomisation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-05 05:28:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stover-2000">
<DESCRIPTION>
<P>Method of randomisation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-06 02:06:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Triulzi-1995">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-06 02:38:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wajon-2001">
<DESCRIPTION>
<P>Random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-06 02:53:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wong-1994">
<DESCRIPTION>
<P>Method of randomisation was not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-04-27 05:26:49 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Armellin-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Armellin-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Boey-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Boldt-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Boldt-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Christenson-1996_x002f_a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Christenson-1996_x002f_b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-DelRossi-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ereth-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-27 05:26:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farouk-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ferraris-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-04 23:57:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ford-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Godet-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jones-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Klein-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-05 02:32:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Menges-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Menges-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Quigley-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-05 04:29:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Safwat-2002">
<DESCRIPTION>
<P>Used sealed envelopes to conceal treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Shore_x002d_Lesserson-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stammers-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stover-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Triulzi-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-06 02:39:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wajon-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wong-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-05-11 07:38:33 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-04 02:39:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Armellin-1995">
<DESCRIPTION>
<P>Reported to be double-blind study but control group received standard care without PRP treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-04 02:46:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Armellin-1997">
<DESCRIPTION>
<P>Single blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-04 02:50:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Boey-1993">
<DESCRIPTION>
<P>Single blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-04 02:59:53 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boldt-1990">
<DESCRIPTION>
<P>Control group received standard treatment (no PRP or PPP)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-04 03:23:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Boldt-1993">
<DESCRIPTION>
<P>Control group received standard treatment (no PRP or PPP)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-04 03:39:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Christenson-1996_x002f_a">
<DESCRIPTION>
<P>Control group received standard treatment (no PRP)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-04 03:44:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Christenson-1996_x002f_b">
<DESCRIPTION>
<P>Control group received standard treatment (no PRP)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-04 03:48:26 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-DelRossi-1990">
<DESCRIPTION>
<P>Control group received standard treatment (no PRP)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-04 04:15:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ereth-1993">
<DESCRIPTION>
<P>Double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-04-27 05:27:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Farouk-2003">
<DESCRIPTION>
<P>Control group received standard treatment (no PRP)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-04 05:08:11 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ferraris-1993">
<DESCRIPTION>
<P>Control group received standard treatment (no PRP)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-04 23:57:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ford-2002">
<DESCRIPTION>
<P>Single blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-11 07:38:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Godet-1995">
<DESCRIPTION>
<P>Control group received standard treatment (no PRP)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-05 00:28:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jones-1990">
<DESCRIPTION>
<P>Control group received standard treatment (no PRP)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-05 02:32:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Klein-2001">
<DESCRIPTION>
<P>Control group received standard treatment (no PRP)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-05 02:32:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liu-1998">
<DESCRIPTION>
<P>Control group received standard treatment (no PRP)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-05 03:26:12 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Menges-1996">
<DESCRIPTION>
<P>Control group received standard treatment (no PRP)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-05 03:33:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Menges-1997">
<DESCRIPTION>
<P>Control group received standard treatment (no PRP)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-05 03:52:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Quigley-1995">
<DESCRIPTION>
<P>Control group received standard treatment (no PRP)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-05 04:29:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Safwat-2002">
<DESCRIPTION>
<P>Single blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-05 04:42:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shore_x002d_Lesserson-1995">
<DESCRIPTION>
<P>Although investigators recruiting patients were unaware of the treatment group to which patients would be assigned the control group received standard treatment with no PRP treatment. Study was assessed as being single blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-05 04:53:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stammers-1993">
<DESCRIPTION>
<P>Single blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-05 05:29:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stover-2000">
<DESCRIPTION>
<P>Control group received standard treatment (no PRP)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-06 02:07:36 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Triulzi-1995">
<DESCRIPTION>
<P>Control group received standard treatment (no PRP)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-06 02:39:27 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wajon-2001">
<DESCRIPTION>
<P>Control group received standard treatment (no PRP)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-03-06 02:53:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wong-1994">
<DESCRIPTION>
<P>Control group received standard treatment (no PRP)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2009-03-06 05:50:13 +0000" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2009-05-14 14:15:26 +0100" MODIFIED_BY="Emma M Sydenham">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-05-14 13:57:05 +0100" MODIFIED_BY="Emma M Sydenham" NO="1">
<TITLE MODIFIED="2009-03-06 04:21:49 +0000" MODIFIED_BY="[Empty name]">Cell salvage techniques</TITLE>
<TABLE COLS="3" ROWS="26">
<TR>
<TD>
<P>
<B>Study</B>
</P>
</TD>
<TD>
<P>
<B>Year</B>
</P>
</TD>
<TD>
<P>
<B>Cell salvage technique</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Armellin</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>Shed mediastinal blood was not collected and reinfused during the post-operative period.</P>
</TD>
</TR>
<TR>
<TD>
<P>Armellin</P>
</TD>
<TD>
<P>1997</P>
</TD>
<TD>
<P>After separation from CPB, the residual blood in the circuit was salvaged and concentrated using a Cell Saver® (Dideco SpA, Mirandola, Italy). This autologous blood was retransfused until the end of the operation. Shed mediastinal chest tube blood (SMCTB) was not collected and retransfused during the post-operative period.</P>
</TD>
</TR>
<TR>
<TD>
<P>Boey</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>Cell saver techniques were not employed.</P>
</TD>
</TR>
<TR>
<TD>
<P>Boldt</P>
</TD>
<TD>
<P>1990</P>
</TD>
<TD>
<P>Within 20 mins after the start of ECC, blood was concentrated using a cell saving system (Cell Saver® IV, Haemonetics®, Munich, FRG; 2 cycles standardised). After termination of ECC, the residual blood of the circuit was concentrated by the use of the cell saver system, and washed erythrocytes and the preoperatively removed autologous plasma were retransfused before the end of the operation. SMCTB was not collected and retransfused during the post-operative period.</P>
</TD>
</TR>
<TR>
<TD>
<P>Boldt</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>All fluids (cardioplegic solution, cooling, suction) were returned to the CPB circuit. Within 20 minutes after the start of CPB, blood in the circuit was concentrated using a hemofiltration device (HF-80, Frensenius, Bad Homberg, Germany). After separation from CPB, the residual blood of the circuit was salvaged and concentrated with the help of the hemofiltration device. This autologous hemofiltered blood was retransfused  until the end of the operation. SMCTB was not collected and retransfused during the post-operative period.</P>
</TD>
</TR>
<TR>
<TD>
<P>Christenson</P>
</TD>
<TD>
<P>1996</P>
</TD>
<TD>
<P>Autotransfusion with the Elmd 500 (Metronic Inc, Parker, Co,USA) was employed and ultrafiltration was included when deemed necessary by the perfusionist.</P>
</TD>
</TR>
<TR>
<TD>
<P>Christenson</P>
</TD>
<TD>
<P>1996/a</P>
</TD>
<TD>
<P>As above.</P>
</TD>
</TR>
<TR>
<TD>
<P>DelRossi</P>
</TD>
<TD>
<P>1990</P>
</TD>
<TD>
<P>Use of cell salvage was not reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>Ereth</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>Salvaged blood from the surgical field was processed by the rapid cell salvage machine. <I>No specific details were provided.</I>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Farouk</P>
</TD>
<TD>
<P>2003</P>
</TD>
<TD>
<P>Use of cell salvage was not reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>Ferraris</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>Use of cell salvage was not reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>Ford</P>
</TD>
<TD>
<P>2002</P>
</TD>
<TD>
<P>Intra-operative cell salvage was used for all patients. <I>No specific details were provided. </I>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Godet</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>Cell Saver IV (Haemonetics) was used to concentrate and wash blood during the intra-operative period. The centrifugation part of the kit was only assembled when blood loss was equal to or exceeded 1000ml for economic reasons. [Translation]</P>
</TD>
</TR>
<TR>
<TD>
<P>Jones</P>
</TD>
<TD>
<P>1990</P>
</TD>
<TD>
<P>Intra-operative blood salvage was used for all patients. <I>No specific details were provided. </I>Reinfusion of shed mediastinal blood for the first 4 hours was used for all patients.</P>
</TD>
</TR>
<TR>
<TD>
<P>Liu</P>
</TD>
<TD>
<P>1998</P>
</TD>
<TD>
<P>Use of cell salvage was not reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>Menges</P>
</TD>
<TD>
<P>1996</P>
</TD>
<TD>
<P>After disconnection from CPB, the remaining blood of the extracorporeal bypass system was collected and concentrated using the haemofiltration technique. This autologous haemofiltered blood was re-transfused until the end of surgery. Shed mediastinal blood was not collected and retransfused during the post-operative period.</P>
</TD>
</TR>
<TR>
<TD>
<P>Menges</P>
</TD>
<TD>
<P>1997</P>
</TD>
<TD>
<P>A haemofiltration technique (HF-80, Fresenius, Bad Homburg, Germany) was used to salvage all blood and all fluids (cardioplegic solution, intrathoracic cooling solution) from the surgical field during CPB. All blood remaining in the bypass circuit was concentrated with the haemofiltration technique and the haemofiltered autologous blood was returned to the patient at this time. During the post-operative period SMCTB was neither collected nor retransfused.</P>
</TD>
</TR>
<TR>
<TD>
<P>Quigley</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>Use of cell salvage was not reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>Safwat</P>
</TD>
<TD>
<P>2002</P>
</TD>
<TD>
<P>An autotransfusion device was used to collect and re-infuse autologous RBC during the course of the operation in both groups.</P>
</TD>
</TR>
<TR>
<TD>
<P>Shore-Lesserson</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>A haematocrit (Hct) on CPB below 20% was treated by hemofiltration if oxygenator volume was adequate or with RBC. Intra-operative Cell Saver® 4 (Haemonetics®, Braintree, MA) was used for all patients. Shed mediastinal chest tube blood was collected and retransfused during the post-operative period.</P>
</TD>
</TR>
<TR>
<TD>
<P>Stammers</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>Autotransfusion with a cell washing system (Cell Saver® 4, Haemonetics®, Inc, Braintree, MA) was employed and ultrafiltration was included when deemed necessary by the perfusionist.</P>
</TD>
</TR>
<TR>
<TD>
<P>Stover</P>
</TD>
<TD>
<P>2000</P>
</TD>
<TD>
<P>All patients in the study received intraooperative red cell salvage with the AT1000 (Medtronic Electromedics, Inc). Salvaged red blood cells were returned to the patients before departing the operating room.</P>
</TD>
</TR>
<TR>
<TD>
<P>Triulzi</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>Intra-operative salvage and bypass blood from the bypass pump were routinely returned to patients when available. Autologous blood not transfused in the operating room was transfused immediately after the operation. SMCTB was routinely used when available.</P>
</TD>
</TR>
<TR>
<TD>
<P>Wajon</P>
</TD>
<TD>
<P>2001</P>
</TD>
<TD>
<P>Cell salvage was not used after the onset of CPB.</P>
</TD>
</TR>
<TR>
<TD>
<P>Wong</P>
</TD>
<TD>
<P>1994</P>
</TD>
<TD>
<P>A Cell Saver® system (Haemonetics®) was used to salvage all blood suctioned from the surgical field before and after CPB. All blood remaining in the bypass circuit was also processed through the Cell Saver® at the end of surgery and the autologous cell saver blood was returned to the patient at this time.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2009-05-14 14:15:26 +0100" MODIFIED_BY="Emma M Sydenham" NO="2">
<TITLE MODIFIED="2009-03-09 00:39:50 +0000" MODIFIED_BY="[Empty name]">Transfusion threshold</TITLE>
<TABLE COLS="5" ROWS="27">
<TR>
<TD>
<P>
<B>Study</B>
</P>
</TD>
<TD>
<P>
<B>Year</B>
</P>
</TD>
<TD>
<P>
<B>Red blood cells (RBC)</B>
</P>
</TD>
<TD>
<P>
<B>Fresh frozen plasma (FFP)</B>
</P>
</TD>
<TD>
<P>
<B>Platelets</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Armellin</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>
<U>During CPB</U>
</P>
<P>Hb=7.0 g/dL</P>
<P>
<U>Post-operative</U>
</P>
<P>Hb&lt;9.0 g/dL if &lt;70 years</P>
<P>Hb&lt;10.0 g/dL if &gt;70 years</P>
</TD>
<TD>
<P>FFP was administered for a prothrombin time (PT) or a partial thromboplastin time (PTT) of greater than 150% of control values in the presence of bleeding (&gt;100 ml/hr).</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Armellin</P>
</TD>
<TD>
<P>1997</P>
</TD>
<TD>
<P>
<U>During CPB</U>
</P>
<P>Hct=20%</P>
<P>
<U>Post-operative</U>
</P>
<P>Hb&lt;9.0 g/dL if &lt;70 years</P>
<P>Hb&lt;10.0 g/dL if &gt;70 years</P>
</TD>
<TD>
<P>As above.</P>
</TD>
<TD>
<P>Platelet concentrates were administered only for a platelet count of less than 50,000/µL³.</P>
</TD>
</TR>
<TR>
<TD>
<P>Boey</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>
<U>During CPB</U>
</P>
<P>Hb&lt;7.0 g/dL or Hct&lt;21%</P>
<P>
<U>Post-operative</U>
</P>
<P>Symptomatic anaemia Hb&lt;10.0 g/dL or Hct&lt;30%</P>
</TD>
<TD>
<P>FFP was administered in the presence of clinical bleeding if the PT or PTT was prolonged &gt;120% of control.</P>
</TD>
<TD>
<P>Platelets were administered if the platelet count was &lt;100 x 10<SUP>9</SUP>/L.</P>
</TD>
</TR>
<TR>
<TD>
<P>Boldt</P>
</TD>
<TD>
<P>1990</P>
</TD>
<TD>
<P>
<U>During CPB</U>
</P>
<P>Hb&lt;7.0 g/dL</P>
<P>
<U>Post-operative</U>
</P>
<P>Hb&lt;9.0 g/dL</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Boldt</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>
<U>During CPB</U>
</P>
<P>Hb&lt;7.0 g/dL</P>
<P>
<U>Post-operative</U>
</P>
<P>Hb&lt;9.0 g/dL</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Christenson</P>
</TD>
<TD>
<P>1996/a</P>
</TD>
<TD>
<P>Hct&lt;20%</P>
</TD>
<TD>
<P>Patients were transfused coagulation factors only when bleeding was uncontrollable.</P>
<P>FFP was transfused when the PTT&gt;35 seconds.</P>
</TD>
<TD>
<P>Patients were transfused coagulation factors only when bleeding was uncontrollable.</P>
<P>Platelets were transfused when platelet count was less than 50,000/µL.</P>
</TD>
</TR>
<TR>
<TD>
<P>Christenson</P>
</TD>
<TD>
<P>1996/b</P>
</TD>
<TD>
<P>As above</P>
</TD>
<TD>
<P>As above</P>
</TD>
<TD>
<P>As above</P>
</TD>
</TR>
<TR>
<TD>
<P>DelRossi</P>
</TD>
<TD>
<P>1990</P>
</TD>
<TD>
<P>Hct&lt;30%</P>
</TD>
<TD>
<P>FFP transfusion was based on activated partial thromboplastin time. No threshold value was reported.</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Ereth</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>Transfusion criteria were not used.</P>
</TD>
<TD>
<P>Transfusion criteria were not used.</P>
</TD>
<TD>
<P>Transfusion criteria were not used.</P>
</TD>
</TR>
<TR>
<TD>
<P>Farouk</P>
</TD>
<TD>
<P>2003</P>
</TD>
<TD>
<P>Transfused to maintain volume and red cell mass appropriate for the age and condition of the patient.</P>
</TD>
<TD>
<P>FFP was transfused for a prothrombin time &gt;20 seconds.</P>
<P>Cryoprecipitate was transfused for a fibrinogen level of &#8804;100 mg/dL.</P>
</TD>
<TD>
<P>Platelets were transfused for platelet counts &lt;100,000 in patients with active bleeding.</P>
</TD>
</TR>
<TR>
<TD>
<P>Ferraris</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>
<U>Post-operative</U>
</P>
<P>Hct&lt;25% if &lt;70 years</P>
<P>&lt;27% if &gt;70 years</P>
<P>NB: the responsible surgeon ultimately determined the need for transfusion based on clinical assessment.</P>
</TD>
<TD>
<P>
<U>Post-operative</U>
</P>
<P>FFP was transfused if PTT ratio was greater than 1.3.</P>
</TD>
<TD>
<P>
<U>Post-operative</U>
</P>
<P>Platelets were transfused if platelet count &lt;75,000/µL.</P>
</TD>
</TR>
<TR>
<TD>
<P>Ford</P>
</TD>
<TD>
<P>2002</P>
</TD>
<TD>
<P>
<U>During CPB</U>
</P>
<P>Hb&lt;6.0 g/dL</P>
<P>
<U>Post-operative</U>
</P>
<P>Hb=8.0 g/dL</P>
</TD>
<TD>
<P>
<U>Post-operative</U>
</P>
<P>FFP was transfused if the prothrombin time was &gt;1.5 times the control.</P>
</TD>
<TD>
<P>
<U>Post-operative</U>
</P>
<P>Platelets were transfused in the presence of excessive bleeding if the platelet count was &lt;100 x 10<SUP>9</SUP>/L or regardless of platelet count if the patient had taken aspirin up to the time of surgery.</P>
</TD>
</TR>
<TR>
<TD>
<P>Godet</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>
<U>Intra-operative</U>
</P>
<P>Hb&lt;8.0 g/dL</P>
<P>
<U>Post-operative</U>
</P>
<P>Hb&lt;10.0 g/dL</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Jones</P>
</TD>
<TD>
<P>1990</P>
</TD>
<TD>
<P>
<U>Post-operative</U>
</P>
<P>Hb&lt;7.0 g/dL if &lt;70 years</P>
<P>Hb&lt;8.0 g/dL if &gt;70 years</P>
<P>Hb&lt;10.0 in two patients with respiratory failure.</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>
<U>Post-operative</U>
</P>
<P>Platelets were transfused if the platelet count was &lt;100 x 10<SUP>9</SUP>/L in patients with active bleeding.</P>
</TD>
</TR>
<TR>
<TD>
<P>Klein</P>
</TD>
<TD>
<P>2001</P>
</TD>
<TD>
<P>
<U>Post-operative</U>
</P>
<P>Hb&lt;9.0 g/dL or Hct&lt;25%</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Liu</P>
</TD>
<TD>
<P>1998</P>
</TD>
<TD>
<P>Hct&lt;30%</P>
</TD>
<TD>
<P>FFP were transfused if the PT/APTT value was 150% higher than control value.</P>
</TD>
<TD>
<P>Platelets were transfused if the platelet count was &lt;100,000/ml with evidence of active bleeding.</P>
</TD>
</TR>
<TR>
<TD>
<P>Menges</P>
</TD>
<TD>
<P>1996</P>
</TD>
<TD>
<P>
<U>During CPB</U>
</P>
<P>Hb&lt;7.0 g/dL</P>
<P>
<U>Post-operative</U>
</P>
<P>Hb&lt;8.5 g/dL</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Menges</P>
</TD>
<TD>
<P>1997</P>
</TD>
<TD>
<P>
<U>During CPB</U>
</P>
<P>Hb&lt;7.0 g/dL</P>
<P>
<I>OR</I>
</P>
<P>Hb&lt;8.0 g/dL after all salvaged blood had been transfused.</P>
</TD>
<TD>
<P>FFP was transfused only if the patient was bleeding (&gt;2 ml/kg/hr chest tube drainage) and the activated partial thromboplastin time &gt;45 seconds.</P>
</TD>
<TD>
<P>Platelets was transfused only if the patient was bleeding (&gt;2 ml/kg/hr chest tube drainage) and the platelet count was &lt;80 x 10<SUP>9</SUP>/L.</P>
</TD>
</TR>
<TR>
<TD>
<P>Quigley</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>Hct&#8804;30%</P>
</TD>
<TD>
<P>FFP was transfused if mediastinal drainage was more than 200 ml/hr for two consecutive hours. Threshold value was not reported.</P>
</TD>
<TD>
<P>Platelets were transfused if mediastinal drainage was more than 200 ml/hr for two consecutive hours. Threshold value was not reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>Safwat</P>
</TD>
<TD>
<P>2002</P>
</TD>
<TD>
<P>Hb&lt;9.0 g/dL</P>
</TD>
<TD>
<P>FFP was transfused when INR &gt;1.4 in the presence of inadequate haemostasis.</P>
</TD>
<TD>
<P>Platelets were transfused if platelet count was &lt;100,000 mm³ in the presence of inadequate haemostasis.</P>
</TD>
</TR>
<TR>
<TD>
<P>Shore-Lesserson</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>
<U>During CPB</U>
</P>
<P>Hct&lt;20%</P>
<P>
<U>Post-operative</U>
</P>
<P>Hct&lt;25% in the presence of hypovolaemia.</P>
</TD>
<TD>
<P>FFP was transfused for a PT&lt;150% of control.</P>
<P>Cryoprecipitate was given for a fibrinogen count &lt;150 mg/dL.</P>
</TD>
<TD>
<P>Platelets were transfused for a platelet count &lt;100,000 mm³ or if the thromboelastograph demonstrated an &#945; angle &lt;40º and a maximum amplitude (MA) &lt;40 mm.</P>
</TD>
</TR>
<TR>
<TD>
<P>Stammers</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>
<U>Peri-operative</U>
</P>
<P>Hb&lt;7.0 g/dL if &lt;70 years</P>
<P>Hb&lt;8.0 g/dL if &gt;70 years</P>
<P>
<U>Post-operative</U>
</P>
<P>Hct&lt;21% except in the case of incomplete revascularisation where RBC were given for a Hct&lt;25%.</P>
</TD>
<TD>
<P>
<U>Peri-operative</U>
</P>
<P>FFP was transfused when bleeding was uncontrollable and when prothrombin times (PT) were &gt;16 seconds.</P>
<P>Cryoprecipitate was transfused when fibrinogen levels were &lt;100 mg/dL.</P>
<P/>
</TD>
<TD>
<P>
<U>Peri-operative</U>
</P>
<P>Platelets were transfused when platelet counts were &lt;100,000/µL.</P>
</TD>
</TR>
<TR>
<TD>
<P>Stover</P>
</TD>
<TD>
<P>2000</P>
</TD>
<TD>
<P>Hct&#8804;24%</P>
</TD>
<TD>
<P>FFP was transfused in the setting of clinical bleeding for PT&gt;150% of normal.</P>
<P>Cryoprecipitate was given if fibrinogen level &lt;100 mg/dL.</P>
</TD>
<TD>
<P>Platelets were transfused in the setting of clinical bleeding for platelet counts &lt;100,000 µL.</P>
</TD>
</TR>
<TR>
<TD>
<P>Triulzi</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>
<U>Intra-operative</U>
</P>
<P>Hct&lt;20% with signs of acute ischemia or uncontrolled major blood loss.</P>
<P>
<U>Post-operative</U>
</P>
<P>Hct&lt;24% or symptomatic anaemia.</P>
</TD>
<TD>
<P>
<U>Intra-operative</U>
</P>
<P>FFP was given for diffuse bleeding not adequately controlled by surgical haemostasis or platelet transfusion.</P>
<P>
<U>Post-operative</U>
</P>
<P>FFP was given for diffuse bleeding with laboratory evidence of a coagulopathy.</P>
</TD>
<TD>
<P>
<U>Intra-operative</U>
</P>
<P>Platelets were given for diffuse bleeding after bypass with adequate surgical haemostasis.</P>
<P>
<U>Post-operative</U>
</P>
<P>Platelets were given for a platelet count &lt;100 x 10<SUP>9</SUP>/L with diffuse bleeding or diffuse bleeding within 24 hours of bypass regardless of platelet count.</P>
</TD>
</TR>
<TR>
<TD>
<P>Wajon</P>
</TD>
<TD>
<P>2001</P>
</TD>
<TD>
<P>
<U>During CPB</U>
</P>
<P>Hb&lt;7.0 g/dL</P>
<P>
<U>Post-operative</U>
</P>
<P>Hb&lt;8.0 g/dL</P>
</TD>
<TD>
<P>FFP was transfused if the patient was bleeding (&gt;2 ml/kg/hr chest tube drainage) or if the patient was clinically coagulopathic and laboratory tests indicated the use of FFP (INR&gt;1.5, activated partial thromboplastin time &gt;45 seconds).</P>
</TD>
<TD>
<P>Platelets were transfused if the patient was bleeding (&gt;2 ml/kg/hr chest tube drainage) or if the patient was clinically coagulopathic and laboratory tests indicated the use of platelets (platelet count &lt;100 x 10<SUP>9</SUP>/L).</P>
</TD>
</TR>
<TR>
<TD>
<P>Wong</P>
</TD>
<TD>
<P>1994</P>
</TD>
<TD>
<P>
<U>During CPB</U>
</P>
<P>Hb&lt;6.0 g/dL</P>
<P>
<I>OR</I>
</P>
<P>Hb&lt;8.0 g/dL after all cell saver blood had been transfused. Allogeneic red blood cells were transfused for higher Hb levels only if judged absolutely vital to the patients well being by the attending surgeon and anaesthesiologist.</P>
</TD>
<TD>
<P>FFP was transfused if the patient was bleeding (&gt;2 ml/kg/hr chest tube drainage) and laboratory tests indicated the use of FFP.</P>
</TD>
<TD>
<P>Platelets were transfused if the patient was bleeding (&gt;2 ml/kg/hr chest tube drainage) and laboratory tests indicated the use of platelets.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2009-04-27 05:40:03 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-03-10 01:40:27 +0000" MODIFIED_BY="[Empty name]">Duration of cardiopulmonary bypass (minutes) - mean (SD)</TITLE>
<TABLE COLS="6" ROWS="23">
<TR>
<TD>
<P>
<B>Study</B>
</P>
</TD>
<TD>
<P>
<B>Year</B>
</P>
</TD>
<TD>
<P>
<B>PRP (n)</B>
</P>
</TD>
<TD>
<P>
<B>PRP - duration of CPB</B>
</P>
</TD>
<TD>
<P>
<B>Control (n)</B>
</P>
</TD>
<TD>
<P>
<B>Control - duration of CPB</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Menges</P>
</TD>
<TD>
<P>1997</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>73.0 (21.4)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>72.2 (19.8)</P>
</TD>
</TR>
<TR>
<TD>
<P>Boey</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>73.3 (20.9)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>76.4 (16.3)</P>
</TD>
</TR>
<TR>
<TD>
<P>Menges</P>
</TD>
<TD>
<P>1996</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>76.3 (23.6)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>80.5 (18.2)</P>
</TD>
</TR>
<TR>
<TD>
<P>Ford</P>
</TD>
<TD>
<P>2002</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>77.0 (59, 103)*</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>72.0 (60, 89)*</P>
</TD>
</TR>
<TR>
<TD>
<P>Boldt</P>
</TD>
<TD>
<P>1990</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>78.6 (4.5)</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>83.5 (17.0)</P>
</TD>
</TR>
<TR>
<TD>
<P>Christenson</P>
</TD>
<TD>
<P>1996/b</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>87.9 (34.8)</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>87.8 (29.0)</P>
</TD>
</TR>
<TR>
<TD>
<P>Boldt</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>89.4 (21.1)</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>87.0 (20.7)</P>
</TD>
</TR>
<TR>
<TD>
<P>Farouk</P>
</TD>
<TD>
<P>2003</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>91.8 (21.9)</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>101.2 (23.9)</P>
</TD>
</TR>
<TR>
<TD>
<P>Christenson</P>
</TD>
<TD>
<P>1996/a</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>97.0 (37.0)**</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>97.0 (37.0)**</P>
</TD>
</TR>
<TR>
<TD>
<P>Jones</P>
</TD>
<TD>
<P>1990</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>102.0 (33.2)</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>106.0 (40.3)</P>
</TD>
</TR>
<TR>
<TD>
<P>Klein</P>
</TD>
<TD>
<P>2001</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>104.2 (21.1)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>107.8 (24.8)</P>
</TD>
</TR>
<TR>
<TD>
<P>Armellin</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>128</P>
</TD>
<TD>
<P>105.0 (36.0)</P>
</TD>
<TD>
<P>128</P>
</TD>
<TD>
<P>107.0 (38.0)</P>
</TD>
</TR>
<TR>
<TD>
<P>Triulzi</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>24</P>
</TD>
<TD>
<P>106.0 (31.0)</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>102.0 (37.0)</P>
</TD>
</TR>
<TR>
<TD>
<P>Armellin</P>
</TD>
<TD>
<P>1997</P>
</TD>
<TD>
<P>142</P>
</TD>
<TD>
<P>106.5 (37.0)</P>
</TD>
<TD>
<P>142</P>
</TD>
<TD>
<P>109.7 (40.0)</P>
</TD>
</TR>
<TR>
<TD>
<P>Ereth</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>113.0 (68, 170)*</P>
</TD>
<TD>
<P>28</P>
</TD>
<TD>
<P>108.0 (68, 148)*</P>
</TD>
</TR>
<TR>
<TD>
<P>Wajon</P>
</TD>
<TD>
<P>2001</P>
</TD>
<TD>
<P>40</P>
</TD>
<TD>
<P>114.0 (39.0)</P>
</TD>
<TD>
<P>44</P>
</TD>
<TD>
<P>108.0 (33.0)</P>
</TD>
</TR>
<TR>
<TD>
<P>Stammers</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>121.2 (41.2)</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>114.6 (38.1)</P>
</TD>
</TR>
<TR>
<TD>
<P>Shore-Lesserson</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>25</P>
</TD>
<TD>
<P>123.0 (45.0)</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>135.0 (39.0)</P>
</TD>
</TR>
<TR>
<TD>
<P>Stover</P>
</TD>
<TD>
<P>2000</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>125.0 (31.0)</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>136.0 (37.0)</P>
</TD>
</TR>
<TR>
<TD>
<P>Liu</P>
</TD>
<TD>
<P>1998</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>127.0 (24.0)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>128.0 (25.0)</P>
</TD>
</TR>
<TR>
<TD>
<P>Wong</P>
</TD>
<TD>
<P>1994</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>140.0 (43.0)</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>132.0 (43.0)</P>
</TD>
</TR>
<TR>
<TD>
<P>Quigley</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>64</P>
</TD>
<TD>
<P>143.0 (34.0)</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>141.0 (33.0)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* Median (IQR)</P>
<P>** Mean CPB time for both groups. Individual trial arm data were not reported.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2009-04-27 05:44:23 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2009-03-10 04:31:31 +0000" MODIFIED_BY="[Empty name]">Quantity of platelet-rich plasma collected</TITLE>
<TABLE COLS="6" ROWS="27">
<TR>
<TD>
<P>
<B>Study</B>
</P>
</TD>
<TD>
<P>
<B>Year</B>
</P>
</TD>
<TD>
<P>
<B>PRP ml/kg</B>
</P>
</TD>
<TD>
<P>
<B>PRP volume collected</B>
</P>
<P>
<B>(mean+/-sd)</B>
</P>
</TD>
<TD>
<P>
<B>Platelet count of PRP</B>
</P>
<P>
<B>(mean+/-sd) </B>
</P>
</TD>
<TD>
<P>
<B>PRP platelet yield x 10¹¹/L</B>
</P>
<P>
<B>(mean+/-sd)</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Armellin</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Armellin</P>
</TD>
<TD>
<P>1997</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>1.7+/-0.3</P>
</TD>
</TR>
<TR>
<TD>
<P>Boey</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>310+/-99 x 10<SUP>9</SUP>/L</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Boldt</P>
</TD>
<TD>
<P>1990</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>301+/-44 x 10<SUP>3</SUP>/ml</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Boldt</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>780+/-80</P>
</TD>
<TD>
<P>250+/-30 x 10<SUP>9</SUP>/L</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Christenson</P>
</TD>
<TD>
<P>1996/a</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>348+/-95</P>
</TD>
<TD>
<P>864+/-139 x 10<SUP>3</SUP>/µL</P>
</TD>
<TD>
<P>3.0+/-0.6</P>
</TD>
</TR>
<TR>
<TD>
<P>Christenson</P>
</TD>
<TD>
<P>1996/b</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>433+/-34</P>
</TD>
<TD>
<P>747+/-157 x 10<SUP>3</SUP>/µL</P>
</TD>
<TD>
<P>3.4+/-0.6</P>
</TD>
</TR>
<TR>
<TD>
<P>DelRossi</P>
</TD>
<TD>
<P>1990</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>220+/-61</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Ereth</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>690 (499, 863)*</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>2.7 (1.7, 3.0) units*</P>
</TD>
</TR>
<TR>
<TD>
<P>Farouk</P>
</TD>
<TD>
<P>2003</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Ferraris</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>8-10</P>
</TD>
<TD>
<P>740+/-69</P>
</TD>
<TD>
<P>150-250 x 10<SUP>3</SUP>/µL</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Ford</P>
</TD>
<TD>
<P>2002</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>321+/-64</P>
</TD>
<TD>
<P>3.38+/-1.06 x 10<SUP>11</SUP>
</P>
</TD>
<TD>
<P>29%+/-8.8% of circulating platelet mass</P>
</TD>
</TR>
<TR>
<TD>
<P>Godet</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>739+/-351</P>
</TD>
<TD>
<P>62+/-31 g/L</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Jones</P>
</TD>
<TD>
<P>1990</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>2.5+/-0.35</P>
</TD>
</TR>
<TR>
<TD>
<P>Klein</P>
</TD>
<TD>
<P>2001</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>233</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>2.93</P>
</TD>
</TR>
<TR>
<TD>
<P>Lui</P>
</TD>
<TD>
<P>1998</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Menges</P>
</TD>
<TD>
<P>1996</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>245+/-36 x 10<SUP>9</SUP>/L</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Menges</P>
</TD>
<TD>
<P>1997</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>239+/-33 x 10<SUP>9</SUP>/L</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Quigley</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>66+/-32 x 10<SUP>9</SUP>/L</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Safwat</P>
</TD>
<TD>
<P>2002</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>333+/-134</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Shore-Lesserson</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>1.2</P>
</TD>
</TR>
<TR>
<TD>
<P>Stammers</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>600+/-100</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Stover</P>
</TD>
<TD>
<P>2000</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>567+/-169</P>
</TD>
<TD>
<P>560+/-189 x 10<SUP>3</SUP>/µL</P>
</TD>
<TD>
<P>3.1</P>
</TD>
</TR>
<TR>
<TD>
<P>Triulzi</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>650+/-124</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>1.42+/-0.74</P>
</TD>
</TR>
<TR>
<TD>
<P>Wajon</P>
</TD>
<TD>
<P>2001</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>628+/-126</P>
</TD>
<TD>
<P>586+/-213 x 10<SUP>3</SUP>/µL</P>
</TD>
<TD>
<P>30%+/-7% of circulating platelet mass</P>
</TD>
</TR>
<TR>
<TD>
<P>Wong</P>
</TD>
<TD>
<P>1994</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>892+/-150</P>
</TD>
<TD>
<P>140+/-27 x 10<SUP>9</SUP>/L</P>
</TD>
<TD>
<P>1.40+/-0.27</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Abbreviations: NR = not reported</P>
<P>* Median (IQR)</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2009-04-28 06:39:58 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2009-04-28 05:30:28 +0100" MODIFIED_BY="[Empty name]">Summary of co-interventions</TITLE>
<TABLE COLS="8" ROWS="27">
<TR>
<TD>
<P>
<B>Study</B>
</P>
</TD>
<TD>
<P>
<B>Year</B>
</P>
</TD>
<TD>
<P>
<B>CS</B>
</P>
</TD>
<TD>
<P>
<B>ANH</B>
</P>
</TD>
<TD>
<P>
<B>EACA</B>
</P>
</TD>
<TD>
<P>
<B>TXA</B>
</P>
</TD>
<TD>
<P>
<B>Aprotinin</B>
</P>
</TD>
<TD>
<P>
<B>PAD</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Armellin</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Armellin</P>
</TD>
<TD>
<P>1997</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Boey</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Boldt</P>
</TD>
<TD>
<P>1990</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Boldt</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Christenson</P>
</TD>
<TD>
<P>1996/a</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Christenson</P>
</TD>
<TD>
<P>1996/b</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>DelRossi</P>
</TD>
<TD>
<P>1990</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Ereth</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Farouk</P>
</TD>
<TD>
<P>2003</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Ferraris</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Ford</P>
</TD>
<TD>
<P>2002</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Godet</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>Yes</P>
</TD>
</TR>
<TR>
<TD>
<P>Jones</P>
</TD>
<TD>
<P>1990</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Klein</P>
</TD>
<TD>
<P>2001</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Liu</P>
</TD>
<TD>
<P>1998</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Menges</P>
</TD>
<TD>
<P>1996</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Menges</P>
</TD>
<TD>
<P>1997</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Quigley</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Safwat</P>
</TD>
<TD>
<P>2002</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Shore-Lesserson</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Stammers</P>
</TD>
<TD>
<P>1993</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Stover</P>
</TD>
<TD>
<P>2000</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Triulzi</P>
</TD>
<TD>
<P>1995</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Wajon</P>
</TD>
<TD>
<P>2001</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
<TR>
<TD>
<P>Wong</P>
</TD>
<TD>
<P>1994</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
<TD>
<P>NR</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Abbreviations: NR = not reported; CS = cell salvage; ANH = acute normovolaemic haemodilution; EACA = epsilon aminocaproic acid; TXA = tranexamic acid; PAD = pre-operative autologous blood donation</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-02-16 15:20:15 +0000" MODIFIED_BY="Emma M Sydenham">
<COMPARISON ID="CMP-001" MODIFIED="2011-02-16 15:20:15 +0000" MODIFIED_BY="Emma M Sydenham" NO="1">
<NAME>Platelet-rich plasmapheresis versus control</NAME>
<DICH_OUTCOME CHI2="98.43949740003809" CI_END="0.8982708938277522" CI_START="0.5863348312127352" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7257323975928096" ESTIMABLE="YES" EVENTS_1="337" EVENTS_2="474" I2="78.66709953357413" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.04659267229357055" LOG_CI_START="-0.23185430579103367" LOG_EFFECT_SIZE="-0.1392234890423021" METHOD="MH" MODIFIED="2011-02-16 15:11:55 +0000" MODIFIED_BY="Emma M Sydenham" NO="1" P_CHI2="5.4429794005272925E-12" P_Q="0.0" P_Z="0.0032210751800193903" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.13083326772976625" TOTALS="YES" TOTAL_1="801" TOTAL_2="788" WEIGHT="99.99999999999996" Z="2.945812569753203">
<NAME>No. exposed to allogeneic RBC transfusion (All Studies)</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8574846465933827" CI_START="0.548884248816184" EFFECT_SIZE="0.686046511627907" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="86" LOG_CI_END="-0.06677364733121739" LOG_CI_START="-0.2605192318716297" LOG_EFFECT_SIZE="-0.16364643960142353" MODIFIED="2009-05-11 05:01:19 +0100" MODIFIED_BY="[Empty name]" ORDER="546" O_E="0.0" SE="0.1138071154151491" STUDY_ID="STD-Armellin-1995" TOTAL_1="128" TOTAL_2="128" VAR="0.012952059519117067" WEIGHT="8.236289661105856"/>
<DICH_DATA CI_END="0.9252000279486662" CI_START="0.6077794164087427" EFFECT_SIZE="0.7498783454987834" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="90" LOG_CI_END="-0.033764362782145264" LOG_CI_START="-0.21625401220519222" LOG_EFFECT_SIZE="-0.1250091874936687" MODIFIED="2009-05-11 05:01:20 +0100" MODIFIED_BY="[Empty name]" ORDER="547" O_E="0.0" SE="0.10719532340943128" STUDY_ID="STD-Armellin-1997" TOTAL_1="137" TOTAL_2="138" VAR="0.011490837360852563" WEIGHT="8.320850522718368"/>
<DICH_DATA CI_END="3.845086034384406" CI_START="0.010402888164868843" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5849060616512035" LOG_CI_START="-1.982846070323241" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2011-02-16 15:11:55 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="548" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Boldt-1990" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="0.492244254879811"/>
<DICH_DATA CI_END="2.4988165463450835" CI_START="0.008167131474760041" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.39773437303938103" LOG_CI_START="-2.087930453067895" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2011-02-16 15:11:55 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="549" O_E="0.0" SE="1.4600918230947433" STUDY_ID="STD-Boldt-1993" TOTAL_1="12" TOTAL_2="12" VAR="2.1318681318681314" WEIGHT="0.5233821857577641"/>
<DICH_DATA CI_END="0.49297553247156495" CI_START="0.010349480816516623" EFFECT_SIZE="0.07142857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.3071746352385513" LOG_CI_START="-1.985081436117925" LOG_EFFECT_SIZE="-1.1461280356782382" ORDER="550" O_E="0.0" SE="0.9856107606091622" STUDY_ID="STD-Christenson-1996_x002f_a" TOTAL_1="20" TOTAL_2="20" VAR="0.9714285714285713" WEIGHT="1.074388645390257"/>
<DICH_DATA CI_END="0.3885376869349723" CI_START="0.04378785658706284" EFFECT_SIZE="0.13043478260869565" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="23" LOG_CI_END="-0.41056684961959766" LOG_CI_START="-1.3586463129762634" LOG_EFFECT_SIZE="-0.8846065812979305" ORDER="551" O_E="0.0" SE="0.5569065698447379" STUDY_ID="STD-Christenson-1996_x002f_b" TOTAL_1="30" TOTAL_2="30" VAR="0.3101449275362319" WEIGHT="2.6855241754625876"/>
<DICH_DATA CI_END="1.0723152043034878" CI_START="0.7995212758907578" EFFECT_SIZE="0.9259259259259259" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" LOG_CI_END="0.030322463871913678" LOG_CI_START="-0.09716997484581309" LOG_EFFECT_SIZE="-0.0334237554869497" ORDER="552" O_E="0.0" SE="0.0748896896005426" STUDY_ID="STD-Ereth-1993" TOTAL_1="28" TOTAL_2="28" VAR="0.005608465608465618" WEIGHT="8.679584869410794"/>
<DICH_DATA CI_END="0.7133237566884246" CI_START="0.0794721076819395" EFFECT_SIZE="0.23809523809523808" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.1467133119012532" LOG_CI_START="-1.099785268894548" LOG_EFFECT_SIZE="-0.6232492903979004" MODIFIED="2009-03-11 03:22:14 +0000" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="0.5598391853201358" STUDY_ID="STD-Farouk-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.3134199134199134" WEIGHT="2.6657267848346473"/>
<DICH_DATA CI_END="1.2153945101855008" CI_START="0.8663785356539233" EFFECT_SIZE="1.0261538461538462" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" LOG_CI_END="0.084717270351327" LOG_CI_START="-0.06229231580394014" LOG_EFFECT_SIZE="0.011212477273693408" MODIFIED="2009-03-10 22:35:33 +0000" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="0.08635415861679173" STUDY_ID="STD-Ford-2002" TOTAL_1="25" TOTAL_2="29" VAR="0.007457040710414024" WEIGHT="8.563561811354043"/>
<DICH_DATA CI_END="3.8148841482433915" CI_START="0.2621311581533772" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5814813536820973" LOG_CI_START="-0.5814813536820973" LOG_EFFECT_SIZE="0.0" ORDER="553" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Godet-1995" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="1.9820213125796953"/>
<DICH_DATA CI_END="0.7689807013531469" CI_START="0.3251056880362332" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="34" LOG_CI_END="-0.1140845592896038" LOG_CI_START="-0.48797543203835864" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="554" O_E="0.0" SE="0.21962534944228784" STUDY_ID="STD-Jones-1990" TOTAL_1="50" TOTAL_2="50" VAR="0.04823529411764704" WEIGHT="6.61343114626576"/>
<DICH_DATA CI_END="1.5623477480712817" CI_START="0.025602494738690536" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.1937777057638096" LOG_CI_START="-1.5917177144358472" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="555" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Klein-2001" TOTAL_1="20" TOTAL_2="20" VAR="1.0999999999999999" WEIGHT="0.9621592422692848"/>
<DICH_DATA CI_END="1.5422965811171738" CI_START="0.005358543169388946" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.1881678958663492" LOG_CI_START="-2.2709532661827994" LOG_EFFECT_SIZE="-1.041392685158225" MODIFIED="2011-02-16 15:11:54 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="556" O_E="0.0" SE="1.444499943433743" STUDY_ID="STD-Menges-1996" TOTAL_1="20" TOTAL_2="20" VAR="2.0865800865800868" WEIGHT="0.5340716479121628"/>
<DICH_DATA CI_END="1.5422965811171738" CI_START="0.005358543169388946" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.1881678958663492" LOG_CI_START="-2.2709532661827994" LOG_EFFECT_SIZE="-1.041392685158225" MODIFIED="2011-02-16 15:11:53 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="557" O_E="0.0" SE="1.444499943433743" STUDY_ID="STD-Menges-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.0865800865800868" WEIGHT="0.5340716479121628"/>
<DICH_DATA CI_END="1.9176218302361834" CI_START="0.8501059669326463" EFFECT_SIZE="1.2767857142857142" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="21" LOG_CI_END="0.2827629650687495" LOG_CI_START="-0.0705269354789891" LOG_EFFECT_SIZE="0.10611801479488017" ORDER="558" O_E="0.0" SE="0.20752423639495385" STUDY_ID="STD-Quigley-1995" TOTAL_1="64" TOTAL_2="52" VAR="0.04306630869130869" WEIGHT="6.810008561327232"/>
<DICH_DATA CI_END="1.3240720472445462" CI_START="0.7552459113392245" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.12191161718029553" LOG_CI_START="-0.12191161718029553" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-10 22:57:35 +0000" MODIFIED_BY="[Empty name]" ORDER="168" O_E="0.0" SE="0.14322297480788662" STUDY_ID="STD-Safwat-2002" TOTAL_1="15" TOTAL_2="15" VAR="0.020512820512820523" WEIGHT="7.824831272417818"/>
<DICH_DATA CI_END="1.803432959937625" CI_START="0.9172460261752922" EFFECT_SIZE="1.2861538461538462" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" LOG_CI_END="0.2561000026730645" LOG_CI_START="-0.03751416108074282" LOG_EFFECT_SIZE="0.10929292079616083" ORDER="559" O_E="0.0" SE="0.17247041320253736" STUDY_ID="STD-Shore_x002d_Lesserson-1995" TOTAL_1="25" TOTAL_2="19" VAR="0.02974604343025397" WEIGHT="7.374907736766695"/>
<DICH_DATA CI_END="0.6848108222924871" CI_START="0.35248156648653844" EFFECT_SIZE="0.491307634164777" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="42" LOG_CI_END="-0.16442938497697474" LOG_CI_START="-0.45286359011231603" LOG_EFFECT_SIZE="-0.3086464875446454" ORDER="560" O_E="0.0" SE="0.16942767986884172" STUDY_ID="STD-Stammers-1993" TOTAL_1="63" TOTAL_2="52" VAR="0.028705738705738712" WEIGHT="7.4229972387188345"/>
<DICH_DATA CI_END="1.3876135637286697" CI_START="0.3395267785510633" EFFECT_SIZE="0.6863905325443787" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.14226853635863929" LOG_CI_START="-0.46912596713214944" LOG_EFFECT_SIZE="-0.16342871538675507" ORDER="561" O_E="0.0" SE="0.35913615780209157" STUDY_ID="STD-Stover-2000" TOTAL_1="26" TOTAL_2="29" VAR="0.12897877984084882" WEIGHT="4.558131985457013"/>
<DICH_DATA CI_END="1.9818867342591606" CI_START="0.4395362742244384" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.29707883072854835" LOG_CI_START="-0.35700527748343475" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="563" O_E="0.0" SE="0.3842122429322726" STUDY_ID="STD-Triulzi-1995" TOTAL_1="24" TOTAL_2="28" VAR="0.14761904761904765" WEIGHT="4.252999666227211"/>
<DICH_DATA CI_END="1.4352439621026587" CI_START="0.6454695330282372" EFFECT_SIZE="0.9625" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.1569257285192679" LOG_CI_START="-0.1901242521581913" LOG_EFFECT_SIZE="-0.016599261819461704" MODIFIED="2009-03-10 23:11:54 +0000" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.2038588765750502" STUDY_ID="STD-Wajon-2001" TOTAL_1="40" TOTAL_2="44" VAR="0.04155844155844155" WEIGHT="6.86957400172206"/>
<DICH_DATA CI_END="3.268740668680464" CI_START="0.440536630451416" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5143804664266098" LOG_CI_START="-0.3560179743313601" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="564" O_E="0.0" SE="0.5112763526430005" STUDY_ID="STD-Wong-1994" TOTAL_1="19" TOTAL_2="19" VAR="0.26140350877192986" WEIGHT="3.019241629509921"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="98.43949740003814" CI_END="0.8982708938277522" CI_START="0.5863348312127351" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7257323975928096" ESTIMABLE="YES" EVENTS_1="337" EVENTS_2="474" I2="78.66709953357415" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.04659267229357055" LOG_CI_START="-0.23185430579103375" LOG_EFFECT_SIZE="-0.1392234890423021" METHOD="MH" MODIFIED="2009-04-30 06:47:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="5.44242428901498E-12" P_Q="0.0" P_Z="0.003221075180019384" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1308332677297663" TOTALS="YES" TOTAL_1="801" TOTAL_2="788" WEIGHT="100.0" Z="2.9458125697532034">
<NAME>No. exposed to allogeneic RBC transfusion (Type of surgery)</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="95.56973905463448" CI_END="0.8763646421044315" CI_START="0.5511878005103752" DF="19" EFFECT_SIZE="0.6950118700616585" ESTIMABLE="YES" EVENTS_1="321" EVENTS_2="458" I2="80.11923001156438" ID="CMP-001.02.01" LOG_CI_END="-0.057315152846504604" LOG_CI_START="-0.25870040327325006" LOG_EFFECT_SIZE="-0.15800777805987737" MODIFIED="2009-04-30 06:47:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.3681946121078E-12" P_Z="0.002100842529283561" STUDIES="20" TAU2="0.14266033538779022" TOTAL_1="776" TOTAL_2="763" WEIGHT="90.19314741500249" Z="3.075593208721195">
<NAME>Cardiac surgery</NAME>
<DICH_DATA CI_END="0.8574846465933827" CI_START="0.548884248816184" EFFECT_SIZE="0.686046511627907" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="86" LOG_CI_END="-0.06677364733121739" LOG_CI_START="-0.2605192318716297" LOG_EFFECT_SIZE="-0.16364643960142353" ORDER="216" O_E="0.0" SE="0.1138071154151491" STUDY_ID="STD-Armellin-1995" TOTAL_1="128" TOTAL_2="128" VAR="0.012952059519117067" WEIGHT="8.236289661105857"/>
<DICH_DATA CI_END="0.9252000279486662" CI_START="0.6077794164087427" EFFECT_SIZE="0.7498783454987834" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="90" LOG_CI_END="-0.033764362782145264" LOG_CI_START="-0.21625401220519222" LOG_EFFECT_SIZE="-0.1250091874936687" ORDER="217" O_E="0.0" SE="0.10719532340943128" STUDY_ID="STD-Armellin-1997" TOTAL_1="137" TOTAL_2="138" VAR="0.011490837360852563" WEIGHT="8.32085052271837"/>
<DICH_DATA CI_END="3.845086034384406" CI_START="0.010402888164868843" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5849060616512035" LOG_CI_START="-1.982846070323241" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="218" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Boldt-1990" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="0.49224425487981127"/>
<DICH_DATA CI_END="2.4988165463450835" CI_START="0.008167131474760041" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.39773437303938103" LOG_CI_START="-2.087930453067895" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="219" O_E="0.0" SE="1.4600918230947433" STUDY_ID="STD-Boldt-1993" TOTAL_1="12" TOTAL_2="12" VAR="2.1318681318681314" WEIGHT="0.5233821857577643"/>
<DICH_DATA CI_END="0.49297553247156495" CI_START="0.010349480816516623" EFFECT_SIZE="0.07142857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.3071746352385513" LOG_CI_START="-1.985081436117925" LOG_EFFECT_SIZE="-1.1461280356782382" ORDER="220" O_E="0.0" SE="0.9856107606091622" STUDY_ID="STD-Christenson-1996_x002f_a" TOTAL_1="20" TOTAL_2="20" VAR="0.9714285714285713" WEIGHT="1.0743886453902574"/>
<DICH_DATA CI_END="0.3885376869349723" CI_START="0.04378785658706284" EFFECT_SIZE="0.13043478260869565" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="23" LOG_CI_END="-0.41056684961959766" LOG_CI_START="-1.3586463129762634" LOG_EFFECT_SIZE="-0.8846065812979305" ORDER="221" O_E="0.0" SE="0.5569065698447379" STUDY_ID="STD-Christenson-1996_x002f_b" TOTAL_1="30" TOTAL_2="30" VAR="0.3101449275362319" WEIGHT="2.6855241754625885"/>
<DICH_DATA CI_END="1.0723152043034878" CI_START="0.7995212758907578" EFFECT_SIZE="0.9259259259259259" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" LOG_CI_END="0.030322463871913678" LOG_CI_START="-0.09716997484581309" LOG_EFFECT_SIZE="-0.0334237554869497" ORDER="222" O_E="0.0" SE="0.0748896896005426" STUDY_ID="STD-Ereth-1993" TOTAL_1="28" TOTAL_2="28" VAR="0.005608465608465618" WEIGHT="8.679584869410794"/>
<DICH_DATA CI_END="0.7133237566884246" CI_START="0.0794721076819395" EFFECT_SIZE="0.23809523809523808" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.1467133119012532" LOG_CI_START="-1.099785268894548" LOG_EFFECT_SIZE="-0.6232492903979004" ORDER="223" O_E="0.0" SE="0.5598391853201358" STUDY_ID="STD-Farouk-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.3134199134199134" WEIGHT="2.6657267848346486"/>
<DICH_DATA CI_END="1.2153945101855008" CI_START="0.8663785356539233" EFFECT_SIZE="1.0261538461538462" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" LOG_CI_END="0.084717270351327" LOG_CI_START="-0.06229231580394014" LOG_EFFECT_SIZE="0.011212477273693408" ORDER="224" O_E="0.0" SE="0.08635415861679173" STUDY_ID="STD-Ford-2002" TOTAL_1="25" TOTAL_2="29" VAR="0.007457040710414024" WEIGHT="8.563561811354045"/>
<DICH_DATA CI_END="0.7689807013531469" CI_START="0.3251056880362332" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="34" LOG_CI_END="-0.1140845592896038" LOG_CI_START="-0.48797543203835864" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="225" O_E="0.0" SE="0.21962534944228784" STUDY_ID="STD-Jones-1990" TOTAL_1="50" TOTAL_2="50" VAR="0.04823529411764704" WEIGHT="6.613431146265762"/>
<DICH_DATA CI_END="1.5623477480712817" CI_START="0.025602494738690536" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.1937777057638096" LOG_CI_START="-1.5917177144358472" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="226" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Klein-2001" TOTAL_1="20" TOTAL_2="20" VAR="1.0999999999999999" WEIGHT="0.9621592422692854"/>
<DICH_DATA CI_END="1.5422965811171738" CI_START="0.005358543169388946" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.1881678958663492" LOG_CI_START="-2.2709532661827994" LOG_EFFECT_SIZE="-1.041392685158225" ORDER="227" O_E="0.0" SE="1.444499943433743" STUDY_ID="STD-Menges-1996" TOTAL_1="20" TOTAL_2="20" VAR="2.0865800865800868" WEIGHT="0.534071647912163"/>
<DICH_DATA CI_END="1.5422965811171738" CI_START="0.005358543169388946" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.1881678958663492" LOG_CI_START="-2.2709532661827994" LOG_EFFECT_SIZE="-1.041392685158225" ORDER="228" O_E="0.0" SE="1.444499943433743" STUDY_ID="STD-Menges-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.0865800865800868" WEIGHT="0.534071647912163"/>
<DICH_DATA CI_END="1.9176218302361834" CI_START="0.8501059669326463" EFFECT_SIZE="1.2767857142857142" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="21" LOG_CI_END="0.2827629650687495" LOG_CI_START="-0.0705269354789891" LOG_EFFECT_SIZE="0.10611801479488017" ORDER="229" O_E="0.0" SE="0.20752423639495385" STUDY_ID="STD-Quigley-1995" TOTAL_1="64" TOTAL_2="52" VAR="0.04306630869130869" WEIGHT="6.810008561327233"/>
<DICH_DATA CI_END="1.803432959937625" CI_START="0.9172460261752922" EFFECT_SIZE="1.2861538461538462" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" LOG_CI_END="0.2561000026730645" LOG_CI_START="-0.03751416108074282" LOG_EFFECT_SIZE="0.10929292079616083" ORDER="231" O_E="0.0" SE="0.17247041320253736" STUDY_ID="STD-Shore_x002d_Lesserson-1995" TOTAL_1="25" TOTAL_2="19" VAR="0.02974604343025397" WEIGHT="7.374907736766697"/>
<DICH_DATA CI_END="0.6848108222924871" CI_START="0.35248156648653844" EFFECT_SIZE="0.491307634164777" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="42" LOG_CI_END="-0.16442938497697474" LOG_CI_START="-0.45286359011231603" LOG_EFFECT_SIZE="-0.3086464875446454" ORDER="232" O_E="0.0" SE="0.16942767986884172" STUDY_ID="STD-Stammers-1993" TOTAL_1="63" TOTAL_2="52" VAR="0.028705738705738712" WEIGHT="7.422997238718836"/>
<DICH_DATA CI_END="1.3876135637286697" CI_START="0.3395267785510633" EFFECT_SIZE="0.6863905325443787" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.14226853635863929" LOG_CI_START="-0.46912596713214944" LOG_EFFECT_SIZE="-0.16342871538675507" ORDER="233" O_E="0.0" SE="0.35913615780209157" STUDY_ID="STD-Stover-2000" TOTAL_1="26" TOTAL_2="29" VAR="0.12897877984084882" WEIGHT="4.558131985457014"/>
<DICH_DATA CI_END="1.9818867342591606" CI_START="0.4395362742244384" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.29707883072854835" LOG_CI_START="-0.35700527748343475" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="234" O_E="0.0" SE="0.3842122429322726" STUDY_ID="STD-Triulzi-1995" TOTAL_1="24" TOTAL_2="28" VAR="0.14761904761904765" WEIGHT="4.252999666227212"/>
<DICH_DATA CI_END="1.4352439621026587" CI_START="0.6454695330282372" EFFECT_SIZE="0.9625" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.1569257285192679" LOG_CI_START="-0.1901242521581913" LOG_EFFECT_SIZE="-0.016599261819461704" ORDER="235" O_E="0.0" SE="0.2038588765750502" STUDY_ID="STD-Wajon-2001" TOTAL_1="40" TOTAL_2="44" VAR="0.04155844155844155" WEIGHT="6.869574001722062"/>
<DICH_DATA CI_END="3.268740668680464" CI_START="0.440536630451416" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5143804664266098" LOG_CI_START="-0.3560179743313601" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="236" O_E="0.0" SE="0.5112763526430005" STUDY_ID="STD-Wong-1994" TOTAL_1="19" TOTAL_2="19" VAR="0.26140350877192986" WEIGHT="3.019241629509922"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.316186573445103" CI_START="0.7597707043785682" DF="1" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.11931745620380059" LOG_CI_START="-0.11931745620380059" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-30 06:44:00 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="2" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="9.806852584997515" Z="0.0">
<NAME>Vascular surgery</NAME>
<DICH_DATA CI_END="3.8148841482433915" CI_START="0.2621311581533772" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5814813536820973" LOG_CI_START="-0.5814813536820973" LOG_EFFECT_SIZE="0.0" ORDER="215" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Godet-1995" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="1.9820213125796957"/>
<DICH_DATA CI_END="1.3240720472445462" CI_START="0.7552459113392245" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.12191161718029553" LOG_CI_START="-0.12191161718029553" LOG_EFFECT_SIZE="0.0" ORDER="214" O_E="0.0" SE="0.14322297480788662" STUDY_ID="STD-Safwat-2002" TOTAL_1="15" TOTAL_2="15" VAR="0.020512820512820523" WEIGHT="7.824831272417819"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="70.47742122847728" CI_END="0.8970357126553851" CI_START="0.5550641606678491" CI_STUDY="95" CI_TOTAL="95" DF="17" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7056290632720192" ESTIMABLE="YES" EVENTS_1="287" EVENTS_2="419" I2="75.8787996159954" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.047190266542946245" LOG_CI_START="-0.25565681324942463" LOG_EFFECT_SIZE="-0.1514235398961854" METHOD="MH" MODIFIED="2011-02-16 15:13:58 +0000" MODIFIED_BY="Emma M Sydenham" NO="3" P_CHI2="1.7845805944105564E-8" P_Q="0.0" P_Z="0.004409008149835479" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.13391294204808188" TOTALS="YES" TOTAL_1="718" TOTAL_2="711" WEIGHT="100.0" Z="2.847312331853046">
<NAME>No. exposed to allogeneic RBC transfusion (Post-operative or trial transfusion trigger)</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.81488279717226" CI_END="0.6153148978884678" CI_START="0.1752899049467363" DF="3" EFFECT_SIZE="0.3284181632662546" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="113" I2="72.26044834453127" ID="CMP-001.03.01" LOG_CI_END="-0.21090256972843985" LOG_CI_START="-0.756243094471919" LOG_EFFECT_SIZE="-0.48357283210017943" NO="1" P_CHI2="0.012770203182155493" P_Z="5.090671172278859E-4" STUDIES="4" TAU2="0.2430072669343213" TOTAL_1="163" TOTAL_2="152" WEIGHT="22.18674571198167" Z="3.475939497671521">
<NAME>Hb &lt; 6.6-7.0 g/dL</NAME>
<DICH_DATA CI_END="0.49297553247156495" CI_START="0.010349480816516623" EFFECT_SIZE="0.07142857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.3071746352385513" LOG_CI_START="-1.985081436117925" LOG_EFFECT_SIZE="-1.1461280356782382" ORDER="565" O_E="0.0" SE="0.9856107606091622" STUDY_ID="STD-Christenson-1996_x002f_a" TOTAL_1="20" TOTAL_2="20" VAR="0.9714285714285713" WEIGHT="1.3565989212756457"/>
<DICH_DATA CI_END="0.3885376869349723" CI_START="0.04378785658706284" EFFECT_SIZE="0.13043478260869565" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="23" LOG_CI_END="-0.41056684961959766" LOG_CI_START="-1.3586463129762634" LOG_EFFECT_SIZE="-0.8846065812979305" ORDER="566" O_E="0.0" SE="0.5569065698447379" STUDY_ID="STD-Christenson-1996_x002f_b" TOTAL_1="30" TOTAL_2="30" VAR="0.3101449275362319" WEIGHT="3.3768236248742003"/>
<DICH_DATA CI_END="0.7689807013531469" CI_START="0.3251056880362332" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="34" LOG_CI_END="-0.1140845592896038" LOG_CI_START="-0.48797543203835864" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="567" O_E="0.0" SE="0.21962534944228784" STUDY_ID="STD-Jones-1990" TOTAL_1="50" TOTAL_2="50" VAR="0.04823529411764704" WEIGHT="8.232333929708117"/>
<DICH_DATA CI_END="0.6848108222924871" CI_START="0.35248156648653844" EFFECT_SIZE="0.491307634164777" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="42" LOG_CI_END="-0.16442938497697474" LOG_CI_START="-0.45286359011231603" LOG_EFFECT_SIZE="-0.3086464875446454" ORDER="568" O_E="0.0" SE="0.16942767986884172" STUDY_ID="STD-Stammers-1993" TOTAL_1="63" TOTAL_2="52" VAR="0.028705738705738712" WEIGHT="9.22098923612371"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.586275298520057" CI_END="1.251901657222055" CI_START="0.6350993770157392" DF="6" EFFECT_SIZE="0.8916736861580579" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="88" I2="48.21459144194171" ID="CMP-001.03.02" LOG_CI_END="0.09757021433505159" LOG_CI_START="-0.19715831327062405" LOG_EFFECT_SIZE="-0.04979404946778618" MODIFIED="2011-02-16 15:13:58 +0000" MODIFIED_BY="Emma M Sydenham" NO="2" P_CHI2="0.07186113896078361" P_Z="0.507799888244304" STUDIES="7" TAU2="0.07736930169878263" TOTAL_1="174" TOTAL_2="189" WEIGHT="35.32644169871902" Z="0.6622673712253666">
<NAME>Hb &lt; 8.0-8.5 g/dL</NAME>
<DICH_DATA CI_END="1.2153945101855008" CI_START="0.8663785356539233" EFFECT_SIZE="1.0261538461538462" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" LOG_CI_END="0.084717270351327" LOG_CI_START="-0.06229231580394014" LOG_EFFECT_SIZE="0.011212477273693408" MODIFIED="2009-03-10 22:38:25 +0000" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="0.08635415861679173" STUDY_ID="STD-Ford-2002" TOTAL_1="25" TOTAL_2="29" VAR="0.007457040710414024" WEIGHT="10.606955419844965"/>
<DICH_DATA CI_END="1.5422965811171738" CI_START="0.005358543169388946" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.1881678958663492" LOG_CI_START="-2.2709532661827994" LOG_EFFECT_SIZE="-1.041392685158225" MODIFIED="2011-02-16 15:13:58 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="569" O_E="0.0" SE="1.444499943433743" STUDY_ID="STD-Menges-1996" TOTAL_1="20" TOTAL_2="20" VAR="2.0865800865800868" WEIGHT="0.6753027753255406"/>
<DICH_DATA CI_END="1.5422965811171738" CI_START="0.005358543169388946" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.1881678958663492" LOG_CI_START="-2.2709532661827994" LOG_EFFECT_SIZE="-1.041392685158225" MODIFIED="2011-02-16 15:13:58 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="570" O_E="0.0" SE="1.444499943433743" STUDY_ID="STD-Menges-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.0865800865800868" WEIGHT="0.6753027753255406"/>
<DICH_DATA CI_END="1.3876135637286697" CI_START="0.3395267785510633" EFFECT_SIZE="0.6863905325443787" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.14226853635863929" LOG_CI_START="-0.46912596713214944" LOG_EFFECT_SIZE="-0.16342871538675507" ORDER="571" O_E="0.0" SE="0.35913615780209157" STUDY_ID="STD-Stover-2000" TOTAL_1="26" TOTAL_2="29" VAR="0.12897877984084882" WEIGHT="5.703888635402313"/>
<DICH_DATA CI_END="1.9818867342591606" CI_START="0.4395362742244384" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.29707883072854835" LOG_CI_START="-0.35700527748343475" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="572" O_E="0.0" SE="0.3842122429322726" STUDY_ID="STD-Triulzi-1995" TOTAL_1="24" TOTAL_2="28" VAR="0.14761904761904765" WEIGHT="5.326233464966319"/>
<DICH_DATA CI_END="1.4352439621026587" CI_START="0.6454695330282372" EFFECT_SIZE="0.9625" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.1569257285192679" LOG_CI_START="-0.1901242521581913" LOG_EFFECT_SIZE="-0.016599261819461704" MODIFIED="2009-03-10 23:13:00 +0000" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="0.2038588765750502" STUDY_ID="STD-Wajon-2001" TOTAL_1="40" TOTAL_2="44" VAR="0.04155844155844155" WEIGHT="8.545582043087457"/>
<DICH_DATA CI_END="3.268740668680464" CI_START="0.440536630451416" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5143804664266098" LOG_CI_START="-0.3560179743313601" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="573" O_E="0.0" SE="0.5112763526430005" STUDY_ID="STD-Wong-1994" TOTAL_1="19" TOTAL_2="19" VAR="0.26140350877192986" WEIGHT="3.7931765847668824"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.89303787958643" CI_END="0.9691035733210001" CI_START="0.6337099836683914" DF="3" EFFECT_SIZE="0.7836648579732478" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="191" I2="49.09247044903539" ID="CMP-001.03.03" LOG_CI_END="-0.013629805077202723" LOG_CI_START="-0.19810945080763537" LOG_EFFECT_SIZE="-0.10586962794241904" MODIFIED="2009-03-10 22:58:15 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.11693195753995589" P_Z="0.024475758984199195" STUDIES="4" TAU2="0.0208326443033718" TOTAL_1="295" TOTAL_2="296" WEIGHT="30.855470890465035" Z="2.2495778003282063">
<NAME>Hb &lt; 9.0 g/dL</NAME>
<DICH_DATA CI_END="0.8574846465933827" CI_START="0.548884248816184" EFFECT_SIZE="0.686046511627907" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="86" LOG_CI_END="-0.06677364733121739" LOG_CI_START="-0.2605192318716297" LOG_EFFECT_SIZE="-0.16364643960142353" ORDER="574" O_E="0.0" SE="0.1138071154151491" STUDY_ID="STD-Armellin-1995" TOTAL_1="128" TOTAL_2="128" VAR="0.012952059519117067" WEIGHT="10.21009150459519"/>
<DICH_DATA CI_END="0.9252000279486662" CI_START="0.6077794164087427" EFFECT_SIZE="0.7498783454987834" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="90" LOG_CI_END="-0.033764362782145264" LOG_CI_START="-0.21625401220519222" LOG_EFFECT_SIZE="-0.1250091874936687" ORDER="575" O_E="0.0" SE="0.10719532340943128" STUDY_ID="STD-Armellin-1997" TOTAL_1="137" TOTAL_2="138" VAR="0.011490837360852563" WEIGHT="10.312696897694801"/>
<DICH_DATA CI_END="3.845086034384406" CI_START="0.010402888164868843" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5849060616512035" LOG_CI_START="-1.982846070323241" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="576" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Boldt-1990" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="0.622482065934987"/>
<DICH_DATA CI_END="1.3240720472445462" CI_START="0.7552459113392245" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.12191161718029553" LOG_CI_START="-0.12191161718029553" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-10 22:58:15 +0000" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="0.14322297480788662" STUDY_ID="STD-Safwat-2002" TOTAL_1="15" TOTAL_2="15" VAR="0.020512820512820523" WEIGHT="9.710200422240058"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.431939031355199" CI_END="2.067366688423982" CI_START="0.5884651753249975" DF="2" EFFECT_SIZE="1.10298381709093" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="27" I2="17.761096219361264" ID="CMP-001.03.04" LOG_CI_END="0.31541751418662073" LOG_CI_START="-0.23027923309530254" LOG_EFFECT_SIZE="0.042569140545659113" NO="4" P_CHI2="0.2964225596268055" P_Z="0.7597654414821766" STUDIES="3" TAU2="0.09048715824311365" TOTAL_1="86" TOTAL_2="74" WEIGHT="11.63134169883428" Z="0.3057888203948231">
<NAME>Hb &lt; 10.0 g/dL</NAME>
<DICH_DATA CI_END="2.4988165463450835" CI_START="0.008167131474760041" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.39773437303938103" LOG_CI_START="-2.087930453067895" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="577" O_E="0.0" SE="1.4600918230947433" STUDY_ID="STD-Boldt-1993" TOTAL_1="12" TOTAL_2="12" VAR="2.1318681318681314" WEIGHT="0.6618049387409916"/>
<DICH_DATA CI_END="3.8148841482433915" CI_START="0.2621311581533772" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5814813536820973" LOG_CI_START="-0.5814813536820973" LOG_EFFECT_SIZE="0.0" ORDER="578" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Godet-1995" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="2.4967632651274756"/>
<DICH_DATA CI_END="1.9176218302361834" CI_START="0.8501059669326463" EFFECT_SIZE="1.2767857142857142" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="21" LOG_CI_END="0.2827629650687495" LOG_CI_START="-0.0705269354789891" LOG_EFFECT_SIZE="0.10611801479488017" ORDER="579" O_E="0.0" SE="0.20752423639495385" STUDY_ID="STD-Quigley-1995" TOTAL_1="64" TOTAL_2="52" VAR="0.04306630869130869" WEIGHT="8.472773494965814"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="98.43949740003814" CI_END="0.8982708938277522" CI_START="0.5863348312127351" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7257323975928095" ESTIMABLE="YES" EVENTS_1="337" EVENTS_2="474" I2="78.66709953357415" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.04659267229357055" LOG_CI_START="-0.23185430579103375" LOG_EFFECT_SIZE="-0.13922348904230217" METHOD="MH" MODIFIED="2011-02-16 15:15:45 +0000" MODIFIED_BY="Emma M Sydenham" NO="4" P_CHI2="5.44242428901498E-12" P_Q="0.0" P_Z="0.003221075180019384" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.13083326772976633" TOTALS="YES" TOTAL_1="801" TOTAL_2="788" WEIGHT="100.00000000000001" Z="2.9458125697532034">
<NAME>No. exposed to allogeneic RBC transfusion (Intra-operative cell salvage)</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="89.52365441796725" CI_END="0.9335021914544261" CI_START="0.5436380649186956" DF="15" EFFECT_SIZE="0.71238144624888" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="323" I2="83.24465182132967" ID="CMP-001.04.01" LOG_CI_END="-0.029884658180411743" LOG_CI_START="-0.26469014206946284" LOG_EFFECT_SIZE="-0.14728740012493732" MODIFIED="2011-02-16 15:15:45 +0000" MODIFIED_BY="Emma M Sydenham" NO="1" P_CHI2="1.2170264795940966E-12" P_Z="0.01393753421674396" STUDIES="16" TAU2="0.1647484314992803" TOTAL_1="519" TOTAL_2="514" WEIGHT="73.92217010082877" Z="2.4588693146351033">
<NAME>Intra-operative cell salvage</NAME>
<DICH_DATA CI_END="0.9252000279486662" CI_START="0.6077794164087427" EFFECT_SIZE="0.7498783454987834" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="90" LOG_CI_END="-0.033764362782145264" LOG_CI_START="-0.21625401220519222" LOG_EFFECT_SIZE="-0.1250091874936687" ORDER="205" O_E="0.0" SE="0.10719532340943128" STUDY_ID="STD-Armellin-1997" TOTAL_1="137" TOTAL_2="138" VAR="0.011490837360852563" WEIGHT="8.32085052271837"/>
<DICH_DATA CI_END="3.845086034384406" CI_START="0.010402888164868843" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5849060616512035" LOG_CI_START="-1.982846070323241" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2011-02-16 15:15:45 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="207" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Boldt-1990" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="0.4922442548798114"/>
<DICH_DATA CI_END="2.4988165463450835" CI_START="0.008167131474760041" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.39773437303938103" LOG_CI_START="-2.087930453067895" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2011-02-16 15:15:45 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="208" O_E="0.0" SE="1.4600918230947433" STUDY_ID="STD-Boldt-1993" TOTAL_1="12" TOTAL_2="12" VAR="2.1318681318681314" WEIGHT="0.5233821857577644"/>
<DICH_DATA CI_END="0.49297553247156495" CI_START="0.010349480816516623" EFFECT_SIZE="0.07142857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.3071746352385513" LOG_CI_START="-1.985081436117925" LOG_EFFECT_SIZE="-1.1461280356782382" ORDER="209" O_E="0.0" SE="0.9856107606091622" STUDY_ID="STD-Christenson-1996_x002f_a" TOTAL_1="20" TOTAL_2="20" VAR="0.9714285714285713" WEIGHT="1.0743886453902576"/>
<DICH_DATA CI_END="0.3885376869349723" CI_START="0.04378785658706284" EFFECT_SIZE="0.13043478260869565" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="23" LOG_CI_END="-0.41056684961959766" LOG_CI_START="-1.3586463129762634" LOG_EFFECT_SIZE="-0.8846065812979305" ORDER="210" O_E="0.0" SE="0.5569065698447379" STUDY_ID="STD-Christenson-1996_x002f_b" TOTAL_1="30" TOTAL_2="30" VAR="0.3101449275362319" WEIGHT="2.685524175462589"/>
<DICH_DATA CI_END="1.0723152043034878" CI_START="0.7995212758907578" EFFECT_SIZE="0.9259259259259259" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" LOG_CI_END="0.030322463871913678" LOG_CI_START="-0.09716997484581309" LOG_EFFECT_SIZE="-0.0334237554869497" ORDER="211" O_E="0.0" SE="0.0748896896005426" STUDY_ID="STD-Ereth-1993" TOTAL_1="28" TOTAL_2="28" VAR="0.005608465608465618" WEIGHT="8.679584869410796"/>
<DICH_DATA CI_END="1.2153945101855008" CI_START="0.8663785356539233" EFFECT_SIZE="1.0261538461538462" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" LOG_CI_END="0.084717270351327" LOG_CI_START="-0.06229231580394014" LOG_EFFECT_SIZE="0.011212477273693408" ORDER="213" O_E="0.0" SE="0.08635415861679173" STUDY_ID="STD-Ford-2002" TOTAL_1="25" TOTAL_2="29" VAR="0.007457040710414024" WEIGHT="8.563561811354045"/>
<DICH_DATA CI_END="3.8148841482433915" CI_START="0.2621311581533772" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5814813536820973" LOG_CI_START="-0.5814813536820973" LOG_EFFECT_SIZE="0.0" ORDER="214" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Godet-1995" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="1.9820213125796962"/>
<DICH_DATA CI_END="0.7689807013531469" CI_START="0.3251056880362332" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="34" LOG_CI_END="-0.1140845592896038" LOG_CI_START="-0.48797543203835864" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="215" O_E="0.0" SE="0.21962534944228784" STUDY_ID="STD-Jones-1990" TOTAL_1="50" TOTAL_2="50" VAR="0.04823529411764704" WEIGHT="6.6134311462657625"/>
<DICH_DATA CI_END="1.5422965811171738" CI_START="0.005358543169388946" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.1881678958663492" LOG_CI_START="-2.2709532661827994" LOG_EFFECT_SIZE="-1.041392685158225" MODIFIED="2011-02-16 15:15:44 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="217" O_E="0.0" SE="1.444499943433743" STUDY_ID="STD-Menges-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.0865800865800868" WEIGHT="0.5340716479121631"/>
<DICH_DATA CI_END="1.3240720472445462" CI_START="0.7552459113392245" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.12191161718029553" LOG_CI_START="-0.12191161718029553" LOG_EFFECT_SIZE="0.0" ORDER="219" O_E="0.0" SE="0.14322297480788662" STUDY_ID="STD-Safwat-2002" TOTAL_1="15" TOTAL_2="15" VAR="0.020512820512820523" WEIGHT="7.8248312724178195"/>
<DICH_DATA CI_END="1.803432959937625" CI_START="0.9172460261752922" EFFECT_SIZE="1.2861538461538462" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" LOG_CI_END="0.2561000026730645" LOG_CI_START="-0.03751416108074282" LOG_EFFECT_SIZE="0.10929292079616083" ORDER="220" O_E="0.0" SE="0.17247041320253736" STUDY_ID="STD-Shore_x002d_Lesserson-1995" TOTAL_1="25" TOTAL_2="19" VAR="0.02974604343025397" WEIGHT="7.374907736766698"/>
<DICH_DATA CI_END="0.6848108222924871" CI_START="0.35248156648653844" EFFECT_SIZE="0.491307634164777" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="42" LOG_CI_END="-0.16442938497697474" LOG_CI_START="-0.45286359011231603" LOG_EFFECT_SIZE="-0.3086464875446454" ORDER="221" O_E="0.0" SE="0.16942767986884172" STUDY_ID="STD-Stammers-1993" TOTAL_1="63" TOTAL_2="52" VAR="0.028705738705738712" WEIGHT="7.422997238718835"/>
<DICH_DATA CI_END="1.3876135637286697" CI_START="0.3395267785510633" EFFECT_SIZE="0.6863905325443787" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.14226853635863929" LOG_CI_START="-0.46912596713214944" LOG_EFFECT_SIZE="-0.16342871538675507" ORDER="222" O_E="0.0" SE="0.35913615780209157" STUDY_ID="STD-Stover-2000" TOTAL_1="26" TOTAL_2="29" VAR="0.12897877984084882" WEIGHT="4.558131985457015"/>
<DICH_DATA CI_END="1.9818867342591606" CI_START="0.4395362742244384" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.29707883072854835" LOG_CI_START="-0.35700527748343475" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="223" O_E="0.0" SE="0.3842122429322726" STUDY_ID="STD-Triulzi-1995" TOTAL_1="24" TOTAL_2="28" VAR="0.14761904761904765" WEIGHT="4.252999666227213"/>
<DICH_DATA CI_END="3.268740668680464" CI_START="0.440536630451416" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5143804664266098" LOG_CI_START="-0.3560179743313601" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="225" O_E="0.0" SE="0.5112763526430005" STUDY_ID="STD-Wong-1994" TOTAL_1="19" TOTAL_2="19" VAR="0.26140350877192986" WEIGHT="3.0192416295099225"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="16.62462793242872" CI_END="1.1103153874234941" CI_START="0.4549548011073411" DF="5" EFFECT_SIZE="0.7107343499871637" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="151" I2="69.92413893217554" ID="CMP-001.04.02" LOG_CI_END="0.045446358572594374" LOG_CI_START="-0.34203174752908705" LOG_EFFECT_SIZE="-0.1482926944782464" MODIFIED="2009-04-30 03:46:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.00526957648664661" P_Z="0.13356124931741278" STUDIES="6" TAU2="0.15680562144015692" TOTAL_1="282" TOTAL_2="274" WEIGHT="26.077829899171252" Z="1.5002052284806675">
<NAME>No intra-operative cell salvage</NAME>
<DICH_DATA CI_END="0.8574846465933827" CI_START="0.548884248816184" EFFECT_SIZE="0.686046511627907" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="86" LOG_CI_END="-0.06677364733121739" LOG_CI_START="-0.2605192318716297" LOG_EFFECT_SIZE="-0.16364643960142353" ORDER="206" O_E="0.0" SE="0.1138071154151491" STUDY_ID="STD-Armellin-1995" TOTAL_1="128" TOTAL_2="128" VAR="0.012952059519117067" WEIGHT="8.236289661105856"/>
<DICH_DATA CI_END="0.7133237566884246" CI_START="0.0794721076819395" EFFECT_SIZE="0.23809523809523808" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.1467133119012532" LOG_CI_START="-1.099785268894548" LOG_EFFECT_SIZE="-0.6232492903979004" ORDER="212" O_E="0.0" SE="0.5598391853201358" STUDY_ID="STD-Farouk-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.3134199134199134" WEIGHT="2.665726784834649"/>
<DICH_DATA CI_END="1.5623477480712817" CI_START="0.025602494738690536" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.1937777057638096" LOG_CI_START="-1.5917177144358472" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="226" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Klein-2001" TOTAL_1="20" TOTAL_2="20" VAR="1.0999999999999999" WEIGHT="0.9621592422692855"/>
<DICH_DATA CI_END="1.5422965811171738" CI_START="0.005358543169388946" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.1881678958663492" LOG_CI_START="-2.2709532661827994" LOG_EFFECT_SIZE="-1.041392685158225" ORDER="216" O_E="0.0" SE="1.444499943433743" STUDY_ID="STD-Menges-1996" TOTAL_1="20" TOTAL_2="20" VAR="2.0865800865800868" WEIGHT="0.5340716479121631"/>
<DICH_DATA CI_END="1.9176218302361834" CI_START="0.8501059669326463" EFFECT_SIZE="1.2767857142857142" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="21" LOG_CI_END="0.2827629650687495" LOG_CI_START="-0.0705269354789891" LOG_EFFECT_SIZE="0.10611801479488017" ORDER="218" O_E="0.0" SE="0.20752423639495385" STUDY_ID="STD-Quigley-1995" TOTAL_1="64" TOTAL_2="52" VAR="0.04306630869130869" WEIGHT="6.810008561327234"/>
<DICH_DATA CI_END="1.4352439621026587" CI_START="0.6454695330282372" EFFECT_SIZE="0.9625" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.1569257285192679" LOG_CI_START="-0.1901242521581913" LOG_EFFECT_SIZE="-0.016599261819461704" ORDER="224" O_E="0.0" SE="0.2038588765750502" STUDY_ID="STD-Wajon-2001" TOTAL_1="40" TOTAL_2="44" VAR="0.04155844155844155" WEIGHT="6.869574001722062"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="98.43949740003812" CI_END="0.8933876247916475" CI_START="0.5712024956195493" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7143565222188502" ESTIMABLE="YES" EVENTS_1="337" EVENTS_2="474" I2="78.66709953357415" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.04896006767112384" LOG_CI_START="-0.24320990376789128" LOG_EFFECT_SIZE="-0.14608498571950754" METHOD="MH" MODIFIED="2011-02-16 15:17:22 +0000" MODIFIED_BY="Emma M Sydenham" NO="5" P_CHI2="5.4427573559223674E-12" P_Q="0.0" P_Z="0.003198684663332221" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.13083326772976633" TOTALS="SUB" TOTAL_1="801" TOTAL_2="788" WEIGHT="200.00000000000003" Z="2.947969650277072">
<NAME>No. exposed to allogeneic RBC transfusion (Post-operative cell salvage)</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.984161037304975" CI_END="1.7013105878288672" CI_START="0.4184920279169986" DF="2" EFFECT_SIZE="0.8437919874099087" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="57" I2="84.5966174152202" ID="CMP-001.05.01" LOG_CI_END="0.23078360477492238" LOG_CI_START="-0.37831281070449313" LOG_EFFECT_SIZE="-0.0737646029647854" MODIFIED="2009-04-30 01:57:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.00151539945187118" P_Z="0.634984596167802" STUDIES="3" TAU2="0.31516941467061876" TOTAL_1="99" TOTAL_2="97" WEIGHT="100.00000000000001" Z="0.47472275807461817">
<NAME>Post-operative cell salvage</NAME>
<DICH_DATA CI_END="0.7689807013531469" CI_START="0.3251056880362332" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="34" LOG_CI_END="-0.1140845592896038" LOG_CI_START="-0.48797543203835864" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="582" O_E="0.0" SE="0.21962534944228784" STUDY_ID="STD-Jones-1990" TOTAL_1="50" TOTAL_2="50" VAR="0.04823529411764704" WEIGHT="35.225465508827114"/>
<DICH_DATA CI_END="1.803432959937625" CI_START="0.9172460261752922" EFFECT_SIZE="1.2861538461538462" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" LOG_CI_END="0.2561000026730645" LOG_CI_START="-0.03751416108074282" LOG_EFFECT_SIZE="0.10929292079616083" ORDER="584" O_E="0.0" SE="0.17247041320253736" STUDY_ID="STD-Shore_x002d_Lesserson-1995" TOTAL_1="25" TOTAL_2="19" VAR="0.02974604343025397" WEIGHT="37.11373246548624"/>
<DICH_DATA CI_END="1.9818867342591606" CI_START="0.4395362742244384" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.29707883072854835" LOG_CI_START="-0.35700527748343475" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="588" O_E="0.0" SE="0.3842122429322726" STUDY_ID="STD-Triulzi-1995" TOTAL_1="24" TOTAL_2="28" VAR="0.14761904761904765" WEIGHT="27.66080202568666"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="86.55693356016769" CI_END="0.8875699919143901" CI_START="0.5536698733989519" DF="18" EFFECT_SIZE="0.7010140976156964" ESTIMABLE="YES" EVENTS_1="290" EVENTS_2="417" I2="79.20443890553517" ID="CMP-001.05.02" LOG_CI_END="-0.05179738936735844" LOG_CI_START="-0.25674910692431235" LOG_EFFECT_SIZE="-0.1542732481458354" MODIFIED="2011-02-16 15:17:22 +0000" MODIFIED_BY="Emma M Sydenham" NO="2" P_CHI2="5.959521764964393E-11" P_Z="0.0031710985909929224" STUDIES="19" TAU2="0.13094170229164398" TOTAL_1="702" TOTAL_2="691" WEIGHT="100.00000000000001" Z="2.9506462668196245">
<NAME>No post-operative cell salvage</NAME>
<DICH_DATA CI_END="0.8574846465933827" CI_START="0.548884248816184" EFFECT_SIZE="0.686046511627907" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="86" LOG_CI_END="-0.06677364733121739" LOG_CI_START="-0.2605192318716297" LOG_EFFECT_SIZE="-0.16364643960142353" ORDER="590" O_E="0.0" SE="0.1138071154151491" STUDY_ID="STD-Armellin-1995" TOTAL_1="128" TOTAL_2="128" VAR="0.012952059519117067" WEIGHT="10.072478798438475"/>
<DICH_DATA CI_END="0.9252000279486662" CI_START="0.6077794164087427" EFFECT_SIZE="0.7498783454987834" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="90" LOG_CI_END="-0.033764362782145264" LOG_CI_START="-0.21625401220519222" LOG_EFFECT_SIZE="-0.1250091874936687" ORDER="591" O_E="0.0" SE="0.10719532340943128" STUDY_ID="STD-Armellin-1997" TOTAL_1="137" TOTAL_2="138" VAR="0.011490837360852563" WEIGHT="10.175812834641413"/>
<DICH_DATA CI_END="3.845086034384406" CI_START="0.010402888164868843" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5849060616512035" LOG_CI_START="-1.982846070323241" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2011-02-16 15:17:22 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="592" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Boldt-1990" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="0.6024114647856736"/>
<DICH_DATA CI_END="2.4988165463450835" CI_START="0.008167131474760041" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.39773437303938103" LOG_CI_START="-2.087930453067895" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2011-02-16 15:17:22 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="593" O_E="0.0" SE="1.4600918230947433" STUDY_ID="STD-Boldt-1993" TOTAL_1="12" TOTAL_2="12" VAR="2.1318681318681314" WEIGHT="0.6405164248389543"/>
<DICH_DATA CI_END="0.49297553247156495" CI_START="0.010349480816516623" EFFECT_SIZE="0.07142857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.3071746352385513" LOG_CI_START="-1.985081436117925" LOG_EFFECT_SIZE="-1.1461280356782382" ORDER="594" O_E="0.0" SE="0.9856107606091622" STUDY_ID="STD-Christenson-1996_x002f_a" TOTAL_1="20" TOTAL_2="20" VAR="0.9714285714285713" WEIGHT="1.3147731752373975"/>
<DICH_DATA CI_END="0.3885376869349723" CI_START="0.04378785658706284" EFFECT_SIZE="0.13043478260869565" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="23" LOG_CI_END="-0.41056684961959766" LOG_CI_START="-1.3586463129762634" LOG_EFFECT_SIZE="-0.8846065812979305" ORDER="595" O_E="0.0" SE="0.5569065698447379" STUDY_ID="STD-Christenson-1996_x002f_b" TOTAL_1="30" TOTAL_2="30" VAR="0.3101449275362319" WEIGHT="3.2859006985363153"/>
<DICH_DATA CI_END="1.0723152043034878" CI_START="0.7995212758907578" EFFECT_SIZE="0.9259259259259259" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" LOG_CI_END="0.030322463871913678" LOG_CI_START="-0.09716997484581309" LOG_EFFECT_SIZE="-0.0334237554869497" ORDER="196" O_E="0.0" SE="0.0748896896005426" STUDY_ID="STD-Ereth-1993" TOTAL_1="28" TOTAL_2="28" VAR="0.005608465608465618" WEIGHT="10.614171240907593"/>
<DICH_DATA CI_END="0.7133237566884246" CI_START="0.0794721076819395" EFFECT_SIZE="0.23809523809523808" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.1467133119012532" LOG_CI_START="-1.099785268894548" LOG_EFFECT_SIZE="-0.6232492903979004" MODIFIED="2009-03-11 04:06:20 +0000" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="0.5598391853201358" STUDY_ID="STD-Farouk-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.3134199134199134" WEIGHT="3.2616833088644968"/>
<DICH_DATA CI_END="1.2153945101855008" CI_START="0.8663785356539233" EFFECT_SIZE="1.0261538461538462" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" LOG_CI_END="0.084717270351327" LOG_CI_START="-0.06229231580394014" LOG_EFFECT_SIZE="0.011212477273693408" ORDER="199" O_E="0.0" SE="0.08635415861679173" STUDY_ID="STD-Ford-2002" TOTAL_1="25" TOTAL_2="29" VAR="0.007457040710414024" WEIGHT="10.472399052388026"/>
<DICH_DATA CI_END="3.8148841482433915" CI_START="0.2621311581533772" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5814813536820973" LOG_CI_START="-0.5814813536820973" LOG_EFFECT_SIZE="0.0" ORDER="198" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Godet-1995" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="2.4252787282628474"/>
<DICH_DATA CI_END="1.5623477480712817" CI_START="0.025602494738690536" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.1937777057638096" LOG_CI_START="-1.5917177144358472" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="596" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Klein-2001" TOTAL_1="20" TOTAL_2="20" VAR="1.0999999999999999" WEIGHT="1.1774455787533729"/>
<DICH_DATA CI_END="1.5422965811171738" CI_START="0.005358543169388946" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.1881678958663492" LOG_CI_START="-2.2709532661827994" LOG_EFFECT_SIZE="-1.041392685158225" MODIFIED="2011-02-16 15:17:21 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="597" O_E="0.0" SE="1.444499943433743" STUDY_ID="STD-Menges-1996" TOTAL_1="20" TOTAL_2="20" VAR="2.0865800865800868" WEIGHT="0.6535975756088874"/>
<DICH_DATA CI_END="1.5422965811171738" CI_START="0.005358543169388946" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.1881678958663492" LOG_CI_START="-2.2709532661827994" LOG_EFFECT_SIZE="-1.041392685158225" MODIFIED="2011-02-16 15:17:21 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="200" O_E="0.0" SE="1.444499943433743" STUDY_ID="STD-Menges-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.0865800865800868" WEIGHT="0.6535975756088874"/>
<DICH_DATA CI_END="1.9176218302361834" CI_START="0.8501059669326463" EFFECT_SIZE="1.2767857142857142" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="21" LOG_CI_END="0.2827629650687495" LOG_CI_START="-0.0705269354789891" LOG_EFFECT_SIZE="0.10611801479488017" ORDER="598" O_E="0.0" SE="0.20752423639495385" STUDY_ID="STD-Quigley-1995" TOTAL_1="64" TOTAL_2="52" VAR="0.04306630869130869" WEIGHT="8.329311144234843"/>
<DICH_DATA CI_END="1.3240720472445462" CI_START="0.7552459113392245" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.12191161718029553" LOG_CI_START="-0.12191161718029553" LOG_EFFECT_SIZE="0.0" ORDER="201" O_E="0.0" SE="0.14322297480788662" STUDY_ID="STD-Safwat-2002" TOTAL_1="15" TOTAL_2="15" VAR="0.020512820512820523" WEIGHT="9.569650600250828"/>
<DICH_DATA CI_END="0.6848108222924871" CI_START="0.35248156648653844" EFFECT_SIZE="0.491307634164777" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="42" LOG_CI_END="-0.16442938497697474" LOG_CI_START="-0.45286359011231603" LOG_EFFECT_SIZE="-0.3086464875446454" ORDER="202" O_E="0.0" SE="0.16942767986884172" STUDY_ID="STD-Stammers-1993" TOTAL_1="63" TOTAL_2="52" VAR="0.028705738705738712" WEIGHT="9.078547429333412"/>
<DICH_DATA CI_END="1.3876135637286697" CI_START="0.3395267785510633" EFFECT_SIZE="0.6863905325443787" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.14226853635863929" LOG_CI_START="-0.46912596713214944" LOG_EFFECT_SIZE="-0.16342871538675507" ORDER="203" O_E="0.0" SE="0.35913615780209157" STUDY_ID="STD-Stover-2000" TOTAL_1="26" TOTAL_2="29" VAR="0.12897877984084882" WEIGHT="5.57619335411836"/>
<DICH_DATA CI_END="1.4352439621026587" CI_START="0.6454695330282372" EFFECT_SIZE="0.9625" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.1569257285192679" LOG_CI_START="-0.1901242521581913" LOG_EFFECT_SIZE="-0.016599261819461704" MODIFIED="2009-03-10 23:14:01 +0000" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.2038588765750502" STUDY_ID="STD-Wajon-2001" TOTAL_1="40" TOTAL_2="44" VAR="0.04155844155844155" WEIGHT="8.402119747366969"/>
<DICH_DATA CI_END="3.268740668680464" CI_START="0.440536630451416" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5143804664266098" LOG_CI_START="-0.3560179743313601" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="204" O_E="0.0" SE="0.5112763526430005" STUDY_ID="STD-Wong-1994" TOTAL_1="19" TOTAL_2="19" VAR="0.26140350877192986" WEIGHT="3.694111267823268"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="76.87767346035854" CI_END="0.9991280243973707" CI_START="0.5412976947473032" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7354085234505541" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="208" I2="84.39078673967974" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-3.788593946663379E-4" LOG_CI_START="-0.2665638224575392" LOG_EFFECT_SIZE="-0.13347134092610272" METHOD="MH" MODIFIED="2011-02-11 20:37:21 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.6201817665262297E-11" P_Q="0.0" P_Z="0.04935140154966257" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.19964245691021493" TOTALS="SUB" TOTAL_1="332" TOTAL_2="336" WEIGHT="400.0" Z="1.965543193524713">
<NAME>No. exposed to allogeneic RBC transfusion (Mean PRP volume collected)</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5623477480712817" CI_START="0.025602494738690536" DF="0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.1937777057638096" LOG_CI_START="-1.5917177144358472" LOG_EFFECT_SIZE="-0.6989700043360187" NO="1" P_CHI2="1.0" P_Z="0.12489714589710033" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.5345388392194383">
<NAME>200-300 ml</NAME>
<DICH_DATA CI_END="1.5623477480712817" CI_START="0.025602494738690536" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.1937777057638096" LOG_CI_START="-1.5917177144358472" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="599" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Klein-2001" TOTAL_1="20" TOTAL_2="20" VAR="1.0999999999999999" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="75.69577913746878" CI_END="1.2028853713381416" CI_START="0.14592560180749636" DF="3" EFFECT_SIZE="0.41896511992999136" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="76" I2="96.03676712997195" ID="CMP-001.06.02" LOG_CI_END="0.08022424332716997" LOG_CI_START="-0.8358685069529684" LOG_EFFECT_SIZE="-0.37782213181289925" MODIFIED="2009-03-10 22:59:48 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.1102230246251565E-16" P_Z="0.1059457903520704" STUDIES="4" TAU2="0.9292642002461984" TOTAL_1="90" TOTAL_2="94" WEIGHT="99.99999999999999" Z="1.6166873292883923">
<NAME>301-500 ml</NAME>
<DICH_DATA CI_END="0.49297553247156495" CI_START="0.010349480816516623" EFFECT_SIZE="0.07142857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.3071746352385513" LOG_CI_START="-1.985081436117925" LOG_EFFECT_SIZE="-1.1461280356782382" ORDER="600" O_E="0.0" SE="0.9856107606091622" STUDY_ID="STD-Christenson-1996_x002f_a" TOTAL_1="20" TOTAL_2="20" VAR="0.9714285714285713" WEIGHT="15.23498999856686"/>
<DICH_DATA CI_END="0.3885376869349723" CI_START="0.04378785658706284" EFFECT_SIZE="0.13043478260869565" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="23" LOG_CI_END="-0.41056684961959766" LOG_CI_START="-1.3586463129762634" LOG_EFFECT_SIZE="-0.8846065812979305" ORDER="601" O_E="0.0" SE="0.5569065698447379" STUDY_ID="STD-Christenson-1996_x002f_b" TOTAL_1="30" TOTAL_2="30" VAR="0.3101449275362319" WEIGHT="23.36358085293741"/>
<DICH_DATA CI_END="1.2153945101855008" CI_START="0.8663785356539233" EFFECT_SIZE="1.0261538461538462" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" LOG_CI_END="0.084717270351327" LOG_CI_START="-0.06229231580394014" LOG_EFFECT_SIZE="0.011212477273693408" MODIFIED="2009-03-10 22:43:22 +0000" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="0.08635415861679173" STUDY_ID="STD-Ford-2002" TOTAL_1="25" TOTAL_2="29" VAR="0.007457040710414024" WEIGHT="30.913183240343205"/>
<DICH_DATA CI_END="1.3240720472445462" CI_START="0.7552459113392245" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.12191161718029553" LOG_CI_START="-0.12191161718029553" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-10 22:59:48 +0000" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.14322297480788662" STUDY_ID="STD-Safwat-2002" TOTAL_1="15" TOTAL_2="15" VAR="0.020512820512820523" WEIGHT="30.48824590815251"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.03708890784076" CI_END="1.1020187023243335" CI_START="0.541319946903699" DF="4" EFFECT_SIZE="0.7723630658110805" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="116" I2="76.52181061191075" ID="CMP-001.06.03" LOG_CI_END="0.0421889649761425" LOG_CI_START="-0.26654596945318615" LOG_EFFECT_SIZE="-0.11217850223852185" MODIFIED="2009-03-10 23:15:15 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.001901146639939566" P_Z="0.15435919638359258" STUDIES="5" TAU2="0.11058446174747166" TOTAL_1="181" TOTAL_2="181" WEIGHT="100.0" Z="1.4243015590934194">
<NAME>501-700 ml</NAME>
<DICH_DATA CI_END="1.0723152043034878" CI_START="0.7995212758907578" EFFECT_SIZE="0.9259259259259259" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" LOG_CI_END="0.030322463871913678" LOG_CI_START="-0.09716997484581309" LOG_EFFECT_SIZE="-0.0334237554869497" ORDER="602" O_E="0.0" SE="0.0748896896005426" STUDY_ID="STD-Ereth-1993" TOTAL_1="28" TOTAL_2="28" VAR="0.005608465608465618" WEIGHT="28.305254167024152"/>
<DICH_DATA CI_END="0.6848108222924871" CI_START="0.35248156648653844" EFFECT_SIZE="0.491307634164777" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="42" LOG_CI_END="-0.16442938497697474" LOG_CI_START="-0.45286359011231603" LOG_EFFECT_SIZE="-0.3086464875446454" ORDER="603" O_E="0.0" SE="0.16942767986884172" STUDY_ID="STD-Stammers-1993" TOTAL_1="63" TOTAL_2="52" VAR="0.028705738705738712" WEIGHT="23.611641957002984"/>
<DICH_DATA CI_END="1.3876135637286697" CI_START="0.3395267785510633" EFFECT_SIZE="0.6863905325443787" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.14226853635863929" LOG_CI_START="-0.46912596713214944" LOG_EFFECT_SIZE="-0.16342871538675507" ORDER="604" O_E="0.0" SE="0.35913615780209157" STUDY_ID="STD-Stover-2000" TOTAL_1="26" TOTAL_2="29" VAR="0.12897877984084882" WEIGHT="13.728610113199945"/>
<DICH_DATA CI_END="1.9818867342591606" CI_START="0.4395362742244384" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.29707883072854835" LOG_CI_START="-0.35700527748343475" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="605" O_E="0.0" SE="0.3842122429322726" STUDY_ID="STD-Triulzi-1995" TOTAL_1="24" TOTAL_2="28" VAR="0.14761904761904765" WEIGHT="12.737512163523053"/>
<DICH_DATA CI_END="1.4352439621026587" CI_START="0.6454695330282372" EFFECT_SIZE="0.9625" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.1569257285192679" LOG_CI_START="-0.1901242521581913" LOG_EFFECT_SIZE="-0.016599261819461704" MODIFIED="2009-03-10 23:15:15 +0000" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="0.2038588765750502" STUDY_ID="STD-Wajon-2001" TOTAL_1="40" TOTAL_2="44" VAR="0.04155844155844155" WEIGHT="21.616981599249872"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0560482217953413" CI_END="2.1183081136874247" CI_START="0.43519669786829235" DF="2" EFFECT_SIZE="0.9601461847783276" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="2.7260168901291624" ID="CMP-001.06.04" LOG_CI_END="0.32598912968181093" LOG_CI_START="-0.36131440858335967" LOG_EFFECT_SIZE="-0.01766263945077439" MODIFIED="2011-02-11 20:37:21 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.35771320732667267" P_Z="0.9197599575988065" STUDIES="3" TAU2="0.01640462883287947" TOTAL_1="41" TOTAL_2="41" WEIGHT="99.99999999999999" Z="0.10073609480554716">
<NAME>&gt;700 ml</NAME>
<DICH_DATA CI_END="2.4988165463450835" CI_START="0.008167131474760041" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.39773437303938103" LOG_CI_START="-2.087930453067895" LOG_EFFECT_SIZE="-0.8450980400142569" MODIFIED="2011-02-11 20:37:21 +0000" MODIFIED_BY="[Empty name]" ORDER="606" O_E="0.0" SE="1.4600918230947433" STUDY_ID="STD-Boldt-1993" TOTAL_1="12" TOTAL_2="12" VAR="2.1318681318681314" WEIGHT="7.587224620810871"/>
<DICH_DATA CI_END="3.8148841482433915" CI_START="0.2621311581533772" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5814813536820973" LOG_CI_START="-0.5814813536820973" LOG_EFFECT_SIZE="0.0" ORDER="607" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Godet-1995" TOTAL_1="10" TOTAL_2="10" VAR="0.4666666666666667" WEIGHT="33.74124717005331"/>
<DICH_DATA CI_END="3.268740668680464" CI_START="0.440536630451416" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5143804664266098" LOG_CI_START="-0.3560179743313601" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="608" O_E="0.0" SE="0.5112763526430005" STUDY_ID="STD-Wong-1994" TOTAL_1="19" TOTAL_2="19" VAR="0.26140350877192986" WEIGHT="58.6715282091358"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="57.51566156762072" CI_END="0.981385160903759" CI_START="0.4576911616413609" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6702024427825038" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="233" I2="84.35208818832976" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-0.008160513082570355" LOG_CI_START="-0.3394274740429812" LOG_EFFECT_SIZE="-0.17379399356277578" METHOD="MH" MODIFIED="2009-04-30 06:42:04 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="4.025391464601569E-9" P_Q="0.0" P_Z="0.03973160502532827" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.23341146191590514" TOTALS="YES" TOTAL_1="376" TOTAL_2="382" WEIGHT="100.0" Z="2.0565284695151638">
<NAME>No. exposed to allogeneic RBC transfusion (Mean platelet yield x 10(11)/L)</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.649442121362533" CI_END="1.4003407080106585" CI_START="0.6789904265362063" DF="3" EFFECT_SIZE="0.9750989358153204" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="118" I2="60.78145370076172" ID="CMP-001.07.01" LOG_CI_END="0.14623371396893745" LOG_CI_START="-0.1681363490358592" LOG_EFFECT_SIZE="-0.010951317533460835" NO="1" P_CHI2="0.053840511941363745" P_Z="0.891383624363244" STUDIES="4" TAU2="0.07212308470845255" TOTAL_1="205" TOTAL_2="204" WEIGHT="47.4391576419234" Z="0.13655363836929832">
<NAME>&lt;1.8</NAME>
<DICH_DATA CI_END="0.9252000279486662" CI_START="0.6077794164087427" EFFECT_SIZE="0.7498783454987834" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="90" LOG_CI_END="-0.033764362782145264" LOG_CI_START="-0.21625401220519222" LOG_EFFECT_SIZE="-0.1250091874936687" ORDER="609" O_E="0.0" SE="0.10719532340943128" STUDY_ID="STD-Armellin-1997" TOTAL_1="137" TOTAL_2="138" VAR="0.011490837360852563" WEIGHT="15.461035897582219"/>
<DICH_DATA CI_END="1.803432959937625" CI_START="0.9172460261752922" EFFECT_SIZE="1.2861538461538462" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" LOG_CI_END="0.2561000026730645" LOG_CI_START="-0.03751416108074282" LOG_EFFECT_SIZE="0.10929292079616083" ORDER="610" O_E="0.0" SE="0.17247041320253736" STUDY_ID="STD-Shore_x002d_Lesserson-1995" TOTAL_1="25" TOTAL_2="19" VAR="0.02974604343025397" WEIGHT="14.388505604419917"/>
<DICH_DATA CI_END="1.9818867342591606" CI_START="0.4395362742244384" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.29707883072854835" LOG_CI_START="-0.35700527748343475" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="611" O_E="0.0" SE="0.3842122429322726" STUDY_ID="STD-Triulzi-1995" TOTAL_1="24" TOTAL_2="28" VAR="0.14761904761904765" WEIGHT="9.937375474577413"/>
<DICH_DATA CI_END="3.268740668680464" CI_START="0.440536630451416" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5143804664266098" LOG_CI_START="-0.3560179743313601" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="612" O_E="0.0" SE="0.5112763526430005" STUDY_ID="STD-Wong-1994" TOTAL_1="19" TOTAL_2="19" VAR="0.26140350877192986" WEIGHT="7.652240665343848"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7685616818294225" CI_END="0.7332126531946136" CI_START="0.31570144759288726" DF="1" EFFECT_SIZE="0.4811198353913099" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="39" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="-0.13477004894006797" LOG_CI_START="-0.5007234267230452" LOG_EFFECT_SIZE="-0.31774673783155655" NO="2" P_CHI2="0.3806624146240334" P_Z="6.651377247693262E-4" STUDIES="2" TAU2="0.0" TOTAL_1="70" TOTAL_2="70" WEIGHT="16.283610123497276" Z="3.403560126308039">
<NAME>2.5-2.9</NAME>
<DICH_DATA CI_END="0.7689807013531469" CI_START="0.3251056880362332" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="34" LOG_CI_END="-0.1140845592896038" LOG_CI_START="-0.48797543203835864" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="613" O_E="0.0" SE="0.21962534944228784" STUDY_ID="STD-Jones-1990" TOTAL_1="50" TOTAL_2="50" VAR="0.04823529411764704" WEIGHT="13.443944087420277"/>
<DICH_DATA CI_END="1.5623477480712817" CI_START="0.025602494738690536" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.1937777057638096" LOG_CI_START="-1.5917177144358472" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="614" O_E="0.0" SE="1.0488088481701514" STUDY_ID="STD-Klein-2001" TOTAL_1="20" TOTAL_2="20" VAR="1.0999999999999999" WEIGHT="2.8396660360769994"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="77.54474938394048" CI_END="2.0225279257698987" CI_START="0.048388456441944304" DF="3" EFFECT_SIZE="0.31283702536421854" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="76" I2="96.13126610913866" ID="CMP-001.07.03" LOG_CI_END="0.3058945267856902" LOG_CI_START="-1.3152582313618857" LOG_EFFECT_SIZE="-0.5046818522880977" MODIFIED="2009-03-10 22:44:27 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="7.771561172376096E-16" P_Z="0.2223456299524611" STUDIES="4" TAU2="3.307614919579837" TOTAL_1="101" TOTAL_2="108" WEIGHT="36.27723223457933" Z="1.2203146793716162">
<NAME>3.0-3.5</NAME>
<DICH_DATA CI_END="0.49297553247156495" CI_START="0.010349480816516623" EFFECT_SIZE="0.07142857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.3071746352385513" LOG_CI_START="-1.985081436117925" LOG_EFFECT_SIZE="-1.1461280356782382" ORDER="615" O_E="0.0" SE="0.9856107606091622" STUDY_ID="STD-Christenson-1996_x002f_a" TOTAL_1="20" TOTAL_2="20" VAR="0.9714285714285713" WEIGHT="3.1426937483208537"/>
<DICH_DATA CI_END="0.3885376869349723" CI_START="0.04378785658706284" EFFECT_SIZE="0.13043478260869565" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="23" LOG_CI_END="-0.41056684961959766" LOG_CI_START="-1.3586463129762634" LOG_EFFECT_SIZE="-0.8846065812979305" ORDER="616" O_E="0.0" SE="0.5569065698447379" STUDY_ID="STD-Christenson-1996_x002f_b" TOTAL_1="30" TOTAL_2="30" VAR="0.3101449275362319" WEIGHT="6.9660541463505155"/>
<DICH_DATA CI_END="1.2153945101855008" CI_START="0.8663785356539233" EFFECT_SIZE="1.0261538461538462" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="26" LOG_CI_END="0.084717270351327" LOG_CI_START="-0.06229231580394014" LOG_EFFECT_SIZE="0.011212477273693408" MODIFIED="2009-03-10 22:44:27 +0000" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="0.08635415861679173" STUDY_ID="STD-Ford-2002" TOTAL_1="25" TOTAL_2="29" VAR="0.007457040710414024" WEIGHT="15.719960058009836"/>
<DICH_DATA CI_END="1.3876135637286697" CI_START="0.3395267785510633" EFFECT_SIZE="0.6863905325443787" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.14226853635863929" LOG_CI_START="-0.46912596713214944" LOG_EFFECT_SIZE="-0.16342871538675507" ORDER="617" O_E="0.0" SE="0.35913615780209157" STUDY_ID="STD-Stover-2000" TOTAL_1="26" TOTAL_2="29" VAR="0.12897877984084882" WEIGHT="10.448524281898123"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="29.983125243353633" CI_END="0.8772530082120017" CI_START="0.4642242400695877" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6381552405849036" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="89" I2="76.65353446918716" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.05687513385905638" LOG_CI_START="-0.33327218603949565" LOG_EFFECT_SIZE="-0.19507365994927603" METHOD="MH" MODIFIED="2009-04-30 06:42:01 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="9.56390591378975E-5" P_Q="0.0" P_Z="0.005664759664536707" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.106840816308869" TOTALS="SUB" TOTAL_1="183" TOTAL_2="190" WEIGHT="400.0" Z="2.7665805030611885">
<NAME>No. exposed to allogeneic RBC transfusion (Mean platelet count of PRP)</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6730354494700735" CI_START="0.012279387090865013" DF="1" EFFECT_SIZE="0.0909090909090909" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="-0.17196206043607729" LOG_CI_START="-1.9108233098803729" LOG_EFFECT_SIZE="-1.0413926851582251" NO="1" P_CHI2="1.0" P_Z="0.01889381904684375" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="2.34761934838202">
<NAME>&lt;250 x 10(3)/uL</NAME>
<DICH_DATA CI_END="1.5422965811171738" CI_START="0.005358543169388946" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.1881678958663492" LOG_CI_START="-2.2709532661827994" LOG_EFFECT_SIZE="-1.041392685158225" ORDER="618" O_E="0.0" SE="1.444499943433743" STUDY_ID="STD-Menges-1996" TOTAL_1="20" TOTAL_2="20" VAR="2.0865800865800868" WEIGHT="50.0"/>
<DICH_DATA CI_END="1.5422965811171738" CI_START="0.005358543169388946" EFFECT_SIZE="0.09090909090909091" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.1881678958663492" LOG_CI_START="-2.2709532661827994" LOG_EFFECT_SIZE="-1.041392685158225" ORDER="619" O_E="0.0" SE="1.444499943433743" STUDY_ID="STD-Menges-1997" TOTAL_1="20" TOTAL_2="20" VAR="2.0865800865800868" WEIGHT="50.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.025757790002504895" CI_END="1.3139103680094832" CI_START="0.021508993276216304" DF="1" EFFECT_SIZE="0.16810975364644032" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.11856573964796427" LOG_CI_START="-1.667379916196255" LOG_EFFECT_SIZE="-0.7744070882741455" NO="2" P_CHI2="0.8724932787790779" P_Z="0.08918229318070839" STUDIES="2" TAU2="0.0" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="1.6997269736882161">
<NAME>250-350 x 10(3)/uL</NAME>
<DICH_DATA CI_END="3.845086034384406" CI_START="0.010402888164868843" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5849060616512035" LOG_CI_START="-1.982846070323241" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="620" O_E="0.0" SE="1.5083103128998356" STUDY_ID="STD-Boldt-1990" TOTAL_1="15" TOTAL_2="15" VAR="2.275" WEIGHT="48.376036406707804"/>
<DICH_DATA CI_END="2.4988165463450835" CI_START="0.008167131474760041" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.39773437303938103" LOG_CI_START="-2.087930453067895" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="621" O_E="0.0" SE="1.4600918230947433" STUDY_ID="STD-Boldt-1993" TOTAL_1="12" TOTAL_2="12" VAR="2.1318681318681314" WEIGHT="51.623963593292196"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6875562209409394" CI_END="1.2546639882766994" CI_START="0.6261983444062696" DF="1" EFFECT_SIZE="0.8863794403329968" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="37" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="0.09852743292777945" LOG_CI_START="-0.20328808494039363" LOG_EFFECT_SIZE="-0.052380326006307085" MODIFIED="2009-03-10 23:34:27 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.40699723067980065" P_Z="0.49631031703809936" STUDIES="2" TAU2="0.0" TOTAL_1="66" TOTAL_2="73" WEIGHT="100.0" Z="0.6803066535211753">
<NAME>550-600 x 10(3)/uL</NAME>
<DICH_DATA CI_END="1.3876135637286697" CI_START="0.3395267785510633" EFFECT_SIZE="0.6863905325443787" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.14226853635863929" LOG_CI_START="-0.46912596713214944" LOG_EFFECT_SIZE="-0.16342871538675507" ORDER="622" O_E="0.0" SE="0.35913615780209157" STUDY_ID="STD-Stover-2000" TOTAL_1="26" TOTAL_2="29" VAR="0.12897877984084882" WEIGHT="24.369132566747968"/>
<DICH_DATA CI_END="1.4352439621026587" CI_START="0.6454695330282372" EFFECT_SIZE="0.9625" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.1569257285192679" LOG_CI_START="-0.1901242521581913" LOG_EFFECT_SIZE="-0.016599261819461704" MODIFIED="2009-03-10 23:34:27 +0000" MODIFIED_BY="[Empty name]" ORDER="181" O_E="0.0" SE="0.2038588765750502" STUDY_ID="STD-Wajon-2001" TOTAL_1="40" TOTAL_2="44" VAR="0.04155844155844155" WEIGHT="75.63086743325204"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2904535876458057" CI_END="0.29162022465997023" CI_START="0.043590427005361115" DF="1" EFFECT_SIZE="0.11274684082637279" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="37" I2="0.0" ID="CMP-001.08.04" LOG_CI_END="-0.5351823597997489" LOG_CI_START="-1.3606088766771136" LOG_EFFECT_SIZE="-0.9478956182384313" NO="4" P_CHI2="0.5899300828447458" P_Z="6.746591808594448E-6" STUDIES="2" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="4.501530384264786">
<NAME>700-870 x 10(3)/uL</NAME>
<DICH_DATA CI_END="0.49297553247156495" CI_START="0.010349480816516623" EFFECT_SIZE="0.07142857142857142" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.3071746352385513" LOG_CI_START="-1.985081436117925" LOG_EFFECT_SIZE="-1.1461280356782382" ORDER="623" O_E="0.0" SE="0.9856107606091622" STUDY_ID="STD-Christenson-1996_x002f_a" TOTAL_1="20" TOTAL_2="20" VAR="0.9714285714285713" WEIGHT="24.200323101777066"/>
<DICH_DATA CI_END="0.3885376869349723" CI_START="0.04378785658706284" EFFECT_SIZE="0.13043478260869565" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="23" LOG_CI_END="-0.41056684961959766" LOG_CI_START="-1.3586463129762634" LOG_EFFECT_SIZE="-0.8846065812979305" ORDER="624" O_E="0.0" SE="0.5569065698447379" STUDY_ID="STD-Christenson-1996_x002f_b" TOTAL_1="30" TOTAL_2="30" VAR="0.3101449275362319" WEIGHT="75.79967689822294"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="67.7165053890985" CI_END="-0.12559090562079" CI_START="-0.3658345763969238" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2457127410088569" ESTIMABLE="YES" I2="82.27906190514692" I2_Q="66.05332683304685" ID="CMP-001.09" MODIFIED="2009-05-01 02:04:12 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="8.54421533524885E-10" P_Q="0.05256026250442125" P_Z="6.093412054950519E-5" Q="5.891593530134159" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.24612715938161556" TOTALS="SUB" TOTAL_1="778" TOTAL_2="774" UNITS="" WEIGHT="300.0" Z="4.009163874029678">
<NAME>Units of allogeneic RBC transfused (All Studies)</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="60.15186488309563" CI_END="0.5606484388654034" CI_START="-1.9330514952055482" DF="6" EFFECT_SIZE="-0.6862015281700724" ESTIMABLE="YES" I2="90.02524691186063" ID="CMP-001.09.01" MODIFIED="2009-05-01 02:04:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="4.1923575722080386E-11" P_Z="0.280738232520769" STUDIES="8" TAU2="2.4331182114142" TOTAL_1="193" TOTAL_2="183" WEIGHT="100.0" Z="1.078662482982945">
<NAME>Total (Intra-operative / Post-operative)</NAME>
<CONT_DATA CI_END="-0.08373354635435581" CI_START="-1.716266453645644" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.4" ORDER="625" SD_1="1.3" SD_2="1.3" SE="0.4164701290861718" STUDY_ID="STD-Boey-1993" TOTAL_1="19" TOTAL_2="20" WEIGHT="15.526142156194473"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="3.33" MEAN_2="5.67" MODIFIED="2009-05-01 02:04:12 +0100" MODIFIED_BY="[Empty name]" ORDER="192" SD_1="0.0" SD_2="0.91" SE="0.0" STUDY_ID="STD-Farouk-2003" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
<CONT_DATA CI_END="-3.5447709195092645" CI_START="-6.855229080490734" EFFECT_SIZE="-5.199999999999999" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="8.1" ORDER="626" SD_1="2.1" SD_2="2.2" SE="0.844520151159394" STUDY_ID="STD-Ferraris-1993" TOTAL_1="12" TOTAL_2="14" WEIGHT="12.86256546912974"/>
<CONT_DATA CI_END="0.7580512126064597" CI_START="-2.07805121260646" EFFECT_SIZE="-0.66" ESTIMABLE="YES" MEAN_1="0.15" MEAN_2="0.81" ORDER="627" SD_1="0.82" SD_2="3.13" SE="0.7235088112801391" STUDY_ID="STD-Klein-2001" TOTAL_1="20" TOTAL_2="20" WEIGHT="13.688066541042133"/>
<CONT_DATA CI_END="1.60885201502252" CI_START="0.39114798497747993" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="7.8" MEAN_2="6.8" ORDER="628" SD_1="0.7" SD_2="1.2" SE="0.3106444913401813" STUDY_ID="STD-Liu-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="15.99842519687611"/>
<CONT_DATA CI_END="2.6391899183420904" CI_START="-0.1391899183420906" EFFECT_SIZE="1.25" ESTIMABLE="YES" MEAN_1="3.27" MEAN_2="2.02" ORDER="629" SD_1="2.73" SD_2="1.97" SE="0.7087833905621957" STUDY_ID="STD-Shore_x002d_Lesserson-1995" TOTAL_1="25" TOTAL_2="19" WEIGHT="13.786413408220314"/>
<CONT_DATA CI_END="0.34372262601520776" CI_START="-3.1437226260152076" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="3.9" ORDER="630" SD_1="2.5" SD_2="6.0" SE="0.8896707489369545" STUDY_ID="STD-Stammers-1993" TOTAL_1="63" TOTAL_2="52" WEIGHT="12.550239704144706"/>
<CONT_DATA CI_END="1.1514934638157879" CI_START="-0.431493463815788" EFFECT_SIZE="0.36" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="0.64" ORDER="631" SD_1="1.79" SD_2="0.91" SE="0.4038306163067217" STUDY_ID="STD-Triulzi-1995" TOTAL_1="24" TOTAL_2="28" WEIGHT="15.58814752439252"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.3153513287227" CI_END="-0.006916640519399053" CI_START="-0.29830250257235297" DF="2" EFFECT_SIZE="-0.152609571545876" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.02" MODIFIED="2009-03-11 00:11:37 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5180541028665677" P_Z="0.04007146148512622" STUDIES="3" TAU2="0.0" TOTAL_1="280" TOTAL_2="281" WEIGHT="100.0" Z="2.0530115072751753">
<NAME>Intra-operative</NAME>
<CONT_DATA CI_END="0.05209451435213727" CI_START="-0.37209451435213725" EFFECT_SIZE="-0.15999999999999998" ESTIMABLE="YES" MEAN_1="0.28" MEAN_2="0.44" ORDER="632" SD_1="0.83" SD_2="0.9" SE="0.10821347536235956" STUDY_ID="STD-Armellin-1995" TOTAL_1="128" TOTAL_2="128" WEIGHT="47.1865351628159"/>
<CONT_DATA CI_END="0.07234780860985199" CI_START="-0.332347808609852" EFFECT_SIZE="-0.13" ESTIMABLE="YES" MEAN_1="0.35" MEAN_2="0.48" ORDER="633" SD_1="0.81" SD_2="0.9" SE="0.10324057493196083" STUDY_ID="STD-Armellin-1997" TOTAL_1="137" TOTAL_2="138" WEIGHT="51.84178541223798"/>
<CONT_DATA CI_END="0.4780086544744564" CI_START="-2.4780086544744564" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="2.9" MODIFIED="2009-03-11 00:11:37 +0000" MODIFIED_BY="[Empty name]" ORDER="172" SD_1="1.8" SD_2="2.3" SE="0.7540999049639687" STUDY_ID="STD-Safwat-2002" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.9716794249461196"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.35769564714601904" CI_END="-0.22068764636539778" CI_START="-0.6515247603462155" DF="2" EFFECT_SIZE="-0.4361062033558067" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.03" MODIFIED="2009-03-10 23:40:35 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8362331836902138" P_Z="7.251840464104135E-5" STUDIES="3" TAU2="0.0" TOTAL_1="305" TOTAL_2="310" WEIGHT="100.0" Z="3.967868246605785">
<NAME>Post-operative</NAME>
<CONT_DATA CI_END="-0.12408772994154554" CI_START="-0.9159122700584548" EFFECT_SIZE="-0.5200000000000001" ESTIMABLE="YES" MEAN_1="0.84" MEAN_2="1.36" ORDER="634" SD_1="1.27" SD_2="1.9" SE="0.20199976794541127" STUDY_ID="STD-Armellin-1995" TOTAL_1="128" TOTAL_2="128" WEIGHT="29.605220609056158"/>
<CONT_DATA CI_END="-0.139894331624549" CI_START="-0.7001056683754511" EFFECT_SIZE="-0.42000000000000004" ESTIMABLE="YES" MEAN_1="0.87" MEAN_2="1.29" ORDER="635" SD_1="0.25" SD_2="1.66" SE="0.14291368136602958" STUDY_ID="STD-Armellin-1997" TOTAL_1="137" TOTAL_2="138" WEIGHT="59.14559834656927"/>
<CONT_DATA CI_END="0.34227742745107903" CI_START="-0.9422774274510791" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.5" MODIFIED="2009-03-10 23:40:35 +0000" MODIFIED_BY="[Empty name]" ORDER="182" SD_1="1.5" SD_2="1.5" SE="0.32769858656448864" STUDY_ID="STD-Wajon-2001" TOTAL_1="40" TOTAL_2="44" WEIGHT="11.249181044374561"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.508444357978771" CI_END="0.852632872318535" CI_START="0.2838073560936648" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.49191816515683856" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="43" I2="6.7716338263661475" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-0.06923792762210179" LOG_CI_START="-0.5469763521150344" LOG_EFFECT_SIZE="-0.3081071398685681" METHOD="MH" MODIFIED="2009-04-30 05:54:44 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.3779240563795525" P_Q="0.0" P_Z="0.011469037718172873" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.04596963036926555" TOTALS="YES" TOTAL_1="253" TOTAL_2="263" WEIGHT="100.0" Z="2.5280733830986715">
<NAME>No. exposed to allogeneic platelet transfusion (All Studies)</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.658996795910493" CI_START="0.07076016780887293" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.194763935247068" LOG_CI_START="-1.1502111458247635" LOG_EFFECT_SIZE="0.02227639471115221" ORDER="640" O_E="0.0" SE="1.3774499704354535" STUDY_ID="STD-Boey-1993" TOTAL_1="19" TOTAL_2="20" VAR="1.8973684210526316" WEIGHT="4.052352308499793"/>
<DICH_DATA CI_END="6.260237612452416" CI_START="0.3821225208799469" EFFECT_SIZE="1.5466666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7965908175264822" LOG_CI_START="-0.41779736585604543" LOG_EFFECT_SIZE="0.18939672583521844" MODIFIED="2009-03-10 22:46:00 +0000" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="0.7133376302373537" STUDY_ID="STD-Ford-2002" TOTAL_1="25" TOTAL_2="29" VAR="0.5088505747126436" WEIGHT="14.193950340565552"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="641" O_E="0.0" SE="0.0" STUDY_ID="STD-Godet-1995" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.3346052970893525" CI_START="0.020813477841245254" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.12535284424629042" LOG_CI_START="-1.6816553450135776" LOG_EFFECT_SIZE="-0.7781512503836436" ORDER="642" O_E="0.0" SE="1.0614455552060438" STUDY_ID="STD-Jones-1990" TOTAL_1="50" TOTAL_2="50" VAR="1.1266666666666667" WEIGHT="6.71571437689661"/>
<DICH_DATA CI_END="1.3503172122776934" CI_START="0.13602246029133971" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.1304358035757748" LOG_CI_START="-0.8663893741649635" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2009-03-10 23:05:09 +0000" MODIFIED_BY="[Empty name]" ORDER="173" O_E="0.0" SE="0.5855400437691199" STUDY_ID="STD-Safwat-2002" TOTAL_1="15" TOTAL_2="15" VAR="0.34285714285714286" WEIGHT="20.25346756224901"/>
<DICH_DATA CI_END="1.2988799319719808" CI_START="0.2690105044186254" EFFECT_SIZE="0.5911111111111111" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.11356900689129175" LOG_CI_START="-0.5702307611798451" LOG_EFFECT_SIZE="-0.22833087714427666" ORDER="643" O_E="0.0" SE="0.40166736862842806" STUDY_ID="STD-Shore_x002d_Lesserson-1995" TOTAL_1="25" TOTAL_2="19" VAR="0.16133667502088553" WEIGHT="37.9877033843909"/>
<DICH_DATA CI_END="1.0795280404974894" CI_START="0.003957156358789865" EFFECT_SIZE="0.06535947712418301" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="0.03323392751802159" LOG_CI_START="-2.4026167891532193" LOG_EFFECT_SIZE="-1.1846914308175989" ORDER="644" O_E="0.0" SE="1.4308307686281978" STUDY_ID="STD-Stover-2000" TOTAL_1="26" TOTAL_2="29" VAR="2.047276688453159" WEIGHT="3.7621422610718938"/>
<DICH_DATA CI_END="2.435745880743468" CI_START="0.034925418582039645" EFFECT_SIZE="0.2916666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3866319767573593" LOG_CI_START="-1.4568583801520576" LOG_EFFECT_SIZE="-0.5351132016973491" ORDER="646" O_E="0.0" SE="1.082875361073031" STUDY_ID="STD-Triulzi-1995" TOTAL_1="24" TOTAL_2="28" VAR="1.1726190476190474" WEIGHT="6.462468083878375"/>
<DICH_DATA CI_END="1.8035832167476056" CI_START="0.026835468167240733" EFFECT_SIZE="0.22" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.2561361853239228" LOG_CI_START="-1.5712908236795102" LOG_EFFECT_SIZE="-0.6575773191777937" MODIFIED="2009-03-11 00:20:03 +0000" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="1.0734396709982017" STUDY_ID="STD-Wajon-2001" TOTAL_1="40" TOTAL_2="44" VAR="1.1522727272727273" WEIGHT="6.572201682447876"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="647" O_E="0.0" SE="0.0" STUDY_ID="STD-Wong-1994" TOTAL_1="19" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="7.220689290521338" CI_END="-0.3672818969216095" CI_START="-1.5576096597532838" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9624457783374467" ESTIMABLE="YES" I2="44.60362661981821" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2009-04-30 02:04:17 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.12467541765657442" P_Q="1.0" P_Z="0.0015271281199318583" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.18953274636097103" TOTALS="YES" TOTAL_1="162" TOTAL_2="159" UNITS="" WEIGHT="99.99999999999999" Z="3.169478393289846">
<NAME>Units of allogeneic plaletets transfused (All Studies)</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.9305730718992706" CI_START="-3.2694269281007298" EFFECT_SIZE="-2.1" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="4.5" ORDER="648" SD_1="2.6" SD_2="0.6" SE="0.5966573556070519" STUDY_ID="STD-Liu-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="16.902701732986422"/>
<CONT_DATA CI_END="0.0450438656356133" CI_START="-1.0450438656356131" EFFECT_SIZE="-0.49999999999999994" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.7" MODIFIED="2009-03-11 00:13:02 +0000" MODIFIED_BY="[Empty name]" ORDER="174" SD_1="0.4" SD_2="1.0" SE="0.2780887148615228" STUDY_ID="STD-Safwat-2002" TOTAL_1="15" TOTAL_2="15" WEIGHT="34.55282630103862"/>
<CONT_DATA CI_END="0.2660984193134146" CI_START="-4.666098419313414" EFFECT_SIZE="-2.1999999999999997" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="3.8" ORDER="649" SD_1="4.5" SD_2="8.1" SE="1.2582365996343219" STUDY_ID="STD-Stammers-1993" TOTAL_1="63" TOTAL_2="52" WEIGHT="5.201680181703645"/>
<CONT_DATA CI_END="0.44661254701531505" CI_START="-2.066612547015315" EFFECT_SIZE="-0.8099999999999998" ESTIMABLE="YES" MEAN_1="0.33" MEAN_2="1.14" ORDER="651" SD_1="1.63" SD_2="2.9" SE="0.641140631627578" STUDY_ID="STD-Triulzi-1995" TOTAL_1="24" TOTAL_2="28" WEIGHT="15.353094501963243"/>
<CONT_DATA CI_END="0.03311323229636465" CI_START="-1.433113232296365" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.8" MODIFIED="2009-03-11 00:19:04 +0000" MODIFIED_BY="[Empty name]" ORDER="183" SD_1="0.6" SD_2="2.4" SE="0.3740442365671351" STUDY_ID="STD-Wajon-2001" TOTAL_1="40" TOTAL_2="44" WEIGHT="27.989697282308065"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="21.521700650352862" CI_END="1.124489336349482" CI_START="0.1723085594835529" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.44018080114993163" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="58" I2="67.47468932068233" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.05095534133097887" LOG_CI_START="-0.7636931482969309" LOG_EFFECT_SIZE="-0.356368903482976" METHOD="MH" MODIFIED="2009-04-30 02:04:14 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.003070074027111791" P_Q="0.0" P_Z="0.08638613367729223" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.9816837515899685" TOTALS="YES" TOTAL_1="248" TOTAL_2="236" WEIGHT="100.00000000000001" Z="1.7147769250899603">
<NAME>No. exposed to fresh frozen plasma transfusion (All Studies)</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.6108166784459295" CI_START="0.2668077666028659" EFFECT_SIZE="1.425" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8814312612268763" LOG_CI_START="-0.5738015325378181" LOG_EFFECT_SIZE="0.15381486434452904" ORDER="652" O_E="0.0" SE="0.8548109465758875" STUDY_ID="STD-Boey-1993" TOTAL_1="20" TOTAL_2="19" VAR="0.7307017543859649" WEIGHT="13.372548267742424"/>
<DICH_DATA CI_END="1.2804065064867485" CI_START="0.004621313413620057" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.10734787237939855" LOG_CI_START="-2.3352345769930722" LOG_EFFECT_SIZE="-1.1139433523068367" ORDER="653" O_E="0.0" SE="1.4347850217395144" STUDY_ID="STD-Christenson-1996_x002f_a" TOTAL_1="20" TOTAL_2="20" VAR="2.058608058608059" WEIGHT="7.531828936563228"/>
<DICH_DATA CI_END="0.8654220538208824" CI_START="0.0032008464427998057" EFFECT_SIZE="0.05263157894736842" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.0627720417341568" LOG_CI_START="-2.4947351601715013" LOG_EFFECT_SIZE="-1.278753600952829" ORDER="654" O_E="0.0" SE="1.4285471741816855" STUDY_ID="STD-Christenson-1996_x002f_b" TOTAL_1="30" TOTAL_2="30" VAR="2.0407470288624787" WEIGHT="7.576338217485269"/>
<DICH_DATA CI_END="1.4176980055556325" CI_START="0.6291715902445578" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.15158372838663545" LOG_CI_START="-0.20123089583669973" LOG_EFFECT_SIZE="-0.024823583725032152" ORDER="655" O_E="0.0" SE="0.20724505672934357" STUDY_ID="STD-Ereth-1993" TOTAL_1="28" TOTAL_2="28" VAR="0.04295051353874883" WEIGHT="22.348420905842996"/>
<DICH_DATA CI_END="0.7165019016999455" CI_START="0.00316478391859835" EFFECT_SIZE="0.047619047619047616" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" LOG_CI_END="-0.14478265258457593" LOG_CI_START="-2.4996559368832627" LOG_EFFECT_SIZE="-1.3222192947339193" MODIFIED="2009-03-11 04:10:03 +0000" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="1.3832642240078046" STUDY_ID="STD-Farouk-2003" TOTAL_1="10" TOTAL_2="10" VAR="1.9134199134199137" WEIGHT="7.909546766287395"/>
<DICH_DATA CI_END="4.1659214616153815" CI_START="0.3230017686118904" EFFECT_SIZE="1.16" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6197110781156697" LOG_CI_START="-0.4907950996618329" LOG_EFFECT_SIZE="0.06445798922691845" MODIFIED="2009-03-10 22:46:49 +0000" MODIFIED_BY="[Empty name]" ORDER="165" O_E="0.0" SE="0.652316825920741" STUDY_ID="STD-Ford-2002" TOTAL_1="25" TOTAL_2="29" VAR="0.42551724137931035" WEIGHT="16.272698744567766"/>
<DICH_DATA CI_END="1.645126172643907" CI_START="0.004989313522464376" EFFECT_SIZE="0.0905982905982906" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.21619921169734543" LOG_CI_START="-2.3019592046601285" LOG_EFFECT_SIZE="-1.0428799964813915" ORDER="656" O_E="0.0" SE="1.4791787188535754" STUDY_ID="STD-Quigley-1995" TOTAL_1="64" TOTAL_2="52" VAR="2.187969682309305" WEIGHT="7.224435828454484"/>
<DICH_DATA CI_END="2.2528209893126636" CI_START="0.2563896566749522" EFFECT_SIZE="0.76" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.35272668376004923" LOG_CI_START="-0.5910994991984665" LOG_EFFECT_SIZE="-0.11918640771920865" ORDER="657" O_E="0.0" SE="0.5544081718847871" STUDY_ID="STD-Shore_x002d_Lesserson-1995" TOTAL_1="25" TOTAL_2="19" VAR="0.3073684210526316" WEIGHT="17.764182333056443"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="658" O_E="0.0" SE="0.0" STUDY_ID="STD-Stover-2000" TOTAL_1="26" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="11.030044535543949" CI_END="-0.19760032814016354" CI_START="-0.7857919346426401" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4916961313914018" ESTIMABLE="YES" I2="45.603120815467236" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2009-05-01 02:11:32 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.08745239291197104" P_Q="1.0" P_Z="0.0010497354129142553" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0674120662332637" TOTALS="YES" TOTAL_1="513" TOTAL_2="514" UNITS="" WEIGHT="100.00000000000001" Z="3.276846178051554">
<NAME>Units of FFP transfused (All Studies)</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="11.030044535543949" CI_END="-0.19760032814016354" CI_START="-0.7857919346426401" DF="6" EFFECT_SIZE="-0.4916961313914018" ESTIMABLE="YES" I2="45.603120815467236" ID="CMP-001.13.01" MODIFIED="2009-05-01 02:11:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08745239291197104" P_Z="0.0010497354129142553" STUDIES="10" TAU2="0.0674120662332637" TOTAL_1="503" TOTAL_2="504" WEIGHT="100.00000000000001" Z="3.276846178051554">
<NAME>Transfusion protocol</NAME>
<CONT_DATA CI_END="-0.4580649027509951" CI_START="-1.3819350972490052" EFFECT_SIZE="-0.9200000000000002" ESTIMABLE="YES" MEAN_1="0.41" MEAN_2="1.33" ORDER="660" SD_1="1.26" SD_2="2.35" SE="0.23568550284224105" STUDY_ID="STD-Armellin-1995" TOTAL_1="128" TOTAL_2="128" WEIGHT="18.311275550041277"/>
<CONT_DATA CI_END="-0.21865784954236633" CI_START="-0.9413421504576336" EFFECT_SIZE="-0.58" ESTIMABLE="YES" MEAN_1="0.39" MEAN_2="0.97" ORDER="661" SD_1="1.2" SD_2="1.8" SE="0.18436162771757766" STUDY_ID="STD-Armellin-1997" TOTAL_1="137" TOTAL_2="138" WEIGHT="22.204349378910976"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="3.8" MODIFIED="2009-05-01 02:11:32 +0100" MODIFIED_BY="[Empty name]" ORDER="662" SD_1="0.0" SD_2="1.5" SE="0.0" STUDY_ID="STD-Christenson-1996_x002f_a" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="3.8" MODIFIED="2009-05-01 02:11:26 +0100" MODIFIED_BY="[Empty name]" ORDER="663" SD_1="0.0" SD_2="1.7" SE="0.0" STUDY_ID="STD-Christenson-1996_x002f_b" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.14260809456756274" CI_START="-1.4573919054324351" EFFECT_SIZE="-0.7999999999999989" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="9.1" ORDER="664" SD_1="0.9" SD_2="1.2" SE="0.33541019662496846" STUDY_ID="STD-Liu-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="12.514721258486452"/>
<CONT_DATA CI_END="0.4192471442558131" CI_START="-1.019247144255813" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.8" MODIFIED="2009-03-11 00:13:58 +0000" MODIFIED_BY="[Empty name]" ORDER="175" SD_1="0.9" SD_2="1.1" SE="0.36696957185394363" STUDY_ID="STD-Safwat-2002" TOTAL_1="15" TOTAL_2="15" WEIGHT="11.141941201019986"/>
<CONT_DATA CI_END="0.6594848323536415" CI_START="-1.8594848323536417" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="1.3" ORDER="665" SD_1="1.6" SD_2="4.4" SE="0.6426061102593197" STUDY_ID="STD-Stammers-1993" TOTAL_1="63" TOTAL_2="52" WEIGHT="4.687264343527436"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="666" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Stover-2000" TOTAL_1="26" TOTAL_2="29" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.5807946482159587" CI_START="-0.3607946482159588" EFFECT_SIZE="0.10999999999999999" ESTIMABLE="YES" MEAN_1="0.29" MEAN_2="0.18" ORDER="667" SD_1="1.0" SD_2="0.67" SE="0.24020576496789067" STUDY_ID="STD-Triulzi-1995" TOTAL_1="24" TOTAL_2="28" WEIGHT="17.996431935457494"/>
<CONT_DATA CI_END="0.23172398081816287" CI_START="-1.0317239808181629" EFFECT_SIZE="-0.39999999999999997" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.7" MODIFIED="2009-03-11 00:21:21 +0000" MODIFIED_BY="[Empty name]" ORDER="185" SD_1="1.1" SD_2="1.8" SE="0.3223140760754386" STUDY_ID="STD-Wajon-2001" TOTAL_1="40" TOTAL_2="44" WEIGHT="13.144016332556392"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.13.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>No transfusion protocol</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="668" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Godet-1995" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.990567385064704" CI_END="2.61407460581471" CI_START="0.20429033799155188" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7307736891521341" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" I2="33.123058520992736" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.4173179782067598" LOG_CI_START="-0.6897521730453848" LOG_EFFECT_SIZE="-0.13621709741931246" METHOD="MH" MODIFIED="2009-04-30 02:04:05 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.2241850620946111" P_Q="0.0" P_Z="0.6295791986184485" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.46445834068210906" TOTALS="YES" TOTAL_1="77" TOTAL_2="75" WEIGHT="100.0" Z="0.4823192183773897">
<NAME>No. exposed to cryoprecipitate transfusion (All Studies)</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9830689537366482" CI_START="0.25728005103972207" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.2973378154189655" LOG_CI_START="-0.5895938867754416" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="669" O_E="0.0" SE="0.5209880722517277" STUDY_ID="STD-Ereth-1993" TOTAL_1="28" TOTAL_2="28" VAR="0.27142857142857146" WEIGHT="57.466455123110826"/>
<DICH_DATA CI_END="98.37892308605257" CI_START="0.29471844101073774" EFFECT_SIZE="5.384615384615385" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.992902064204765" LOG_CI_START="-0.5305926887899249" LOG_EFFECT_SIZE="0.7311546877074201" ORDER="670" O_E="0.0" SE="1.4823133094095686" STUDY_ID="STD-Shore_x002d_Lesserson-1995" TOTAL_1="25" TOTAL_2="19" VAR="2.1972527472527474" WEIGHT="15.887829600358193"/>
<DICH_DATA CI_END="1.8614718488844337" CI_START="0.029248062213281713" EFFECT_SIZE="0.23333333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.26985647275070673" LOG_CI_START="-1.5339029021615178" LOG_EFFECT_SIZE="-0.6320232147054056" ORDER="671" O_E="0.0" SE="1.0595371855763476" STUDY_ID="STD-Triulzi-1995" TOTAL_1="24" TOTAL_2="28" VAR="1.1226190476190474" WEIGHT="26.64571527653099"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.04127881619212" CI_END="0.6562012033910707" CI_START="-2.180724247583119" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7622615220960243" ESTIMABLE="YES" I2="50.510714777049394" I2_Q="0.0" ID="CMP-001.15" MODIFIED="2009-04-30 02:04:00 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.13257090371637392" P_Q="1.0" P_Z="0.29222345089280777" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.8577988447760937" TOTALS="YES" TOTAL_1="115" TOTAL_2="108" UNITS="" WEIGHT="100.0" Z="1.0532565313592253">
<NAME>Units of cryoprecipitate transfused (All Studies)</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.274529654770822" CI_START="-2.8745296547708215" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="2.4" ORDER="672" SD_1="7.1" SD_2="4.3" SE="1.5686664035779836" STUDY_ID="STD-Ereth-1993" TOTAL_1="28" TOTAL_2="28" WEIGHT="15.783239012556717"/>
<CONT_DATA CI_END="-0.3298905024925971" CI_START="-4.6701094975074025" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="3.3" ORDER="673" SD_1="3.3" SD_2="7.4" SE="1.1072190686282757" STUDY_ID="STD-Stammers-1993" TOTAL_1="63" TOTAL_2="52" WEIGHT="25.136084205238586"/>
<CONT_DATA CI_END="0.05222828025116483" CI_START="-0.6122282802511647" EFFECT_SIZE="-0.27999999999999997" ESTIMABLE="YES" MEAN_1="0.08" MEAN_2="0.36" ORDER="674" SD_1="0.41" SD_2="0.78" SE="0.16950733935507953" STUDY_ID="STD-Triulzi-1995" TOTAL_1="24" TOTAL_2="28" WEIGHT="59.0806767822047"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="247.17461860053928" CI_END="-103.34730425616176" CI_START="-173.2068812535593" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="MD" EFFECT_SIZE="-138.27709275486052" ESTIMABLE="YES" I2="89.48112061537404" I2_Q="93.43922511923186" ID="CMP-001.16" MODIFIED="2011-02-16 15:20:15 +0000" MODIFIED_BY="Emma M Sydenham" NO="16" P_CHI2="0.0" P_Q="1.8162138459842936E-12" P_Z="8.564237450903417E-15" Q="60.9684080416379" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="24511.5389614359" TOTALS="SUB" TOTAL_1="1041" TOTAL_2="1039" UNITS="" WEIGHT="500.0" Z="7.758939671121324">
<NAME>Blood loss (All Studies)</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="42.04952990428414" CI_END="146.9763802840572" CI_START="-402.04844122370514" DF="4" EFFECT_SIZE="-127.53603046982396" ESTIMABLE="YES" I2="90.48740851775261" ID="CMP-001.16.01" MODIFIED="2009-03-11 04:11:09 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.6292024063169208E-8" P_Z="0.36251573297912165" STUDIES="5" TAU2="63436.58374922617" TOTAL_1="105" TOTAL_2="105" WEIGHT="100.00000000000001" Z="0.9105818777576847">
<NAME>Intra-operative blood loss</NAME>
<CONT_DATA CI_END="-251.88735765228094" CI_START="-458.1126423477191" EFFECT_SIZE="-355.0" ESTIMABLE="YES" MEAN_1="605.0" MEAN_2="960.0" MODIFIED="2009-03-11 04:11:09 +0000" MODIFIED_BY="[Empty name]" ORDER="194" SD_1="68.52" SD_2="151.6" SE="52.6094577048652" STUDY_ID="STD-Farouk-2003" TOTAL_1="10" TOTAL_2="10" WEIGHT="29.63066053757381"/>
<CONT_DATA CI_END="681.3441196795294" CI_START="-1217.3441196795293" EFFECT_SIZE="-268.0" ESTIMABLE="YES" MEAN_1="1622.0" MEAN_2="1890.0" ORDER="675" SD_1="758.0" SD_2="1331.0" SE="484.36814511278504" STUDY_ID="STD-Godet-1995" TOTAL_1="10" TOTAL_2="10" WEIGHT="6.581728969274793"/>
<CONT_DATA CI_END="-29.724039127583126" CI_START="-322.2759608724169" EFFECT_SIZE="-176.0" ESTIMABLE="YES" MEAN_1="1050.0" MEAN_2="1226.0" ORDER="676" SD_1="304.1" SD_2="431.3" SE="74.63196366169123" STUDY_ID="STD-Jones-1990" TOTAL_1="50" TOTAL_2="50" WEIGHT="28.42743651573166"/>
<CONT_DATA CI_END="214.55684288466307" CI_START="14.443157115336945" EFFECT_SIZE="114.5" ESTIMABLE="YES" MEAN_1="1349.5" MEAN_2="1235.0" ORDER="677" SD_1="95.0" SD_2="207.6" SE="51.0503476971509" STUDY_ID="STD-Liu-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="29.7031714747746"/>
<CONT_DATA CI_END="1243.270498255367" CI_START="-843.2704982553671" EFFECT_SIZE="200.0" ESTIMABLE="YES" MEAN_1="2600.0" MEAN_2="2400.0" MODIFIED="2009-03-11 00:15:13 +0000" MODIFIED_BY="[Empty name]" ORDER="176" SD_1="1300.0" SD_2="1600.0" SE="532.290647422377" STUDY_ID="STD-Safwat-2002" TOTAL_1="15" TOTAL_2="15" WEIGHT="5.6570025026451525"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.45091992633054" CI_END="2.369502653157326" CI_START="-89.7627367331415" DF="3" EFFECT_SIZE="-43.696617039992084" ESTIMABLE="YES" I2="32.59820330056394" ID="CMP-001.16.02" MODIFIED="2009-03-11 00:23:34 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.21671039004879433" P_Z="0.06300597442403899" STUDIES="4" TAU2="714.3142656846383" TOTAL_1="324" TOTAL_2="330" WEIGHT="100.00000000000001" Z="1.859149331767138">
<NAME>Post-operative blood loss - 0-12 hours</NAME>
<CONT_DATA CI_END="-13.99941786471647" CI_START="-130.00058213528354" EFFECT_SIZE="-72.0" ESTIMABLE="YES" MEAN_1="311.0" MEAN_2="383.0" ORDER="678" SD_1="202.0" SD_2="267.0" SE="29.592677514885334" STUDY_ID="STD-Armellin-1995" TOTAL_1="128" TOTAL_2="128" WEIGHT="34.7423191342172"/>
<CONT_DATA CI_END="-10.82704415891753" CI_START="-119.17295584108247" EFFECT_SIZE="-65.0" ESTIMABLE="YES" MEAN_1="310.0" MEAN_2="375.0" ORDER="679" SD_1="199.0" SD_2="256.0" SE="27.639771071505308" STUDY_ID="STD-Armellin-1997" TOTAL_1="137" TOTAL_2="138" WEIGHT="37.36912786655064"/>
<CONT_DATA CI_END="208.08407521959924" CI_START="-73.28407521959929" EFFECT_SIZE="67.39999999999998" ESTIMABLE="YES" MEAN_1="487.9" MEAN_2="420.5" ORDER="680" SD_1="181.6" SD_2="261.4" SE="71.77890835203978" STUDY_ID="STD-Boey-1993" TOTAL_1="19" TOTAL_2="20" WEIGHT="9.416425728111351"/>
<CONT_DATA CI_END="89.50958274589266" CI_START="-97.50958274589266" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="407.0" MEAN_2="411.0" MODIFIED="2009-03-11 00:23:34 +0000" MODIFIED_BY="[Empty name]" ORDER="187" SD_1="191.0" SD_2="245.0" SE="47.70984746836386" STUDY_ID="STD-Wajon-2001" TOTAL_1="40" TOTAL_2="44" WEIGHT="18.47212727112082"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="103.99963453411907" CI_END="-97.89816684209777" CI_START="-396.44927522962394" DF="8" EFFECT_SIZE="-247.17372103586086" ESTIMABLE="YES" I2="92.30766527609725" ID="CMP-001.16.03" MODIFIED="2011-02-16 15:20:15 +0000" MODIFIED_BY="Emma M Sydenham" NO="3" P_CHI2="-1.7763568394002505E-15" P_Z="0.0011730587423878058" STUDIES="9" TAU2="45440.861659764385" TOTAL_1="194" TOTAL_2="177" WEIGHT="100.00000000000001" Z="3.2453511478926305">
<NAME>Post-operative blood loss - 0-24 hours</NAME>
<CONT_DATA CI_END="-71.01227045229821" CI_START="-320.9877295477018" EFFECT_SIZE="-196.0" ESTIMABLE="YES" MEAN_1="500.0" MEAN_2="696.0" MODIFIED="2011-02-16 15:20:15 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="682" SD_1="210.0" SD_2="130.0" SE="63.77042156569664" STUDY_ID="STD-Boldt-1990" TOTAL_1="15" TOTAL_2="15" WEIGHT="11.716825385422792"/>
<CONT_DATA CI_END="-185.0444504927159" CI_START="-514.9555495072841" EFFECT_SIZE="-350.0" ESTIMABLE="YES" MEAN_1="600.0" MEAN_2="950.0" MODIFIED="2011-02-16 15:20:14 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="683" SD_1="150.0" SD_2="250.0" SE="84.16254115301732" STUDY_ID="STD-Boldt-1993" TOTAL_1="12" TOTAL_2="12" WEIGHT="11.043883009361556"/>
<CONT_DATA CI_END="-145.3033858346597" CI_START="-299.09661416534027" EFFECT_SIZE="-222.2" ESTIMABLE="YES" MEAN_1="407.8" MEAN_2="630.0" ORDER="684" SD_1="87.7" SD_2="78.5" SE="39.233687339099575" STUDY_ID="STD-DelRossi-1990" TOTAL_1="9" TOTAL_2="9" WEIGHT="12.347153855505313"/>
<CONT_DATA CI_END="-330.3509937906623" CI_START="-574.6490062093377" EFFECT_SIZE="-452.5" ESTIMABLE="YES" MEAN_1="547.5" MEAN_2="1000.0" MODIFIED="2009-03-11 04:13:14 +0000" MODIFIED_BY="[Empty name]" ORDER="195" SD_1="132.6" SD_2="145.8" SE="62.32206671797719" STUDY_ID="STD-Farouk-2003" TOTAL_1="10" TOTAL_2="10" WEIGHT="11.760207220805155"/>
<CONT_DATA CI_END="119.43954884871711" CI_START="3.5604511512828907" EFFECT_SIZE="61.5" ESTIMABLE="YES" MEAN_1="1048.7" MEAN_2="987.2" ORDER="685" SD_1="82.0" SD_2="103.7" SE="29.561537510758807" STUDY_ID="STD-Liu-1998" TOTAL_1="20" TOTAL_2="20" WEIGHT="12.524543752516514"/>
<CONT_DATA CI_END="-274.2172486964508" CI_START="-657.7827513035493" EFFECT_SIZE="-466.0" ESTIMABLE="YES" MEAN_1="482.0" MEAN_2="948.0" MODIFIED="2011-02-16 15:20:14 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="686" SD_1="273.0" SD_2="342.0" SE="97.85014052110502" STUDY_ID="STD-Menges-1996" TOTAL_1="20" TOTAL_2="20" WEIGHT="10.543772968104566"/>
<CONT_DATA CI_END="-245.59760179579507" CI_START="-622.4023982042049" EFFECT_SIZE="-434.0" ESTIMABLE="YES" MEAN_1="503.0" MEAN_2="937.0" MODIFIED="2011-02-16 15:20:13 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="687" SD_1="251.0" SD_2="349.0" SE="96.1254388806626" STUDY_ID="STD-Menges-1997" TOTAL_1="20" TOTAL_2="20" WEIGHT="10.608282061204056"/>
<CONT_DATA CI_END="135.2386514802771" CI_START="-377.2386514802771" EFFECT_SIZE="-121.0" ESTIMABLE="YES" MEAN_1="770.0" MEAN_2="891.0" ORDER="688" SD_1="404.0" SD_2="448.0" SE="130.73640816946377" STUDY_ID="STD-Shore_x002d_Lesserson-1995" TOTAL_1="25" TOTAL_2="19" WEIGHT="9.276258452794277"/>
<CONT_DATA CI_END="149.6005377480765" CI_START="-271.6005377480765" EFFECT_SIZE="-61.0" ESTIMABLE="YES" MEAN_1="1166.0" MEAN_2="1227.0" ORDER="689" SD_1="513.0" SD_2="619.0" SE="107.45122839463718" STUDY_ID="STD-Stammers-1993" TOTAL_1="63" TOTAL_2="52" WEIGHT="10.17907329428579"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.6400325779469689" CI_END="-220.2406345620218" CI_START="-348.74904074108406" DF="1" EFFECT_SIZE="-284.4948376515529" ESTIMABLE="YES" I2="39.025601476049744" ID="CMP-001.16.04" NO="4" P_CHI2="0.20032106232461278" P_Z="4.026975145769088E-18" STUDIES="2" TAU2="873.3168611111171" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="8.678025853151743">
<NAME>Post-operative blood loss - 0-48 hours</NAME>
<CONT_DATA CI_END="-161.03750415309565" CI_START="-327.7624958469043" EFFECT_SIZE="-244.39999999999998" ESTIMABLE="YES" MEAN_1="718.9" MEAN_2="963.3" ORDER="691" SD_1="99.0" SD_2="80.5" SE="42.53266718391615" STUDY_ID="STD-DelRossi-1990" TOTAL_1="9" TOTAL_2="9" WEIGHT="40.0675072473051"/>
<CONT_DATA CI_END="-251.85301286095887" CI_START="-370.74698713904127" EFFECT_SIZE="-311.30000000000007" ESTIMABLE="YES" MEAN_1="872.9" MEAN_2="1184.2" ORDER="692" SD_1="111.6" SD_2="77.1" SE="30.330652811965653" STUDY_ID="STD-Klein-2001" TOTAL_1="20" TOTAL_2="20" WEIGHT="59.93249275269489"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="34.06609361622065" CI_END="-85.7936763047484" CI_START="-374.41554104808745" DF="6" EFFECT_SIZE="-230.10460867641794" ESTIMABLE="YES" I2="82.38717926512393" ID="CMP-001.16.05" MODIFIED="2009-03-11 00:22:35 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="6.532584438168065E-6" P_Z="0.0017770003138930161" STUDIES="7" TAU2="27835.16166143612" TOTAL_1="389" TOTAL_2="398" WEIGHT="100.0" Z="3.1251738054115688">
<NAME>Total post-operative blood loss</NAME>
<CONT_DATA CI_END="6.85783283951703" CI_START="-192.85783283951702" EFFECT_SIZE="-93.0" ESTIMABLE="YES" MEAN_1="619.0" MEAN_2="712.0" ORDER="693" SD_1="342.0" SD_2="464.0" SE="50.94881009405421" STUDY_ID="STD-Armellin-1995" TOTAL_1="128" TOTAL_2="128" WEIGHT="17.81504295628275"/>
<CONT_DATA CI_END="0.32684538521752415" CI_START="-188.32684538521752" EFFECT_SIZE="-94.0" ESTIMABLE="YES" MEAN_1="613.0" MEAN_2="707.0" ORDER="694" SD_1="333.0" SD_2="456.0" SE="48.12682586478917" STUDY_ID="STD-Armellin-1997" TOTAL_1="137" TOTAL_2="138" WEIGHT="17.980239713998746"/>
<CONT_DATA CI_END="-653.1625334074037" CI_START="-1424.8374665925962" EFFECT_SIZE="-1039.0" ESTIMABLE="YES" MEAN_1="423.0" MEAN_2="1462.0" ORDER="695" SD_1="328.0" SD_2="817.0" SE="196.85946764125924" STUDY_ID="STD-Christenson-1996_x002f_a" TOTAL_1="20" TOTAL_2="20" WEIGHT="8.141436100764476"/>
<CONT_DATA CI_END="-222.65800484148855" CI_START="-647.3419951585115" EFFECT_SIZE="-435.0" ESTIMABLE="YES" MEAN_1="423.0" MEAN_2="858.0" ORDER="696" SD_1="318.0" SD_2="501.0" SE="108.33974340010225" STUDY_ID="STD-Christenson-1996_x002f_b" TOTAL_1="30" TOTAL_2="30" WEIGHT="13.699572695048998"/>
<CONT_DATA CI_END="216.03983455584643" CI_START="-332.0398345558464" EFFECT_SIZE="-58.0" ESTIMABLE="YES" MEAN_1="233.0" MEAN_2="291.0" ORDER="697" SD_1="322.0" SD_2="303.0" SE="139.81881132379863" STUDY_ID="STD-Godet-1995" TOTAL_1="10" TOTAL_2="10" WEIGHT="11.44106181982087"/>
<CONT_DATA CI_END="-62.99874281274052" CI_START="-481.0012571872595" EFFECT_SIZE="-272.0" ESTIMABLE="YES" MEAN_1="463.0" MEAN_2="735.0" ORDER="698" SD_1="205.0" SD_2="519.0" SE="106.63525393111033" STUDY_ID="STD-Triulzi-1995" TOTAL_1="24" TOTAL_2="28" WEIGHT="13.827609288952477"/>
<CONT_DATA CI_END="74.04558827920836" CI_START="-170.04558827920835" EFFECT_SIZE="-48.0" ESTIMABLE="YES" MEAN_1="582.0" MEAN_2="630.0" MODIFIED="2009-03-11 00:22:35 +0000" MODIFIED_BY="[Empty name]" ORDER="186" SD_1="225.0" SD_2="339.0" SE="62.26930149833792" STUDY_ID="STD-Wajon-2001" TOTAL_1="40" TOTAL_2="44" WEIGHT="17.095037425131686"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-05-12 04:38:12 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Adverse events and other outcomes</NAME>
<DICH_OUTCOME CHI2="0.9294766552114082" CI_END="9.230269037952961" CI_START="0.10599306349638357" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9891129825396348" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.9652143597469915" LOG_CI_START="-0.9747225553372599" LOG_EFFECT_SIZE="-0.004754097795134121" METHOD="MH" MODIFIED="2009-05-12 04:37:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.33499910393816323" P_Q="0.0" P_Z="0.992335356271698" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="246" TOTAL_2="242" WEIGHT="100.0" Z="0.009606354088106514">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="699" O_E="0.0" SE="0.0" STUDY_ID="STD-Armellin-1997" TOTAL_1="137" TOTAL_2="138" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="700" O_E="0.0" SE="0.0" STUDY_ID="STD-Boey-1993" TOTAL_1="19" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.723921203524791" CI_START="0.014385324265142151" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8878378346245852" LOG_CI_START="-1.84208034406391" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="701" O_E="0.0" SE="1.6035674514745464" STUDY_ID="STD-Christenson-1996_x002f_a" TOTAL_1="20" TOTAL_2="20" VAR="2.5714285714285716" WEIGHT="50.498206456755675"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="702" O_E="0.0" SE="0.0" STUDY_ID="STD-Shore_x002d_Lesserson-1995" TOTAL_1="25" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="71.73802435585941" CI_START="0.12545647975131194" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8557494121620408" LOG_CI_START="-0.901506902722716" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2009-03-11 00:24:39 +0000" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="1.6196260080021871" STUDY_ID="STD-Wajon-2001" TOTAL_1="45" TOTAL_2="45" VAR="2.623188405797101" WEIGHT="49.501793543244325"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.320592511181172" CI_END="2.1258692988730896" CI_START="0.14791797991044148" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5607622421694723" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.3275365600353101" LOG_CI_START="-0.8299790328909253" LOG_EFFECT_SIZE="-0.2512212364278076" METHOD="MH" MODIFIED="2009-05-12 04:38:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7242492226925433" P_Q="0.0" P_Z="0.39490212535677127" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="265" TOTAL_2="264" WEIGHT="99.99999999999999" Z="0.8507610239709363">
<NAME>Re-operation for bleeding</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.759699828991163" CI_START="0.007502629511399606" EFFECT_SIZE="0.14389233954451347" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4408618466658545" LOG_CI_START="-2.124786498988651" LOG_EFFECT_SIZE="-0.8419623261613982" ORDER="704" O_E="0.0" SE="1.5070745384015931" STUDY_ID="STD-Armellin-1997" TOTAL_1="137" TOTAL_2="138" VAR="2.271273664298375" WEIGHT="20.354453153779872"/>
<DICH_DATA CI_END="15.208600307956246" CI_START="0.06575227040958258" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1820892464985915" LOG_CI_START="-1.1820892464985915" LOG_EFFECT_SIZE="0.0" ORDER="705" O_E="0.0" SE="1.3887301496588271" STUDY_ID="STD-Ereth-1993" TOTAL_1="28" TOTAL_2="28" VAR="1.9285714285714284" WEIGHT="23.971387688564935"/>
<DICH_DATA CI_END="17.603979554200347" CI_START="0.07643726214615698" EFFECT_SIZE="1.16" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2456108554883214" LOG_CI_START="-1.1166948770344847" LOG_EFFECT_SIZE="0.06445798922691845" MODIFIED="2009-03-10 22:47:50 +0000" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="1.3876300808858644" STUDY_ID="STD-Ford-2002" TOTAL_1="25" TOTAL_2="29" VAR="1.9255172413793102" WEIGHT="24.009410253973524"/>
<DICH_DATA CI_END="5.33925597435076" CI_START="0.046823003280040215" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7274807422819938" LOG_CI_START="-1.3295407336099563" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="706" O_E="0.0" SE="1.2083045973594573" STUDY_ID="STD-Jones-1990" TOTAL_1="50" TOTAL_2="50" VAR="1.46" WEIGHT="31.66474890368166"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="707" O_E="0.0" SE="0.0" STUDY_ID="STD-Shore_x002d_Lesserson-1995" TOTAL_1="25" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.884866694009082" CI_END="0.1775738680428114" CI_START="-2.2534973313365096" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.037961731646849" ESTIMABLE="YES" I2="41.90156211040905" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2009-05-12 04:37:39 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.14209917852598708" P_Q="1.0" P_Z="0.09420159706690998" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.783291746611323" TOTALS="YES" TOTAL_1="177" TOTAL_2="174" UNITS="" WEIGHT="100.0" Z="1.673638856713081">
<NAME>Length of hospital stay (LOS) - days</NAME>
<GROUP_LABEL_1>PRP</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PRP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.09740559368322943" CI_START="-3.497405593683228" EFFECT_SIZE="-1.6999999999999993" ESTIMABLE="YES" MEAN_1="10.5" MEAN_2="12.2" ORDER="709" SD_1="2.9" SD_2="2.9" SE="0.91706052144883" STUDY_ID="STD-Christenson-1996_x002f_a" TOTAL_1="20" TOTAL_2="20" WEIGHT="23.67964273444663"/>
<CONT_DATA CI_END="0.32649458689068234" CI_START="-2.92649458689068" EFFECT_SIZE="-1.299999999999999" ESTIMABLE="YES" MEAN_1="10.9" MEAN_2="12.2" ORDER="710" SD_1="2.9" SD_2="3.5" SE="0.8298594258467313" STUDY_ID="STD-Christenson-1996_x002f_b" TOTAL_1="30" TOTAL_2="30" WEIGHT="26.13025470645719"/>
<CONT_DATA CI_END="-0.2398908309134331" CI_START="-4.960109169086566" EFFECT_SIZE="-2.5999999999999996" ESTIMABLE="YES" MEAN_1="10.8" MEAN_2="13.4" ORDER="711" SD_1="4.2" SD_2="7.8" SE="1.2041594578792296" STUDY_ID="STD-Stammers-1993" TOTAL_1="63" TOTAL_2="52" WEIGHT="17.222402005751196"/>
<CONT_DATA CI_END="2.679326364495492" CI_START="-0.8793263644954912" EFFECT_SIZE="0.9000000000000004" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="9.1" ORDER="713" SD_1="4.0" SD_2="2.1" SE="0.9078362554264214" STUDY_ID="STD-Triulzi-1995" TOTAL_1="24" TOTAL_2="28" WEIGHT="23.92761637785202"/>
<CONT_DATA CI_END="2.9517376366092103" CI_START="-4.351737636609209" EFFECT_SIZE="-0.6999999999999993" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="10.7" MODIFIED="2009-03-11 00:25:41 +0000" MODIFIED_BY="[Empty name]" ORDER="189" SD_1="8.9" SD_2="8.1" SE="1.8631656833562504" STUDY_ID="STD-Wajon-2001" TOTAL_1="40" TOTAL_2="44" WEIGHT="9.04008417549297"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-02-16 15:11:56 +0000" MODIFIED_BY="Emma M Sydenham">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-05-11 07:38:34 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAPMAAAPYCAIAAACAF1gAAAAldElEQVR42u3dvW4cydmG4QGcOGDA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-05-11 07:38:34 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeAAAACcCAMAAACQnYipAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAGHklEQVR42u2diW7rIBBF/apI/Byfy8+NlLav8cpqg+OVnKu2idmM
5zLDYA9u04Cq8a9RCKFiyBcyqBsQDMEAggEEAwgGEAwgGDh41LKgh0obqjqCV5mias3XExPNHAwg
GEAwgGAAwWArgnXwJQ59aB917IRaa9grJVibqwrNBPwaY2B4pYnudaPXkb+/vQrpIbFLGVVoLJgq
/6qgp5btmtFC/ZF1trAUyEPkTpY2nTxN99XY9rFLNF16+2sXTJUfM0zj19SxQm6TxjlNn26grlyD
X3LTEYtoZkxlLN3M5JuZisFZzeypNCSXarBe9qR0+O01KMxy+Zm05HnnjDH8lhNsHJGahFS1n93b
TpPlHcXSUgZDm6Md9qpNdKsSnY3WjgbpJvIRZKfKuxTpxHpML9mJrKEDcpysP45bq9tZ3unI+mhd
n0HGU8FoeVvVtVWwSRcajqazNX4pTHQmsnY2lMqypPxGPAnPgy08R1Ll1Af+Gkt7DQ2+AQjZcXAR
Dd7jisCHTEMAgiEYQDC4OAh8r9uLrifw/QGr3+O3X0w0czCAYADBAIIBBINTCB5iP3Qy+51wG72Q
R+D73gRnRMnv+KyXwPdjTbQOAtuT4epedHsYED/qZpcbltdE4uXjsZE+NX5gezRcvYlHtztpU1x8
FxgfljcEvh+gwVOUvG+VF8NnY4H0JpWbjMEn6m5nDdar/KOMFjMD6OF3Z4KTQemrw9XNTHXYPNhE
W1HyEU3Txbqvl6trKD/NybKC3hfC1YPg9yBtqB47gefUgWVUEzbL82D7efAUNsutSkz0PfCEy6oJ
JvB96xsdAIIBBAMIBjhZDYHvSZ/zo9/4vtDQ922FQeA7czCAYADBAIIBBIM6CNZ6iI0NX2zIG9/X
4krr4PaVtWb4FmS5/BLTcWcTrYOYeCcB3b2nBgc66r5A3klAeW9IsEvcFBOv4wlY6PvOwZkaDlgm
QfD1u5j4Fw8o8M3n4HG+dcPgxwRMdBZuGfge4VZ4Hmzh98bvi2aN9AEaHAEhOw544zteNIBgAMEA
ggEEAwgGEAzBAIIvC7lEExfsBhqMBgMIBpcFT5OqRH1PkzYYp7LBUJeLdAMTzRwMIBjgZIGznc96
3sIrnaMlr78FjspYrf0srT35NGp1D0avSJV0o8udep86czUES3dt7U8Jv4NIVH9UVNtx4Vf2YGxA
moJuiHfRyTN/+hysNlibiNpwhG59yhpflL5G4PIO1+Ivw9e0oUq6obKvvTaClbx+pMR1HCz03+eK
2s1YeX0P/JbWdiNWrToNVs04LZVb6nW11RY9eL8b8WoVzsGlDuzb1nWLOcKvsrIbYbWPv9Exzn1v
LdC2W+pxo2PJ05FhHVm6AF1RO1hLr26jV738JmLr4Eg14U5W5QaKe9GVA4IhGEAwgGAAwWAHPHZd
ZYOzoCIEsyKuaPmLiWYOBhAMIBhAMDhomTSzYDrdv6ZHmxLs6/XP5fr5PL9H/9zDX0w0gGBwHsES
n3m6RMmYqoIyIlOqLM1w+V06845rtEcSXqQcJqN8glV7qpgnMRsAmM4TpdLF1E1vjMuceNQZMio3
0dKOquHDSx8GnAxDV5yiYpcUb5CmGs4R61A11kc5UKmV14NAE6Xvjcik3rvK6FHQdzVsn5n2O00j
NLa1RpSbYx+rqZ54e7e64P6SZcew8yra1EZ7h8qGnHvNds/EuerdZfRVMjrVoml5bZ1of70CKmnL
YwasmJC4FVQnrFDjdlP531Ukax8ZlW9dkfFCVP41qwynoLjhxanwjIlcrbIX+8monGA1fuReSl90
Ya+NWPuf32VYOS3eAbvJ6GulgsjMAPYGsWT7nVKmdRHHXnKWdWcY6QVx7Cajcg3uzcNkJXo602bD
L+qWVDJmdjmSP0C9c9pN9X1UJzEciMfqohwqI2vrylTe3+/wk/G2iB3cUPvQvxd9/sMG/160yhXP
ZvIStZy1xUtY1A4MSz3xYY54ZEOnPk9GW2wA34GMmuL/1E7XlddWnOCfy0npebke/d5jeD3uoT/0
aC14XFg5IBiCAQQDCAYQDHZeJrF/tG6C2T2KiQYQDCAYQDCAYADBAIIBuDf+A8Ef0QjQDnluAAAA
AElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2011-02-16 15:11:56 +0000" MODIFIED_BY="Emma M Sydenham" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Platelet-rich plasmapheresis versus control, outcome: 1.1 No. exposed to allogeneic RBC transfusion (All Studies).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-05-13 13:36:53 +0100" MODIFIED_BY="Emma M Sydenham">
<APPENDIX ID="APP-01" MODIFIED="2009-05-13 13:36:53 +0100" MODIFIED_BY="Emma M Sydenham" NO="1">
<TITLE MODIFIED="2008-09-17 18:09:32 +0100" MODIFIED_BY="Emma M Sydenham">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-13 13:36:53 +0100" MODIFIED_BY="Emma M Sydenham">
<P>The Cochrane Library and the databases MEDLINE and EMBASE were initially searched using unrestricted search terms with exploded MeSH (Medical subject heading) terms and specific text-word terms for platelet-rich plasmapheresis.</P>
<UL>
<LI>The exploded MeSH terms included:exp Plateletpheresis/</LI>
</UL>
<UL>
<LI>The specific text-word terms included: plateletphere$, platelet rich plasma, platelet rich, platelet rich plasmapheresis, thrombocytopheresis, thrombocytophere$, thrombocyte rich plasma and autologous platelet$</LI>
</UL>
<UL>
<LI>To maximise the sensitivity for the retrieval of all potentially relevant studies, electronic searches were initially unrestricted. To improve the specificity of the searches, two search filters were used.</LI>
<LI>Firstly, the ISPOT filter (<LINK REF="REF-Laupacis-1997" TYPE="REFERENCE">Laupacis 1997</LINK>), which identifies blood transfusion studies using the MeSH terms: 'blood transfusion', 'hemorrhage', and 'anesthesia'. The ISPOT filter combines these MeSH terms with the text-word terms: transfusion$, bleed$, blood loss$, hemorrhag$.</LI>
<LI>Secondly, a modified version of the Cochrane Collaboration filter (<LINK REF="REF-Dickersin-1996" TYPE="REFERENCE">Dickersin 1996</LINK>, <LINK REF="REF-Robinson-2002" TYPE="REFERENCE">Robinson 2002</LINK>), which primarily identifies randomised controlled trials.</LI>
<LI>These search filters were combined with the MeSH and text-word terms specific for platelet-rich plasmapheresis.</LI>
<LI>Reference lists of relevant reviews and identified articles were searched for additional relevant studies.</LI>
</UL>
<P>NB: The truncation character "$" (dollar sign) indicates the use of unlimited truncation to retrieve all possible suffix variations of the root word or phrase.</P>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE and EMBASE - unrestricted search strategy</HEADING>
<P>1 exp Plateletpheresis/<BR/>2 plateletpheres$.tw<BR/>3 platelet rich plasma$.tw<BR/>4 (platelet and rich and pheresis).tw<BR/>5 (platelet and rich).tw<BR/>6 plasmapheres$.tw<BR/>7 thrombocytopheres$.tw<BR/>8 (thrombocyte and rich and plasma$).tw<BR/>9 autologous plateletpheres$.tw<BR/>10 or/1-9</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE and EMBASE - restricted search strategy (ISPOT search filter)</HEADING>
<P>1       exp Plateletpheresis/<BR/>2       plateletpheres$.tw<BR/>3       platelet rich plasma$.tw<BR/>4       (platelet and rich and pheresis).tw<BR/>5       (platelet and rich).tw<BR/>6       plasmapheres$.tw<BR/>7       thrombocytopheres$.tw<BR/>8      (thrombocyte and rich and plasma$).tw<BR/>9       autologous plateletpheres$.tw<BR/>10     or/1-9<BR/>11     exp Blood Transfusion/<BR/>12     exp HEMORRHAGE/<BR/>13     exp ANESTHESIA/<BR/>14     transfusion$.tw.<BR/>15     bleed$.tw.<BR/>16     blood loss$.tw.<BR/>17     hemorrhag$.tw.<BR/>18     or/11-17</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE - restricted search strategy (ISPOT &amp; RCT filter)</HEADING>
<P>1       exp Plateletpheresis/<BR/>2       plateletpheres$.tw<BR/>3       platelet rich plasma$.tw<BR/>4       (platelet and rich and pheresis).tw<BR/>5       (platelet and rich).tw<BR/>6       plasmapheres$.tw<BR/>7       thrombocytopheres$.tw<BR/>8      (thrombocyte and rich and plasma$).tw<BR/>9       autologous plateletpheres$.tw<BR/>10     or/1-9<BR/>11     exp Blood Transfusion/<BR/>12     exp HEMORRHAGE/<BR/>13     exp ANESTHESIA/<BR/>14     transfusion$.tw.<BR/>15     bleed$.tw.<BR/>16     blood loss$.tw.<BR/>17     hemorrhag$.tw.<BR/>18     or/11-17<BR/>19     randomized controlled trial.pt.<BR/>20     controlled clinical trial.pt.<BR/>21     randomized controlled trials.sh.<BR/>22     random allocation.sh.<BR/>23     double blind method.sh.<BR/>24     single blind method.sh.<BR/>25     or/19-24<BR/>26     (animal not human).sh.<BR/>27     25 not 26<BR/>28     clinical trial.pt.<BR/>29     exp Clinical trials/<BR/>30     (clin$ adj25 trial$).ti,ab.<BR/>31     ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.<BR/>32     placebos.sh.<BR/>33     placebo$.ti,ab.<BR/>34     random$.ti,ab.<BR/>35     research design.sh.<BR/>36     or/28-35<BR/>37     comparative study.sh.<BR/>38     exp Evaluation studies/<BR/>39     follow up studies.sh.<BR/>40     prospective studies.sh.<BR/>41     (control$ or prospectiv$ or volunteer$).ti,ab.<BR/>42     or/37-41<BR/>43     42 not 26<BR/>44     43 not 26<BR/>45     27 or 36 or 43<BR/>46     10 and 18 and 45</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE - restricted search strategy (ISPOT &amp; RCT filter)</HEADING>
<P>1       exp Plateletpheresis/<BR/>2       plateletpheres$.tw<BR/>3       platelet rich plasma$.tw<BR/>4       (platelet and rich and pheresis).tw<BR/>5       (platelet and rich).tw<BR/>6       plasmapheres$.tw<BR/>7       thrombocytopheres$.tw<BR/>8      (thrombocyte and rich and plasma$).tw<BR/>9       autologous plateletpheres$.tw<BR/>10     or/1-9<BR/>11    exp Blood Transfusion/<BR/>12    exp HEMORRHAGE/<BR/>13    exp ANESTHESIA/<BR/>14    transfusion$.tw.<BR/>15    bleed$.tw.<BR/>16    blood loss$.tw.<BR/>17    hemorrhag$.tw.<BR/>18    or/11-17 <BR/>19    exp clinical trial/<BR/>20    controlled study/<BR/>21    randomized controlled trial$.tw.<BR/>22    comparative stud$.ti,ab.<BR/>23    random allocation.tw.<BR/>24    crossover trial.ti,ab.<BR/>25    double blind procedure.sh.<BR/>26    (cli$ adj25 trial$).ti,ab.<BR/>27    ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.<BR/>28    placebo$.sh.<BR/>29    placebo$.ti,ab. or placebo$.tw.<BR/>30    random$.ti,ab. or random$.tw.<BR/>31    or/19-30<BR/>32    animal/ not (human/ and animal/)<BR/>33    31 not 32<BR/>34   "COMPARATIVE STUDY".mp.<BR/>35    "EVALUATION STUDIES".mp.<BR/>36    "FOLLOW UP STUDIES".mp.<BR/>37    "CROSSOVER TRIAL$".mp.<BR/>38   exp prospective study/<BR/>39    exp longitudinal study/<BR/>40    (control$ or prospectiv$ or volunteer$).ti,ab.<BR/>41    or/34-40<BR/>42    41 not 32<BR/>43    31 or 41<BR/>44    10 and 18 and 43</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>